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ABSTRACT
Ragas, Moner A. Ph.D., Biomedical Sciences Program, Department of Neuroscience, Cell
Biology, and Physiology, Wright State University, 2016. Refining a Post-Stroke
Pharmacological and Physical Treatment to Reduce Infarct Volume or Improve Functional
Recovery, Using Gene Expression Changes in the Peri-Infarct Region to Examine Potential
Mechanisms in Male and Female Rats.

Stroke, a life-threatening medical condition, is the fifth-leading cause of death in
the United States with an estimated annual cost of treatments above $70 billion. A
combination of innovative approaches was used in our lab to optimize the pre-clinical
stroke research design by choosing the most appropriate animal model and methodologies
to increase the translational capability of the stroke research.
The first study, modeled after ongoing clinical trials using fluoxetine, refined the
appropriate timing of fluoxetine and ascorbic acid delivery if a rat was on simvastatin for
7 days pre-stroke and throughout the remainder of the study. Administration of fluoxetine
and ascorbic acid at 6-12 hours or 48-54 hours (the time used in clinical trials) after stroke
in male 10-12 month old rats resulted in larger infarct volume and indicated a high risk of
hemorrhagic transformation, while administration of the same drugs 20-26 hours after
stroke dramatically reduced infarct volume and the risk of bleeding in the brain. The ability
of the combination therapy (fluoxetine and simvastatin) to improve motor recovery
following stroke was estimated in both rehabilitated and non-rehabilitated female 10-12
month rats. The combination of drugs and rehabilitation improved motor function recovery,
III

but ultimately, the same functional recovery was seen with the drugs when there was no
rehabilitation, making this treatment potentially useful for stroke patients who cannot
undergo rehabilitation. The Forelimb Asymmetry test for the motor function was refined
so that it showed greater sensitivity and correlated better with results from the Montoya’s
staircase grasping test. Finally, the potential mechanisms by which the pharmacological
treatment works to aid recovery were investigated, exploring any putative sex-specific
pattern of gene expression in the peri-infarct region in male and female rats at post-stroke
day 7. A preliminary genetic analysis along with protein-protein interaction prediction
reveal a fundamental role of animal sex in the response to drug treatment. The study shows
a variation in the influences of the drug on pro- and anti-inflammatory biomarkers of
microglia, regulation of neurotrophic factors and synaptic plasticity, with a new possible
role of a neuropeptide Orexin and receptors in mediating the functional recovery in male
rats.
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CHAPTER I
INTRODUCTION

1.1 Stroke and its Current Treatment
Stroke is a life-threatening medical condition that occurs when the normal blood
supply to the brain is interrupted. There are two main types of strokes: ischemic, which
happens when a thrombus or embolus blocks a cerebral artery supplying blood to the brain.
This leads to deprivation of oxygen and nutrients to one area of the brain followed by
cellular death in the affected area. The second type of stroke is hemorrhagic, which occurs
when a weakened blood vessel ruptures and leaks either near the surface of the brain
resulting in subarachnoid hemorrhage or into the tissue deep within the brain, as in
intracerebral hemorrhage. In addition to these two forms of stroke, a transient ischemic
attack (TIA), known as a mini-stroke, may occur as a short-term episode of transient
neurologic dysfunction when the blood supply to part of the brain is briefly interrupted.
The TIA is considered a warning sign of stroke risk.
According to the American Heart Association, stroke is the fifth-leading cause of
death in the United States (Mozaffarian et al., 2016). The majority of strokes, ~ 87%, are
ischemic (Rosamond et al., 2008). In ischemic stroke, there is an immediate loss of neurons
after the initial insult depends upon where the stroke was, resulting in permanent damage
to the brain, and increasing the risk of long-lasting disabilities (Saver, 2006). Stroke can
affect people of all ages and backgrounds. In the United States, every 40 seconds someone
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has a stroke and, on average, every 4 minutes one American dies of a stroke (Mozaffarian
et al., 2016). Approximately 800,000 strokes occur every year in the United States.
Depending on the location of stroke and severity of the attack, patients may experience
serious problems with speech, walking, seeing, and understanding. The condition can
potentially be fatal if not timely treated. The estimated annual direct and indirect costs
associated with stroke treatment in the United States was $71.55 billion in 2010 and that
expected to double by 2030 (Mozaffarian et al., 2016).
Ischemic stroke is a leading cause of the majority of long-term disabilities. One
ongoing cardiovascular cohort study, the Framingham study, shows that survivors of an
ischemic stroke who were at least 65 years of age experienced serious disabilities after
stroke (Gore-Felton et al., 2003). Some of the limitations observed were muscular
weakness on one side of the body, inability to walk, aphasia, depression, and dependence
in daily living tasks.
Intravenous thrombolysis with recombinant tissue plasminogen activators (rt-PA),
such as alteplase, reteplase, and tenecteplase, are the only FDA-approved pharmacological
therapies available for ischemic stroke. These clot buster medications are believed to be
effective in breaking up blood clots if given within 3 to 4.5 hours after symptom onset
("Tissue plasminogen activator for acute ischemic stroke. The National Institute of
Neurological Disorders and Stroke rt-PA Stroke Study Group," 1995). However, a recent
review indicated uncertainty for the short time window data; and recommended reevaluating the safety and efficacy of the treatment within that time window (Alper,
Malone-Moses, McLellan, Prasad, & Manheimer, 2015)
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Stroke sufferers arriving at a hospital outside of this therapeutic window may not
be eligible to receive the therapy, as later application results in hemorrhagic transformation
(Lees et al., 2010). Unfortunately, only a small percentage of stroke patients reach the
hospital in time to be considered for the clot buster (Wahl & Schwab, 2014). Patients
presenting within 48 hours of symptom onset are given the anti-coagulant agent, aspirin,
to keep blood clots from forming and to reduce the risk of early recurrent ischemic stroke.

Figure 1. Mechanism of action of recombinant t-PA (Adapted from (Chhabra, 2014)

According to the guidelines from the American Heart Association/American Stroke
Association for the initial management of patients with acute ischemic stroke, intravenous
rt-PA (such as Alteplase) can only be given to a selected group of patients within a short
time window of the onset of stroke symptoms (Del Zoppo, Saver, Jauch, Adams, &
American Heart Association Stroke, 2009). Patient must be under 80 years of age, have no
history of previous stroke or diabetes, not be taking any oral anticoagulant medications, or
have an NIH Stroke Score greater than 25 (Adams et al., 2007). The National Institutes of
Health Stroke Scale, or NIH Stroke Scale (NIHSS) is a tool used by healthcare providers
to objectively quantify the impairment caused by a stroke. The use of rt-PA in stroke
3

patients beyond that therapeutic time frame could lead to potential side effects such as
bleeding complications and angioedema (Miller, Simpson, & Silver, 2011). Currently, less
than 8.5% of patients are able to take the only available pharmacological treatment, rt-PA,
within the required time after the onset of stroke symptoms (A. M. Corbett et al., 2015).
This limitation has necessitated studies to come up with a more efficient treatment that is
readily available and can be delayed over four and half hours.
Even with the success of endovascular therapy, in which a clot is removed under
direct angiographic visualization as in the MERCI retriever (Mechanical Embolus
Removal in Cerebral Ischemia), intravenous rt-PA within the first 4.5 hours remains the
standard of care. That is because not all patients are suitable candidates for MERCI
retriever and sometimes even ideal candidates have major complications after a mechanical
removal of the thrombus. Endovascular therapy is for patients who have (NIHSS) ≥ 6 and
demonstrated large occlusion in middle cerebral artery, internal carotid artery, or anterior
cerebral artery on imaging. For these reasons, there is a pressing need to identify a
pharmacological therapy that can safely be administered beyond that short time window
for the majority of stroke patients.
For fifteen years after rt-PA was approved, several experimental studies failed to
translate their data into clinically useful neurorestorative therapies for acute ischemic
stroke (Dirnagl, 2006). The majority of these preclinical studies were performed using
rodent models of permanent or transient focal cerebral ischemia in which induction of
middle cerebral artery occlusion (MCAo) is done by insertion of a surgical filament into
the external carotid artery to block the middle cerebral artery at its origin (Longa,
Weinstein, Carlson, & Cummins, 1989). This widely used model, however, is susceptible
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to issues of anatomical accuracy and requires careful practice to avoid surgical
complications, such as damage to adjacent tissues and bleeding. In addition, the MCAo
model produces a larger infarct volume in animal brain and always have a higher mortality
rate in aged rats, which limit the assessment of functional disabilities in adult animals after
stroke (R. Y. Wang, Wang, & Yang, 2003).
In 2011, a randomized, double-blind placebo-controlled trial called FLAME
(Fluoxetine in Motor Recovery of Patients with Acute Ischemic Stroke) examined the
influence of the anti-depressant selective serotonin reuptake inhibitor, fluoxetine, on
functional motor recovery after acute ischemic stroke (Chollet et al., 2011). This study led
to a fundamental change in ischemic stroke treatment and re-ignited hope that this drug
could improve motor recovery and reduce post-stroke disabilities. Experimental studies in
our lab have shown that administration of a drug combination consisting of the antidepressant fluoxetine and the cholesterol-lowering drug simvastatin in addition to Lascorbic acid (Vitamin C), in an adult rat model of ischemic stroke 20-26 hours after
symptom onset, successfully improves motor recovery and reduces functional impairment
in the rats. Furthermore, the drug combination significantly increased neurogenesis up to
19-fold in treated animals versus controls (A. M. Corbett et al., 2015). The underlying
mechanisms by which this drug combination works to enhance functional motor recovery
in stroke patients are not at all clear. Based on animal studies in our laboratory and others,
there are some potential mechanisms whereby fluoxetine might augment functional
recovery in ischemic brain. These include stimulation of neurogenesis, where a robust pool
of newly generated neurons migrate to ischemic areas; stimulation of angiogenesis;
regulation of neurotrophic factors; and synaptic plasticity (Siepmann et al., 2015).
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A modified procedure to induce focal ischemic stroke by endothelin-1 (A. M.
Corbett et al., 2015) was performed in these animals to produce relatively small infarcts
compared to the widely used model of MCAo with a gradual injury perfusion similar to
that in humans. A post-stroke drug combination of fluoxetine and simvastatin, in addition
to L-ascorbic acid (FSA), was orally delivered in a stress-free environment to improve
functional motor recovery after stroke and to complement the limited availability of the
only available pharmacological therapy, tissue plasminogen activator (tPA) (A. M. Corbett
et al., 2015).
By reviewing pre-clinical studies on stroke, there are gaps in previous research that
contributed to the unsuccessful translation. Some questions were asked: What would be the
best animal model with biological similarities to the human brain that can efficiently
simulate the pathological

processes after

ischemic stroke?

How could

we

design appropriate methodologies to mimic the clinical situation closely? The lack of
translation could not be entirely attributed to the choice of animal model, but also in how
such models and their resultant data are applied (Howells et al., 2010).
1.2 Problems with Translating Pre-Clinical Animal Studies to Human Clinical Trials
Despite tremendous investments in advancing translational stroke research, many
pre-clinical studies failed in translating their findings from animal studies into human
clinical trials, thus have not been adopted into clinical practice. The main factors causing
the failures of neuroprotective treatments have been explained in the STAIR (Stroke
Therapy Academic Industry Roundtable) guidelines for preclinical stroke trials (Stroke
Therapy Academic Industry, 1999). The factors include inappropriate time windows of
drug administration, ineffective dose, using medications that can not cross the blood-brain6

barrier, the age of the animal is young, morbidities and mortalities in young animals, and
the heterogeneity of stroke subtypes in patients. In addition to animal age, sex bias is
another essential factor that should be considered when translating research from
preclinical studies. Young male animals are usually employed in preclinical studies (Beery
& Zucker, 2011). Some other explanations of this unsuccessful translation could be related
to poor experimental design: lack of randomization or using inappropriate animal models
that do not accurately mimic the disease condition in a human. An example of poor
experimental design is choosing animal strains for particular study without taking into
account the variation in their drug metabolism, which can lead to an unclear conclusion
regarding the efficacy and toxicity of the medicine treatment. Moreover, not all animal
models used for inducing focal ischemic stroke have brain blood vessel collateralization
that mimics human cerebral vasculature. Also, using ineffective assessment methodologies
along with inappropriate statistical analyses may contribute to the failure of research
translation. The number of animals that are employed in the experimental studies is
imperative, an inadequate statistical power when few animals are used, along with
inaccurate statistical analyses can substantially influence results. A publication bias is
another important factor contributing to this failure (S. Liu, 2009). Studies suggest that
research directions of authors and reviewers (Joyce, Rabe-Hesketh, & Wessely, 1998),
conflicts of interest (Perlis et al., 2005), research funding sources (Liss, 2006) are few
examples of factors influencing publication bias.
1.3 Randomization in Animal Studies
A growing body of evidence is indicating that randomization and blinding outcome
assessment in pre-clinical studies can minimize the potential risk of bias (Bath, Macleod,
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& Green, 2009). Some of the key solutions to avoid any possible biases are random
assignment of test animals to experimental and control groups without any prejudice. Being
blinded to groups in functional assessments and when evaluation and analysis performed
is vital. No information should be known to the observer who performs the analysis besides
animal’s number. In our experiments, we have controlled for bias, and we have tried to be
as objective as possible. In cases where there may be some subjectivity in the observation
(e.g. examining whether only tips of fingers or palms of the hand are touching a wall in
Forelimb Asymmetry tests), we typically use one observer to perform an entire series of
evaluations, so the same bias is present throughout a study. To confirm that a proposed
change in methodology is reliable, we have multiple different observers use the same
method and evaluate the results across the different monitors to determine the inherent
variability due to subjectivity.
1.4 Animal Models of Stroke and Age of Model
Animal models are essential to preclinical stroke research. Due to the complexity
of interactions in the brain vasculature during the stroke, there is no in vitro model that can
properly mimic these complicated pathophysiological mechanisms in humans. We chose
rats as rodents are one of the most relevant animal models used in stroke research (Casals
et al., 2011). Rats have been employed in stroke research due to their close resemblance to
cerebrovascular physiology and anatomy to human, and reproducibility of stroke damage
(Ginsberg & Busto, 1989). Nevertheless, no single animal model can precisely represent
the variables affecting ischemic stroke patients (Bacigaluppi, Comi, & Hermann, 2010).
We previously have done multiple studies on different strains of rats such as: Fisher, LongEvans, Wister, and Sprague-Dawley, to determine which one would make a better model
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of the medical situation in humans. The majority of stroke studies are conducted using
young animals which might react differently to stroke injury by initiating spontaneous
neurogenesis (Casals et al., 2011). A large number of preclinical studies on stroke use 2month-old animals (100 grams) with MCAo method of stroke induction for preclinical
studies on ischemic stroke. In contrast to these studies, we utilized a group of 10-12-monthold rats (400-600 grams) because they have more similarity to human patients, who in most
cases are middle-aged or older. Also, neurogenesis typically decreases with age (Walter,
Keiner, Witte, & Redecker, 2011), hence requiring the drugs to be tested under similar
conditions in both rats and humans. In our lab, adult male and female Sprague-Dawley rats
were favored over all other strains for their brain blood vessel collateral circulation
resembles that in people and because of the animal age correlates with the middle-aged
person in clinical trials.
1.5 Sex-dependent Differences
Increasing evidence suggests that an animal’s sex may influence the results of
stroke studies by multiple mechanisms, therefore animal’s sex is a potentially informative
consideration for the development of new pharmacological treatment for stroke. The
effectiveness of the drug may vary depending on animal sex (K. Li et al., 1996). A study
indicated that there are sex differences in rat and mouse brains; and that gonadal hormones
modulate prostaglandins (PGE2) in brain. (Dean, Knutson, Krebs-Kraft, & McCarthy,
2012). The PGE2 regulates the response to injury after stroke with female rats showing
better outcomes than males to the same injury. An experimental study using MCAo models
of stroke has demonstrated that female rats have a prominently reduced infarct volume
compared with male rats, and ovariectomized rats have infarct volumes that are similar in
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size to male rats (Alkayed et al., 1998). Female steroid hormone estradiol plays a role in
this neuroprotective effect in rats. Studies showed that administration of exogenous
estrogen decreases infarct volume size in both male and female rats (Toung, Traystman, &
Hurn, 1998). An interesting study showed that the amount of hydrogen peroxide produced
by macrophages from male mice is more than female animals, and causing more tissue
damage than macrophages from females (Y. Chen & Johnson, 1993). A study on human
granulosa-luteal cell culture demonstrates that high concentrations of estrogen inhibit the
activity of the inflammatory interleukin-1 (IL-1). IL-1 is a highly inflammatory molecule
released early in ischemic tissue, which activates many inflammatory processes through
activation of T cells and induce expression of acute-phase proteins. IL-1 plays a role in the
neuronal injury that occurs following stroke (Polan, Daniele, & Kuo, 1988).
We examined the drug combination, FSA, in both male and female animals to
explore possible sex-de pendent changes in response to treatment. The findings are
presented in details in the results section.
1.6 Post-Stroke Physical Rehabilitation
One of the criticisms of stroke work in animal studies is that they do not include
physical rehabilitation, whereas human stroke patients undergo some form of
rehabilitation. Choosing the right animal model of rehabilitation is important when
interpreting results. We used Sprague-Dawley rats for the similarities to the neurovascular
branching and the limb movements of the human arm (Yamori, Horie, Handa, Sato, &
Fukase, 1976) and (Whishaw et al., 2002). One rehabilitative method that encourages the
use of impaired limb while constraint the unaffected limb called constraint-induced
movement therapy (CIMT). This technique was developed by Taub et al. (Taub, Uswatte,
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Mark, & Morris, 2006). Studies showed that CIMT after stroke can improve functional
reorganization and plasticity of the brain in the adult rats (Qu et al., 2015); and in stroke
patients (Nijland, Kwakkel, Bakers, & van Wegen, 2011) and (Wittenberg et al., 2003).
However, other studies showed that this technique of rehabilitation increases animal stress
which decreases neurogenesis (Livingston-Thomas, Hume, Doucette, & Tasker, 2013) and
(Yanagita, Amemiya, Suzuki, & Kita, 2007).
We are one of few laboratories that examined whether post-stroke voluntary
rehabilitation could enhance functional recovery in the impaired limb. Other studies used
enriched environments to improve cognitive and social stimulation and enhance poststroke recovery following stroke (Biernaskie & Corbett, 2001) and (Janssen et al., 2010).
Although these studies may contribute to our understanding of the mechanisms of
neuroplasticity, the intensity of initiated rehabilitation might not be enough to produce the
desired effect. We have tested the impact of physical rehabilitation at different intensities
on recovery with and without drug treatment. The findings from our studies are interesting
in that they mirror some observations about rehabilitation from human clinical trials when
evaluating the intensity of physical rehabilitation, and show that our drug combination may
work equally well without rehabilitation (see Results section on Physical Rehabilitation).

1.7 Functional Tests in Animal Studies
Measuring the level of impairment and the influence of post-stroke treatment on
motor recovery in animal models relies heavily on the applied functional assessment
methods. To improve the translation of experimental therapies into clinical trials,
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appropriate methods of functional measurements should be used to assess what is in the
real-life clinical setting (Macrae, 2011). Due to the range of deficits that accompany
ischemic stroke, a diversity of sensitive functional tests is needed. The chosen tests should
precisely reflect the extent of deficit after ischemic stroke, and demonstrate the level of
recovery reached by treatment. Different functional tests have been used in stroke research
to assess deficits associated with ischemic stroke in rodent models. Table 1 and 2 show
animal behavioral tests with a strong or weak resemblance to functional tests in human
(Schaar, Brenneman, & Savitz, 2010).

Table 1. Animal behavioral tests with a strong resemblance to human trials.
Functional Test

Function

Forelimb Asymmetry Test

Measures spontaneous forelimb use and placing deficits

Montoya Staircase Test

Assesses forelimb extension, grasping skills, side bias and
independent use of forelimbs

Grid Walking

Measures sensorimotor function, motor coordination and
placing deficits during locomotion

Reaching Chamber

Measures skilled forepaw use and motor functioning

Pasta Test

Evaluates manual dexterity and fine motor skills

Ladder Rung Walking test

Measures stepping, placing and coordination

Corner Test

Evaluates sensorimotor and postural asymmetries

Composite Scores

Evaluates a variety of motor, sensory, reflex and balance
responses
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Table 2. Animal behavioral tests with a less resemblance to human trials.
Functional Test

Function

Ledged Tapered Beam

Assesses hindlimb functioning

Accelerated Rotarod

Measures motor coordination and balance

Adhesive Removal

Assesses tactile responses and asymmetries

Morris Water Maze

Measures spatial learning and memory (humans use
location cues to find places everyday but the test is not
applicable to human)

1.8 Methods for Post-Stroke Assessment of Motor Function in Clinical Trials
To increase the odds of translation of results from pre-clinical animal studies to
human clinical trials, only accurate and reliable behavioral tests that mimic functional tests
in clinical trials should be performed. In clinical studies, there are different ways to
measure motor function and independence in activities of daily living (ADLs). One of the
major criticisms of pre-clinical stroke studies in animals is that the post-stroke functional
tests bear no resemblance to standard functional tests given to human stroke patients. In
the previous section, I have evaluated whether certain post-stroke functional tests bear any
resemblance to clinical tests performed on post-stroke patients. In this section, I will give
more detail about what the major stroke tests for humans entail.
1.8.1 Modified Rankin Scale (mRS)
The Modified Rankin Scale (mRS) is one of the most commonly used methods to
measure recovery in human stroke patients (Rankin, 1957), (Bonita & Beaglehole, 1988).
This test uses a questionnaire to assess patient functional status and the ability of the patient
to perform everyday life tasks by asking simple questions to both patient and caregiver.
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A free Modified Rankin Scale calculator called mRS-9Q is available online (Patel
et al., 2012). One of the ADL tasks evaluated in the mRS pertains to the ability of the
patient to grasp an object and move it. A parallel behavioral assessment in animals includes
Montoya Staircase. In this assessment the ability of each animal to grasp and hold onto an
object with either forepaw is quantified and analyzed in order to evaluate gross arm
movement, hand clasping, and fine finger movement control.
Table 3. Modified Rankin Scale (mRS) (Rankin, 1957).

Another assessment criterion in the mRS is the balance and strength of affected
arm, and the ability of the patient to use hands to support the entire body weight when
getting into and out of a chair. This test aims to recognize abnormal function and determine
whether patients are getting back to their normal function by doing the daily activities or
not. We utilize Forelimb Asymmetry analysis to evaluate animal functional recovery based
on the animal use of full palm to support their body weight when they rear up and explore
the cylinder wall (See Methods section). In our modified Forelimb Asymmetry analysis,
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we define forelimb function by the placement of the whole palm on the wall of the cylinder
that indicates its use for body support. We do not count a half touch (fingertip touch) as a
sign of getting back to normal function but as an indicator of injury.
1.8.2 Fugl-Meyer Assessment (FMA)
The Fugl-Meyer scale is used to evaluate and measure motor recovery in poststroke hemiplegic patients (Fugl-Meyer, Jaasko, Leyman, Olsson, & Steglind, 1975). It has
been widely used in stroke patients. The test is designed to assess impairment in motor
functioning, sensation, balance, joint range of motion and joint pain (See Appendix I for
full protocol). Each is scored on a 3-point ordinal scale, in which 0 = cannot perform; 1 =
performs partially and 2 = performs fully. The motor score ranges from 0 to 100 points,
which indicate hemiplegia or normal motor performance, respectively. Out of 100 points,
66 points are for the upper extremity. This includes forearm supination/pronation, wrist
flexion/extension, and tennis ball grasping, grasping of a cylinder and finger flexion
(Duncan et al., 1994).
Table 4. Standard methods for post-stroke assessment of motor function and global
disability. Information obtained from “Post-Stroke Rehabilitation: Assessment,
Referral, and Patient Management Quick Reference Guide” by the US Agency for
Health Care Policy and Research.
Assessment scale
Modified Rankin
Scale (mRS) for
global disability

Approximate time
to administer
5 minutes

Fugl-Meyer
30-40 minutes
Assessment (FMA)
(Fugl-Meyer et al.,
1975)

Strengths
Overall assessment of
disability.

Excellent validity and
reliability for assessing
sensorimotor function
and balance.
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Weaknesses
Walking is the
only explicit
assessment
criterion. Low
sensitivity.
Very complex
test and timeconsuming

Depending on the severity of the stroke and its location, both dexterity and
coordination might be impaired on the contralateral side, and sometimes on the ipsilateral
side if the deficit is bilateral. Upper limb reaching, grasping and withdrawing are natural
movement skills organized by the cerebral motor cortex. Many neurons interact with spinal
circuits to regulate these locomotor movements. Brain damage to the motor cortex often
impairs the contralateral arm and can affect these movements.
An experiment by Whishaw et al. (See Figure 2) evaluated rat forelimb reaching
using a comparative scale to that used to evaluate human performance (Whishaw,
Whishaw, & Gorny, 2008). Each forelimb reach was divided into ten movements that were
rated on a 3-point scale. Damage to the motor cortex, basal ganglia, brainstem, and spinal
cord alters these movements (Leisman, Braun-Benjamin, & Melillo, 2014). Disruption of
corticospinal connections leads to impairment of skilled finger, hand and arm movements.
One common post-stroke motor deficit is impairment in fine motor movement and
extension of the fingers (Trombly, Radomski, Trexel, & Burnet-Smith, 2002), however,
the mechanisms of this weakening are not well understood. A comparative analysis that
was performed on 21 species, including rats, indicates a similar role of the corticospinal
tract in the evolution of digital dexterity among all examined species (Heffner & Masterton,
1983). Therefore, rehabilitation that improves fine motor control and digit strength would
greatly enhance the lives of stroke patients. Here we examine rat forearm extension/reach,
(Montoya Staircase using advance, pronation, and grasping; and Forelimb Asymmetry
using touching and stabilizing) in order to evaluate the potential benefit of drug therapy or
rehabilitation on forearm and digit movements post-stroke.
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Figure 2. Similarities of hand shaping movements and position of the digits and wrist
in rat and human subjects during a reaching movement. Adapted from (Sacrey,
Alaverdashvili, & Whishaw, 2009).
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1.9 Neurogenesis after Stroke
In order to develop an effective treatment for stroke, the acute and chronic events
that are involved in ischemic stroke, as well as the associated mechanisms, must be clearly
understood (Hossmann, 2006). One of the devastating effects of stroke is the loss of the
neuronal circuitries, which support cognitive and sensory-motor capacities, due to neuronal
cell death and dysfunction. This could lead to severe disabilities. During the first 3-6
months following a stroke, patients might be able to regain some neurological abilities, but
a majority of patients stay impaired to a critical degree (Duncan, Jorgensen, & Wade,
2000). It is now known that when an individual experiences a stroke, the brain sends
signals to stem cell populations to divide and to move immature neurons to areas of damage
in a process of neurogenesis. This process is most active during embryonic development.
It was believed that adult brain is a physiologically static organ incapable of regeneration;
however, neurogenesis has been shown to continue in two locations in the adult brain: the
subventricular zone (SVZ) of the lateral ventricles, and the subgranular zone (SGZ),
forming part of the dentate gyrus (DG) of the hippocampus (Barlow & Targum, 2007). A
resident population of neural stem/progenitor cells can provide a source of new neurons
(Elder, De Gasperi, & Gama Sosa, 2006).
After ischemic insult, recruitment of neural precursor cells from the major stem cell
niches within the subventricular zone (SVZ) and the subgranular zone (SGZ) of the dentate
gyrus into the damaged area are imperative compensatory responses in ischemic brain
(Arvidsson, Collin, Kirik, Kokaia, & Lindvall, 2002). Neuronal proliferation within the
subventricular zone has been shown to peak between 7 and ten days followed by a decline
in proliferation activity during three weeks post-stroke (Parent, Vexler, Gong, Derugin, &
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Ferriero, 2002). However, this therapeutic response is insufficient to support a full recovery
after stroke due to the limited survival of newly formed neuroblasts that migrate to the
damaged area.

Figure 3: Intrinsic programs and external factors controlling adult neurogenesis.
Adapted from (Lledo, Alonso, & Grubb, 2006).

Stroke incidence triggers neurogenesis by stimulating neural progenitor cells of the
SVZ to divide and migrate to the peri-infarct area (Arvidsson et al., 2002). It is possible
that radial microglia are involved with guiding migration of neuroblasts to the ischemic
brain tissue (Cao et al., 2013). There is evidence that neurogenesis is linked to angiogenesis
(Ohab & Carmichael, 2008), which is a process of forming new blood vessels to enhance
vascularization of the surviving neuronal cells (Greenberg & Jin, 2005). For up to four
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months of brain damage, neuroblasts are continuously produced in neurogenic areas
including the subventricular zone (SVZ) leading to a pool of cells that can develop into
fully grown neurons (Thored et al., 2007). On the other hand, neurogenesis is inhibited by
inflammation that occurs during stroke recovery (Jakubs et al., 2006). Neuronal, glial, and
endothelial progenitor cells release growth factors that support synaptic plasticity of
surviving neurons (J. Chen et al., 2005).

1.10 Drugs Used for our Studies
In an attempt to boost the recovery of ischemic brain, we tested a combination
therapy of two FDA-approved drugs as a potential delayed post-stroke treatment. These
include simvastatin (Zocor) and fluoxetine (Prozac), in addition to L-ascorbic acid
(Vitamin C). The drug combination showed an increase in anterior subventricular
neurogenesis and neurotrophic factors in both male and female animal models of ischemic
stroke, as well as enhanced neuronal survival and plasticity (A. M. Corbett et al., 2015).
Some studies examining fluoxetine’s effect on neurogenesis employed a synthetic
nucleoside, bromodeoxyuridine (BrdU), to determine whether the brain is undergoing
neurogenesis (Malberg, Eisch, Nestler, & Duman, 2000). These studies, however, are only
evaluating the posterior sub-ventricular zone in the same slices as those of the dentate
gyrus. The fact that this area is more caudally located than the previously examined area
may explain why these studies did not highlight any effect of fluoxetine on neurogenesis.
Fluoxetine is widely prescribed to treat depression and other mood disorders by blocking
the presynaptic reuptake of serotonin. Simvastatin is a cholesterol-lowering drug that
belongs to a group of drugs called HMG CoA reductase inhibitors. Vitamin C (L-ascorbic
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acid) is an anti-oxidant that is added to the mixture to enhance the effect of the
antidepressant and because of the serotonin sensitivity to oxidation. Statins have been
shown to up-regulate the brain-derived neurotrophic factor (BDNF), which is a member of
neurotrophic factors that mostly participate in nervous system development. The
mechanism by which statins influence the BDNF up-regulation is mediated by an
endothelial nitric-oxide synthase (eNOS) enzyme. Vitamin C enhances the catalytic
activity of this enzyme through an unclear mechanism(s) (Huang, Vita, Venema, &
Keaney, 2000). Each drug was chosen to contribute unique mechanisms when combined
in the mixture to improve outcomes. Neurogenesis and BDNF are believed to be involved
in the recovery of function following stroke.
The initial experiments on this drug combination were conducted on Westar male
sham stroke rats that received different combinations of fluoxetine, simvastatin, and Lascorbic acid to assess the impact of drug combination on neurogenesis versus controls. A
mix of the three drugs significantly increased neurogenesis nineteen times compared to
either the control or simvastatin and ascorbic acid. Fluoxetine alone producing a 10-fold
increase in neurogenesis, approximately half of that seen with the drug combination (A.
M. Corbett et al., 2015). A combination of low dose (0.5 mg/kg) simvastatin and 20 mg/kg
L-ascorbic acid treatment showed no increase in neurogenesis over controls. However,
when both were added to 5 mg/kg fluoxetine, neurogenesis nearly doubled over that when
using fluoxetine alone in male sham-operated rats. The combination of drugs produced a
synergistic effect rather than additive. Both simvastatin and fluoxetine are FDA-approved
drugs that have been around for many years, so there is ample information on the
pharmacokinetics, metabolites, and elimination of each.
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Evaluation of the fluoxetine, simvastatin, and ascorbic acid compared to fluoxetine
and ascorbic acid tested in functional recovery of female Long Evans rats post-stroke
suggested that simvastatin and fluoxetine are both crucial to the most effective drug
combination, though currently, it is not clear whether the L-ascorbic acid is essential in
female rats. In these experiments, combining fluoxetine with L-ascorbic acid showed no
increased functional recovery over fluoxetine alone in female rats after stroke induction.
Whereas the addition of both simvastatin and L-ascorbic acid to fluoxetine showed
approximately 2-fold increase over fluoxetine alone in functional recovery, which
paralleled nicely the increase in neurogenesis that we observed in the subventricular zone.
Taken together, this suggests that both fluoxetine and simvastatin are the key players to
increasing neurogenesis and functional recovery over fluoxetine alone. Studies that have
used rats to evaluate BDNF production after ischemic stroke have shown BDNF expression
to rise for a limited time (eight days after a stroke) (Kokaia, Andsberg, Yan, & Lindvall,
1998), (Bejot et al., 2011). However, our delayed drug treatment (fluoxetine in addition to
L-ascorbic acid) increased BDNF expression near the peri-infarct area 31 days after stroke.

1.10.1 Fluoxetine
Racemic fluoxetine ( N-methyl-3-phenyl-3-[4- (trifluoromethyl) phenoxy]propan1-amine), also known by trade name Prozac, is a selective serotonin reuptake inhibitor
(SSRI) that was approved by the FDA for use in clinical practice since 2000. It is used to
treat major depression and other mood disorders such as panic disorder, obsessive–
compulsive disorder (OCD) and bulimia nervosa. Fluoxetine crosses the blood–brain
barrier (Warren, 2012), and studies showed fluoxetine to increase the expression of BDNF,
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which plays a role in neurogenesis (Schabitz et al., 2007) and enhances cognition in
patients with vascular dementia (X. Liu et al., 2013).

Figure 4. Chemical structure of fluoxetine

1.10.2 Pharmacokinetics of Fluoxetine
Fluoxetine binds with high affinity to plasma proteins such as albumin and α1glycoprotein, and is metabolized in the liver by isoenzymes of the cytochrome P450 system
(CYP2D6) to its active metabolite norfluoxetine (Alfaro, Lam, Simpson, & Ereshefsky,
2000). Plasma concentrations of fluoxetine and its metabolite, norfluoxetine, peak in 6 to
8 hours after oral administration. Using high-performance liquid chromatography (HPLC)
method, we were able to detect fluoxetine and norfluoxetine in brain homogenate after
seven days of single dose oral administration (A. Corbett, McGowin, Sieber, Flannery, &
Sibbitt, 2012). Pharmacokinetic studies in rats show that distribution of the drug into tissues
is similar to that in humans with faster elimination time in rats (4-7 hrs) (Benfield, Heel, &
Lewis, 1986). In our study, the plasma levels of fluoxetine and norfluoxetine were
detectable within 2 to 4 hours of ingestion, but not after 24 hours.
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The elimination rate of fluoxetine and norfluoxetine in human is slow compared to
other antidepressants due to the ability of drugs to inhibit their metabolism mediator
(CYP2D6). Thus elimination half-life ranges from 1-3 days, after a single dose, to 4-6 days,
after long-term use (Ouellet et al., 1998). The brain to plasma ratio of fluoxetine in patients
is 2.6:1 (Strauss, Layton, Hayes, & Dager, 1997) .
Numerous experimental studies have raised as many questions as they provide
answers about the efficiency of fluoxetine in treating post-stroke deficits. Some of these
studies showed SSRIs (fluoxetine in particular) as an active agent in producing functional
recovery after focal brain injury in rat models (Windle & Corbett, 2005). Few pre-clinical
studies showed fluoxetine effectiveness on infarct size and demonstrated a potent
neuroprotective action of the drug through its anti-inflammatory action on microglia (Lim
et al., 2009). Moreover, fluoxetine has been shown to improve ischemia-induced spatial
cognitive deficits in rats through increasing hippocampal neurogenesis after stroke (W. L.
Li et al., 2009).
Although many previous studies provided convincing evidence that selective
serotonin reuptake inhibitors (SRRIs) are useful in the recovery process in animal models
of stroke, the drug can have varying effects on neurogenesis and overall recovery based on
animal age and sex. Moreover, the timing of drug administration is a paramount factor; an
appropriate therapeutic time window should be established in animal models. Also, the
method of drug administration has a significant influence on the outcome, as stress would
antagonize the effects of fluoxetine on the brain (Balch et al., 2015).
The FLAME clinical trial (Fluoxetine in Motor Recovery of Patients with Acute
Ischemic Stroke), which was published in 2011 in THE LANCET neuro has shown that
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the anti-depressant fluoxetine could help repair the damage caused by stroke and improve
functional motor recovery in patients. The study was conducted in ischemic stroke patients
with hemiparesis at nine stroke centers in France. A total of 113 stroke patients from
different stroke centers across France were enrolled in the trial and randomized to
fluoxetine (N = 57) or placebo (N= 56) groups for 90 days. Fluoxetine (Prozac) 20 mg/day
or placebo was delivered for three months starting five to ten days after stroke onset.
Following the FLAME trial, most of the stroke studies that examined SSRIs’ effects on
motor recovery have been conducted using fluoxetine more than other SSRIs, such as
citalopram, sertraline, paroxetine, and escitalopram (Mead et al., 2013).
In this trial, the primary outcome was mean change in the Fugl-Meyer Motor Scale
(FMMS) between baseline (day 0) and day 90. Secondary endpoints were assessed by the
NIH Stroke Scale (NIHSS) and modified Rankin Scale (mRS). All patients included in this
study were aged 18-85 years. The mean age of patients was 66.4 years in the fluoxetine
group and 62.9 years in the placebo group. The study reported that at three months, 15
(26%) of acute stroke patients who received fluoxetine and 5 (9%) of patients allocated to
placebo had a modified Rankin score (mRS) between 0 and 2, which means they can
perform daily activities with no dependency on other people.
Some ongoing large-scale trials have continued to examine the effectiveness of
fluoxetine when given 2-15 days following stroke onset. These include the AFFINITY
(Assessment of Fluoxetine in stroke recovery) trial in Australia, the FOCUS (Fluoxetine
or control under supervision) trial in the United Kingdom, and the EFFECTS (Efficacy of
Fluoxetine – a randomized controlled trial in stroke) in Sweden (Mead et al., 2013).
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The promising results of the FLAME clinical trial provided clear evidence of the
role of fluoxetine in stroke recovery independently of depression when given to ischemic
stroke patients. However, the mechanisms involved in recovery from stroke or dementia
are not entirely understood (Dam et al., 1996).
Fluoxetine has neuroprotective properties that may be associated with its antiinflammatory effects (D. Liu et al., 2011). A recently published study suggested a
neuroprotective role of fluoxetine in ischemic stroke through changing inflammatory
activated microglia into a neuroprotective activated microglia in a process called microglia
polarization (Su, Yi, Xu, & Zhang, 2015). The study was conducted in vitro on both
primary microglia cells and murine microglial cell line (BV-2) and demonstrated that
fluoxetine significantly down-regulates the gene expression and protein production of proinflammatory mediators (M1 activation indexes) while up-regulating the M2 activation
indexes (neurotrophins, Stat 3, Stat 6, arginase expression) in both cell line and primary
cells. Nonetheless, in vitro studies do not necessarily correlate with in vivo efficacy. A
study in a rat cerebral ischemia model of middle cerebral artery occlusion indicated an antiinflammatory role of fluoxetine through suppression of microglial activation and
neutrophil infiltration (Lim et al., 2009). To assess these findings, we developed our
customized PCR arrays (Custom RT2 PCR Array from Qiagen) with 38 genes of interest
that have been shown to be differentially expressed in inflammation in response to
activation of different types of microglia. Most pharmacological studies have been
conducted using a racemic form of fluoxetine, however, increasing evidence indicates that
the enantiomers of racemic drugs often differ markedly in their pharmacodynamic and
kinetic properties (Williams & Lee, 1985). We tested the anti-inflammatory effects of
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racemic fluoxetine and compared the effects of its enantiomers (R (-)-fluoxetine and S (+)fluoxetine) on microglia activation using the RT2 PCR Array technique to profile microglia
markers in both female and male Sprague-Dawley rats.

Figure 5. The (R)-enantiomer and the (S)-enantiomer of fluoxetine

In addition to its beneficial effect on neurogenesis, fluoxetine also influences
angiogenesis by stimulating expression of vascular endothelial growth factor (VEGF), one
of the main neurotrophic factors that mediate angiogenesis as well as neurogenesis and
neuroprotection following ischemic stroke. This upregulation suggests a broad role of
fluoxetine in brain recovery after stroke (Gaillard & Mir, 2011). Preclinical findings in
aged mice also showed that fluoxetine induces a rise in serum concentrations of VEGF
(Kubera et al., 2009). We tested the effect of fluoxetine on neurotrophins, its receptors, and
synaptic plasticity genes.
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1.10.3 Simvastatin
Simvastatin (also known by trade name Zocor) is a cholesterol-lowering medication
that belongs to the class of drugs known as statins. Simvastatin is used mainly to treat
dyslipidemia and prevent stroke and heart attacks in high-risk individuals. It has beneficial
effects on coronary diseases (Alberts, 1990), and usually is used to reduce the risk of
cardiovascular morbidity and mortality ("Randomised trial of cholesterol lowering in 4444
patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S),"
1994).

Figure 6. Chemical structure of simvastatin

1.10.4 Pharmacokinetics of Simvastatin
After an oral dose, simvastatin is quickly absorbed and metabolized from its
inactive lactone prodrug form into pharmacologically active metabolite (simvastatin βhydroxy acid), which acts by inhibiting the enzyme 3-hydroxy-3-methylglutarylcoenzyme-A (HMG-CoA) reductase (Gotto, 1997). The HMG-CoA is a rate-limiting
enzyme of the metabolic pathway responsible for the biosynthesis of cholesterol (Pedersen,
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2010). Simvastatin undergoes extensive first-pass metabolism in the liver. The drug can
cross blood-brain-barrier. The bioavailability of simvastatin after oral administration is 5%
(about 95% is excreted), with peak plasma concentrations reached at 4 hours.
Simvastatin is known to enhance endothelial function, inhibit a thrombogenic
response and reduce oxidative stress and inflammation (Liao & Laufs, 2005). Also, statins
have been shown to provide neuroprotection against ischemic injury. The mechanisms by
which statins provide neuroprotection are not clearly understood. However, some studies
suggest statin action through upregulating of endogenous tissue plasminogen activator
(Asahi et al., 2005), and restoring endothelial nitric oxide synthase (eNOS) activity during
hypoxia. This enzyme generates nitric oxide in blood vessels that is involved with
regulating vascular function and neurogenesis (Estrada & Murillo-Carretero, 2005;
Hernandez-Perera et al., 1998; Laufs, Fata, & Liao, 1997). Others proposed a beneficial
role of statins through inhibiting inflammatory response and platelet aggregation (Sanchez
et al., 2008). Statins have also been shown to stimulate neurogenesis and angiogenesis, and
to promote new synapses formation (Rodriguez-Yanez, Agulla, Rodriguez-Gonzalez,
Sobrino, & Castillo, 2008).
Statin treatment has been shown to reduce the incidence of ischemic stroke among
people who are at high risk of cardiovascular diseases, and therefore it is recommended for
use in stroke patients to prevent recurrent stroke (Tuttolomondo et al., 2013). In addition
to their role in ischemic stroke, statins promote neurovascular recovery after hemorrhagic
stroke (Yang, Han, Zhang, Chopp, & Seyfried, 2012).
Due to its lipophilic nature (Thelen et al., 2006), simvastatin can readily cross the
blood-brain barrier and passively diffuse across the endothelial cells allowing more
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widespread tissue distribution (Wood, Eckert, Igbavboa, & Muller, 2010). Moreover,
studies have found that simvastatin upregulates growth factors such as brain-derived
neurotrophic factor (BDNF) and Vascular endothelial growth factor (VEGF), which are
important in promoting neurogenesis and angiogenesis (Yang et al., 2012), (Wu et al.,
2008). Simvastatin also reduces the infarct volume after ischemic stroke (Zacco et al.,
2003) and has the potential to protect against neuronal excitotoxicity caused by
overstimulation of glutamate receptors during an ischemic injury (Zhu et al., 2012). Recent
rodent studies suggest a beneficial role of statins when combined with tPA in extending
the therapeutic window for tPA as the combination drug improved thrombolysis of clot at
the MCA occlusion site (L. Zhang, Zhang, & Chopp, 2012). Information from pooled data
of stroke patients showed the effect of dose-related simvastatin/tPA combination on the
outcome after tPA thrombolysis for ischemic stroke. The study noticed an association
between the dosage of simvastatin (20mg, 40mg, and 80mg) and increased risk of
intracerebral hemorrhagic transformation ( 2%, 6% and 13%, respectively) (Scheitz et al.,
2014). Optimizing the dose of statins when combined with tPA is crucial to extend the
therapeutic window for tPA (Lapchak & Han, 2010). So far there is only one trial that
investigated the effect of pre-treatment with statins on brain injury in cerebral ischemia and
showed a beneficial effect of statin on reducing brain injury after stroke (Blanco et al.,
2007). The study also looked at the influence of statin withdrawal on the outcome of acute
ischemic stroke patients and recommended that statin should be continued in the acute
phase of ischemic stroke because the withdrawal was associated with increased risk of
death or dependency at 90 days due to the reoccurrence of stroke.
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1.10.5 Ascorbic Acid (Vitamin C)
Vitamin C or L-ascorbic acid is a potent reducing agent and effective antioxidant
that protects against the potential damage caused by free radicals to lipid membrane and
DNA during cell injury.

Figure 7. Chemical structure of ascorbic acid (Vitamin C)
Vitamin C can cross the blood–brain barrier in the oxidized form. This passage is
mediated by BBB glucose transporters (Agus et al., 1997). A study of tissue distribution of
vitamin C that calculated the concentration of radiolabeled ascorbic acid in mice showed
up to 3 fold increase of ascorbic acid in the brain compared to the blood concentration
(Hornig, 1975). Multiple studies have demonstrated that consumption of vitamin C rich
food can lower the risk of stroke (G. C. Chen, Lu, Pang, & Liu, 2013). However, the
findings are still inconclusive and need further investigation to understand the different
effects of dietary vitamin C and circulating vitamin C on the risk of stroke (Rabadi &
Kristal, 2007). As vitamin C is water soluble and tends to be quickly absorbed and excreted
from the body, it might be beneficial to use the slow-release (extended) formulation of
vitamin C rather than the plain-release form. As one study indicates that there are
pharmacokinetic differences between plain and slow release formulations of ascorbic acid
(Viscovich, Lykkesfeldt, & Poulsen, 2004).
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Table 5. Dosing of the Pharmacologic Agents
Drug

Our Experimental
Rat Dose

Human equivalent

Fluoxetine

Typical
Human Adult
Dose
20 mg/day

5 mg/kg

40 mg/day

Simvastatin

10-20 mg/day

1 mg/kg

8 mg/day

Vitamin C

500 mg/day

20 mg/kg

160 mg/day

1.11 Drug Delivery Method in Animal Studies
The most common routes of drug administration in laboratory animals are using
oral delivery through forced feeding tube passed into the stomach (gavage), subcutaneous,
intraperitoneal or intravenous injection. All of these methods of drug delivery are highly
stressful for animals, as they involve some restraint, which is a major stressor for rodents.
Distress due to physical restriction and morbidity are some of the common adverse
reactions associated with these procedures, and they can negatively influence the outcome.
Because stress can adversely affect neurogenesis (Sahay & Hen, 2007), and many
physiological processes such as glucose metabolism, body temperature and cerebral blood
flow (Meijer, Spruijt, van Zutphen, & Baumans, 2006), it is crucial to minimize the
unnecessary stress during drug delivery by using a reliable method of voluntary drug
administration. A study on rats that underwent gavage procedure indicates that a 32%
mortality rate was attributable to granulomatous inflammation or asphyxia caused by
impacted food and bedding material in the oropharynx (Germann & Ockert, 1994). Our
laboratory sought to eliminate these unwanted effects by developing a technique for
voluntary oral drug administration to rats using premixed drug-cookie dough balls (A.
Corbett et al., 2012). In our method, we incorporate the drug combination in a powder form
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with 4 gram of sugar cookie dough and present it to the animal in a glass dish at the same
time every day. This method allows for more drug delivery to the bloodstream than the
gavage method due to drug absorption through lingual and buccal membranes. The
voluntary oral ingestion of a drug resulted in reduced level of the stress hormone
(corticosterone) in male rats when compared to a subcutaneous injection of the same drug
(Goldkuhl, Carlsson, Hau, & Abelson, 2008).

1.12 Possible Drug Mechanism of Action
To understand the mechanisms by which the drug combination (FSA) works to
induce motor function, I consider potential pathways that might be involved in drug action.
These include:

1.12.1 Modulation of the Blood-Brain-Barrier Permeability
The Blood-brain-barrier (BBB) consists of a network of elements consisting of
brain endothelial cells connected by tight junctions, a basement membrane, pericytes and
astrocyte feet forming an interface between the brain and circulatory system (Hawkins,
O'Kane, Simpson, & Vina, 2006). The blood-brain-barrier has a high selective permeability
that separates the circulating blood from the brain extracellular fluid and allows the passage
of molecules that are essential to neural function while it protects the brain from exposure
to harmful molecules. After ischemic insult to the brain, impairment of the blood-brainbarrier integrity is a central event of the pathophysiology, in which the ischemic structural
damage causes abnormal leaks across the blood-brain-barrier (del Zoppo & Hallenbeck,
2000). Also, endothelial cells of the BBB upregulate the expression of matrix
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metalloproteases (MMPs) activation, which is a family of enzymes responsible for
degrading the extracellular matrix proteins, and protease-activated receptor 1 (PAR1) in
the ischemic area (Rosell & Lo, 2008). The pericytes are also involved in microvascular
dysfunction after stroke through constricting the obstructed vessel (Yemisci et al., 2009).
Furthermore, stroke downregulates the expression of a cell surface molecule, beta-1
integrin, which is essential for endothelial cell adhesion and migration during angiogenesis
resulting in increased BBB permeability (del Zoppo & Milner, 2006).
A recent study indicates that fluoxetine suppresses matrix metalloproteases
(MMPs) activation in adult male mice after spinal cord injury (J. Y. Lee, Kim, Choi, Oh,
& Yune, 2012). This inhibitory action prevents disruption of blood-brain-barrier after
spinal cord injury.
To investigate the effect of fluoxetine and its enantiomers (R (-)-fluoxetine and S
(+)-fluoxetine) on blood-brain barrier, we used a method for determining BBB integrity
based on intracardiac perfusion of an Evans Blue (EB) dye. Brain tissue homogenates from
the cerebral cortex and the cerebellum were examined in each male and female rat to
measure the amount of fluorescence that indicates the EB concentration. We noticed a
significant difference in the BBB permeability in both cortex and cerebellum when both
male and female rats treated with S-fluoxetine were compared to male rats treated with Rfluoxetine. Animals that received S-fluoxetine enantiomer treatment showed less BBB
permeability than the ones treated with R-fluoxetine. However, the change was not
significant among the female R- fluoxetine and S-fluoxetine groups when compared to
each other. One possible explanation of this action is that S-fluoxetine is more efficient in
inhibiting the breakdown of the tight junctions that connect endothelial cells of the BBB.
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1.12.2 Upregulation of Neurotrophins or their Receptors
Some of the potential targets of ischemic stroke treatments are growth factors,
particularly those that have been shown to get involved in promoting neural regeneration
and angiogenesis, as well as inhibiting the neurotoxicity and inflammatory process within
ischemic penumbra. Neurotrophins are a family of growth factors that prevent neuronal
damage and promote neuronal survival and repair (Y. Zhang, Zhang, Katiella, & Huang,
2014). Administration of neurotrophins in experimental animals have shown to correlate
with functional motor recovery after stroke. The potential benefit to human health that
would come from a better understanding of the regulation of neurotrophins and their
receptors after stroke cannot be overstated.
Studies have demonstrated that brain is not a static organ, and damage to the adult
brain can induce the formation of new neurons, in a process of neurogenesis that continues
throughout life (Eriksson et al., 1998). This injury-induced neurogenesis is augmented by
different types of growth factors that eventually lead to efficient brain repair and recovery
of function. In the first stages of ischemia, regenerative mechanisms in the brain are
activated in the first few hours (Rickhag et al., 2006), followed by reduced tissue edema,
some repair of injured neurons, activation of neuronal pathways and migration of
neuroblasts and glial cells into the area around infarct, known as the penumbra (Marlier,
Verteneuil, Vandenbosch, & Malgrange, 2015). The process is accompanied by
angiogenesis in the peri-infarct zone. In surviving tissue, activation of both growth
promoting and inhibiting factors occurs, but full recovery is limited due to the limited
capacity for the anatomical reorganization of the brain (Carmichael, 2005). Reactivation
of existing neural pathways after stroke insult seems to be one of the cellular responses
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involved in functional recovery. Other strategies include combining of new neural
pathways following neurogenesis (Wieloch & Nikolich, 2006). Over the past several years,
many experimental studies aimed at stimulating functional recovery during the first weeks
after stroke have proposed different therapeutic strategies. The plans include activating
brain plasticity, changing the housing environment to an enriched environment as well as
adding training and physical rehabilitation (Biernaskie & Corbett, 2001). Animal studies
reported that post-ischemic administration of growth factors such as vascular endothelial
growth factor (VEGF) (Z. G. Zhang et al., 2000), brain-derived neurotrophic factor
(BDNF) (Schabitz et al., 2004) , epidermal growth factor (EGF) (Teramoto, Qiu, Plumier,
& Moskowitz, 2003), Heparin-binding epidermal growth factor-like growth factor (HBEGF) (Jin et al., 2004), nerve growth factor (NGF) (Dahlqvist et al., 1999), Insulin-like
growth factor-1 (IGF-1) (X. F. Liu, Fawcett, Thorne, DeFor, & Frey, 2001; X. F. Liu,
Fawcett, Thorne, & Frey, 2001), erythropoietin (EPO) (Leist et al., 2004), stem cell factor
(SCF) (Schneider et al., 2005) and granulocyte colony-stimulating factor (GCSF) (Kawada
et al., 2006) can stimulate angiogenesis, promote neurogenesis, reduce infarct volume and
improve recovery in animal models of ischemic stroke. Some studies showed that improved
environment can upregulate growth factors such as nerve growth factor (NGF) and enhance
recovery (Dahlqvist et al., 1999), others focused on the role of some growth factors in
promoting recovery of function. For example; blockade of basic fibroblast growth factor
(bFGF) in ischemic rats reduces motor recovery (Rowntree & Kolb, 1997). Based on their
role in angiogenesis and neurogenesis, we proposed neuroprotective properties of
neurotrophins in improving the recovery after ischemic injury.
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1.12.3 Orexin Receptor Upregulation
Orexin is a neuropeptide regulator of appetite, sleep and glucose metabolism. There
are two types of orexins known as orexin-A and orexin-B, also called hypocretin-1 (HCRT1) and hypocretin-2 (HCRT-2) (Sakurai et al., 1998). Orexins mediate their action through
activating two G-protein-coupled receptors, orexin receptor 1 (OXR1) and orexin receptor
2 (OXR2), that are expressed in the brain (Trivedi, Yu, MacNeil, Van der Ploeg, & Guan,
1998). The activation of orexin receptors excites orexin neurons and promotes the release
of presynaptic glutamate (Yamanaka, Tabuchi, Tsunematsu, Fukazawa, & Tominaga,
2010). Orexin is associated with neuronal cell apoptosis and autoimmune function (de
Lecea et al., 1998). Some animal studies have recently shown that orexin-A exerts
neuroprotective effects by increasing the Hypoxia-inducible factor-1 activity and reducing
the oxidative stress in rats (Yuan et al., 2011). Orexin also plays a major role in modulating
the inflammatory response in ischemic brain injury (Song, Kim, Kim, Song, & Lee, 2015),
a study showed that orexin controls inflammation by regulating pro-inflammatory
cytokines such as the IL-6 and TNF-α in microglia and protecting the neurons against
oxidative stress caused by cerebral ischemia (Xiong et al., 2013). Also, two separate studies
in rats (Kitamura et al., 2010) and mice (Harada, Fujita-Hamabe, & Tokuyama, 2011)
indicated that intracerebroventricular injection of orexin-A into the animal brain before
stroke surgery reduced infarct size. Furthermore, studies reveal that orexins play a positive
role in stimulating hippocampal neurogenesis (Kim et al., 2010), and increasing the
expression of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in
cortical neuron cultures (Yamada et al., 2009), which is a primary mechanism for
neuroprotection.
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1.12.4 Changes in Microglial Activation
Besides the neuronal loss and cognitive dysfunction after stroke, inflammation of
the central nervous system is one of the pathological processes resulting from ischemic
stroke. Microglia, the resident macrophage of the CNS and the primary immune cells that
contribute to neuroinflammation, is an integral component of the inflammatory immune
response in the brain. There has been much debate regarding the precise origin of
microglial progenitors. Studies suggest that microglia arise from peripheral mesodermal
tissue in the yolk sac. Like macrophages, activation of microglia leads to multiple activities
including antigen presentation, phagocytosis, cytokine production and the release of matrix
metalloproteinases that deteriorate the blood brain barrier and cause peripheral leukocyte
infiltration (Iadecola & Anrather, 2011). Stimulation of microglia with various signals can
drive a range of different inflammatory or anti-inflammatory responses in a process called
microglia polarization as shown in Figure 8.
Emerging evidence indicates that microglia polarization is involved in many types
of central nervous system injuries including stroke (Hu et al., 2012). Activated microglia
can be polarized into two main opposing phenotypes: cytotoxic pro-inflammatory
phenotype M1, and neuroprotective, anti-inflammatory phenotype M2; which can be
further subdivided into M2a, M2b, and M2c (Mantovani et al., 2004). Targeting the
polarization mechanism to drive microglia from detrimental phenotype to beneficial
phenotype could help in protecting brain tissue from further damage and resolve
inflammation. Although immunosuppression might be an effective strategy in
counteracting the inflammatory response to ischemic injury, a complete inhibition of the
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inflammatory process without an increase in neurotrophic factors may worsen the outcome
resulting in compromising repair mechanisms.

Figure 8. Microglia polarization into a range of functional phenotypes: proinflammatory M1 and anti-inflammatory M2 phenotypes. M2 microglia has three
subsets; M2a, M2b, and M2c based on stimulating pathway (upper panel). Molecular
markers of all phenotypes are categorized in the table as follow: (1.) signaling
molecules, (2.) cytokines, (3.) chemokines, (4.) scavenger receptor expression and (5.)
tryptophan metabolism effector molecules (AD, 2012).
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1.13 Hypotheses
Three hypotheses were proposed:
1) That earlier delivery of the combination drug would result in smaller infarct size,
and a closer examination of the wall touches in Forelimb Asymmetry test may allow us to
refine the analysis and get similar contralateral deficits to Montoya Staircase.
2) That post-stroke physical rehabilitation can boost motor recovery when
combined with the combination drug therapy.
3) That the drug combination exerts sex-dependent neuroprotective effects by
modulating microglia activities from pro-inflammatory to anti-inflammatory.

1.14 Specific Aims
Specific Aim I
A). To examine whether administering the combination drug at an earlier time point
after the onset of stroke symptoms would reduce infarct volume.
B). To improve the sensitivity of the Forelimb Asymmetry test by refining wall
touches into a more specified parameter that correlates better with functional tests
from Montoya staircase.
Specific Aim II
To investigate the impact of moderate rehabilitation with the impaired arm on
functional recovery with and without post-stroke drug treatment.
Specific Aim III
To explore sex-dependent changes in gene expression of inflammation and
polarization markers expressed by microglia in the peri-infarct zone in response to
combination drug treatment. Neurotrophic factors and synaptic plasticity genes will also
be examined in male rats.
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CHAPTER II
MATERIALS AND METHODS

We used 10-12-month-old male Sprague-Dawley rats (generally 450-500 grams) to
accomplish our specific aims 1 and part of specific aim 3. We compared our results with
those from previous work in our lab in which 10-12-month-old female Sprague-Dawley
rats were used for sex-dependent changes in gene expression. Female Sprague-Dawley
rats were used in specific aim 2, where we evaluated the effect of rehabilitation on
functional recovery with and without drug treatment. All animals are obtained from Harlan
Laboratories (Indianapolis, IN) and fed Harlan rat chow. Animal experiments are approved
by the Institutional Animal Care and Use Committee at Wright State University, and
procedures followed are in accordance with institutional guidelines.

2.1 Surgery for Stroke Induction
All animals underwent endothelin-1-induced stroke procedure using the
vasoconstrictive peptide ET-1 (Sigma, St. Louis, MO, USA). The procedure is based on
modifications to Windle’s protocol (Windle et al., 2006). Anesthesia was induced with 5%
isoflurane, and the animals were maintained on 2-2.5% isoflurane using an anesthesia mask
on the stereotactic apparatus (Stoelting Co., USA). A micro-drill was used to drill two close
holes in the skull using two different set of coordinates relative to bregma to hit the forelimb
motor cortex. It is critical to determine the location of stroke induction precisely to assure
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destroying the forelimb motor cortex itself rather than the tissues surrounding it. Bregma
position can be determined by looking at fusion lines on the skull surface where the coronal
suture meets the sagittal suture. The basic surgical procedures are described in a previous
study (A. M. Corbett et al., 2015), with the following modifications: two holes are drilled
in the skull, with positions relative to bregma of (0.0 mm A.P., 2.5 mm M.L.) and (1.5 mm
A.P., and 2.5 mm M.L.). The procedure starts with cleaning the surgical area using
proviodine-iodine solution, followed by 70% ethanol then proviodine-iodine solution
again. At the top of the animal head, a midline incision is made, and bupivacaine (0.25%)
is administered to the incision to provide local analgesia for 12 hours. A 0.9 mm burr
micro-drill is used to drill two holes in the skull (Fine Science Tools, Foster City, CA). A
needle containing endothelin-1 was inserted into both holes in the skull, then lowered to a
depth of 2 mm. One and one-half microliters of endothelin-1 (600 pmols) was injected
into each hole over a period of 5 minutes. After that, the incision site was sutured and
painted with a povidone-iodine solution to prevent infection. To avoid adverse effects of
analgesics on neurogenesis (Hoehn, Palmer, & Steinberg, 2005), (Sargeant, Miller, & Day,
2008), no post-operative analgesics besides bupivacaine were used.
Endothelin-1 induced stroke surgery has advantages over the most commonly used
ischemic stroke induction, the Middle Cerebral Artery Occlusion (MCAo). The ET-1
induced operation produces about 5% of ischemia in the cortex, which is similar to the
majority of human strokes, compared to 45-50% injury seen in a single hemisphere in the
MCAo, stroke model. It has a gradual reperfusion that closely mimics reperfusion in stroke
patients (Mecca, O'Connor, Katovich, & Sumners, 2009). In addition to that, the large
damage caused by blocking the middle cerebral artery and other arterial openings before
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the middle cerebral artery can cause feeding difficulties in the animal and damage to the
hypothalamus (Dittmar, Spruss, Schuierer, & Horn, 2003). This damage can affect drug
intake and negatively influence the study outcomes. The intraluminal suture method of
Middle Cerebral Artery occlusion (MCAo) has a high mortality rate in old animals. We
had a smaller mortality rate in older experimental animals (under 10%) using ET-1 induced
stroke model, which makes this technique a valuable model for basic and translational
stroke research.

Figure 9. Schematic of a rat skull depicting the position of injection holes in
accordance to bregma.
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2.2 Voluntary Oral Administration of the Drug
Our method involves putting the drug in a 4-gram ball of purchased Pillsbury®
sugar cookie dough. The cookie dough was weighed, rounded into a ball and then a
depression pushed into the ball with a finger. The individually-weighed drugs
(Pharmaceutical grade crushed tablets or contents of capsules) were put into the depression
in the dough ball, and rim edges of the depression were brought together and sealed so that
all the dry chemicals were enclosed in the dough ball. The dough ball was thoroughly
mixed manually to incorporate all of the chemicals into the dough and reformed into a ball.
The ball is presented to the animal in a glass dish at the same time every day and placed in
an animal cage overnight to allow complete ingestion. Control animals receive the 4-gram
ball of sugar cookie dough with no drugs added.

Figure 10. Voluntary Oral Administration of the Drugs. A. Drug incorporation into
4 gm of cookie dough; B. Rat is voluntarily consuming medication at the same time
every day (A. Corbett et al., 2012).
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2.3 Functional Tests
2.3.1 Montoya Staircase Test
Montoya staircase assesses grasping motor function, a motor function that often
show deficits following stroke, which is responsible for many stroke patients’ disabilities
in everyday living. Thus, functional improvements in this motor function in rat models of
stroke should translate well into clinical trials, which would test the same function. Rats
are fasted overnight and then placed on a restricted diet consisting of 85% of their ad
libitum rat chow while they are trained to pick up sucrose pellets, painted with maple
extract, on the Montoya staircase (Montoya, Campbell-Hope, Pemberton, & Dunnett,
1991). The Montoya staircase consists of a raised platform with seven stairwells on each
side containing sucrose pellets (three per stairwell), allowing left and right forelimb
function to be independently assessed. Painting the sucrose pellets with maple extract or
using chocolate flavored sucrose pellets is important during the training phase to entice rats
through their sense of smell to reach down the sides of the platform and pick up the sucrose
pellets, as they have a limited downward vision in this apparatus.
Rats must be properly trained before surgery for dependable post-operative data.
Training occurred during the dark-phase consisting of 15-minute trials inside the Montoya
staircase. Training lasts anywhere from 10-14 days. At the end of the training period, the
rat’s pre-stroke performance is determined by the best overall performance (highest total
number of pellets retrieved) during the last three days of training. The majority of animals
learn to retrieve between 15-18 pellets with each of their paws.
On post-stroke day 3-5, the rats are tested on the Montoya staircase again, and their
best performance is used as a measure of their post-stroke baseline performance. To
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normalize their performance, we divide the number of pellets taken by each paw poststroke by the number of pellets retrieved by each paw pre-stroke. Thus, when the quotient
is 1, the animal had fully regained pre-stroke function in a particular limb, and when the
quotient is less than 1, that means the animal has a functional deficit in that limb. Animals
that failed to reach training criteria, retrieving at least nine pellets with the left paw, on
Montoya staircase test, are tested on Forelimb Asymmetry test as a backup assessment.

Figure 11. A rat on a central platform in the Montoya staircase box is reaching for
pellets. Adapted from (Schaar et al., 2010).
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2.3.2 Forelimb Asymmetry Test (Cylinder test)
The animal is placed in a transparent vertical cylinder and videotaped for 5 minutes.
Rats would rear up and touch the walls of the cylinder with their right and left forepaws to
explore their environment. Normally before stroke induction, the majority of rats show
little preference for the right or left paw during this exploration behavior. However, when
rats were tested again on post-stroke day 4, they usually show a preference for touching
the wall with their ipsilateral (right) paw, while they held their left paw back toward their
body. Typically in this analysis, we look at the percentage of touches to the wall by right
or left paw post-stroke and divide that by their pre-stroke performance percentages.
However, since I am aiming to improve the sensitivity of the test, wall touches were refined
into palm touches versus fingertips and palm touches to determine which of these correlate
better with results obtained from Montoya staircase test.

Figure 12. A Sprague-Dawley rat is rearing up against the cylinder wall and exploring
the arena. Both paws show full palm touches. Adapted from (Schallert, Fleming,
Leasure, Tillerson, & Bland, 2000)
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2.4 Exclusions
All animals that underwent stroke and displayed less than 20% baseline
contralateral deficit in the Montoya staircase are excluded from the Specific Aim 1 (Part
B) since we didn’t have a Montoya Staircase functional analysis to compare with the
Forelimb Asymmetry test. Animals must have learned to pick up at least nine pellets with
at least their left forepaw or they are excluded from the Montoya staircase analysis. Any
animal failing entirely to ingest post-stroke daily medicine or vehicle for a total of 3 days
is completely excluded from the study: no animal was excluded for this reason in my work.
During stroke induction surgery, movement of the needle through the cortex sometimes
nicks a blood vessel and causes some bleeding, if a surgical artifact generates substantial
bleeding, the animal is not included in the study: there were none excluded on this criterion
in the study. When infarct volume is measured, a rat brain is excluded from the analysis if
the brain was damaged either during dissection or the cryostat sectioning, such that we
could not mount the individual slices or could not accurately determine the entire infarct
volume. One animal was excluded based on this criterion (Rat 855 from the 6-12 hours
treatment group).
2.5 Physical Rehabilitation Procedure
Recovery after ischemic stroke is a complicated process that occurs through a
combination of restoration and compensation of functions as a response to both
pharmacologic and physical therapies. In addition to drug treatment, post-stroke physical
rehabilitation has been considered essential for enhancing functional motor recovery in
stroke patients. Studies indicate that rehabilitation induces brain plasticity after stroke
(Kleim, Jones, & Schallert, 2003), with an evidence of promoting neuroplasticity by
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increasing BDNF production (Mang, Campbell, Ross, & Boyd, 2013). Another study
shows that post-surgical rehabilitation sessions in rats that require the use of both
forelimbs; therefore force the animal to use the impaired forelimb, can stimulate the BDNF
production in the brain leading to improved functional motor recovery (LivingstonThomas, McGuire, Doucette, & Tasker, 2014).
We examined whether post-stroke physical rehabilitation could improve functional
motor recovery in drug-treated versus vehicle-treated rats (Ragas et al., 2015). Our lab
designed a hanging rack to hold peanut butter just outside of an opening in the rat’s cage
(Figure 13). Because of the position of the shelf, the rat is only able to reach it with the
contralateral paw (left paw) to the infarcted right hemisphere. The shelf was hung every
other night with approximately 1-2 grams of peanut butter beginning eight days post-stroke
and continuing for an overall period of five and half weeks. All other animals began to eat
from the shelves within three days. Using this observation, we were able to determine if
the animal underwent rehabilitation or not. We saw no difference in the number of
completely-cleared versus partially-cleared shelves between the drug groups. This method
enabled physical rehabilitation of the contralateral limb without the stress of physical
restraint of the ipsilateral limb.
Rehabilitation was begun on post-stroke day 8 and continued every other day until
post-stroke day 45. During rehabilitation, the hanging shelves were loaded with 1-2 grams
of peanut butter and hung around 5:00 pm each day. The shelves were collected 24 hours
later and evaluated for whether the animal used its impaired paw. Animals generally began
to eat from the shelves within three days and continued through the end of the rehabilitation
period.
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A.

B.

C.

D.

Figure 13. Voluntary Physical Rehabilitation. (A). Hanging shelf for rat
rehabilitation. (B). the animal has not eaten from the shelf. (C). the animal has
partially eaten from the shelf. (D). the animal has completely cleared the shelf of all
peanut butter (Ragas et al., 2015).

50

2.6 Preparing Tissues for Immunohistochemistry (IHC) Experiment
Rats were injected with sodium pentobarbital (Euthasol; 100 mg/kg, i.p.) and
returned to their cages to allow them to obtain a surgical plane of anesthesia. Animals were
then perfused through the left ventricle of the heart using 100 ml of phosphate buffered
solution (PBS) followed by 150 ml of 4% paraformaldehyde in PBS as a fixative. A bluntedged cannula was used to deliver solutions through a small incision in the ventricle, to
ensure it did not cross the interventricular septum. After 15-20 minutes of fixation, brains
were removed and placed in the same fixative solution overnight at 4°C then immersed in
30% sucrose solution for three days at the same temperature. After that, brain tissues were
stored at −80°C until use. Coronal sections of 50μm starting anterior to the infarct site were
sliced on a cryostat at −25°C. Each slice was immersed into one of six vials, containing
PBS, which is labeled according to the type of proposed experiment. The infarct analysis
vials were labeled as 1:500 8-OHdG (8-hydroxy-deoxyguanosine antibody) and Control;
the other four vials were used for other projects in our lab using different staining
techniques such as H&E and Prussian blue.
Immunohistochemistry staining was performed on free-floating coronal sections in
the 8-OHdG vial. The sections were incubated overnight at 4°C with a primary antibody
(1:500 dilution of mouse monoclonal antibody against 8-OHdG, Abcam) to detect the
nucleic acids damage by oxidative stress. Sections were then treated with horse radish
peroxidase biotinylated secondary antibodies (donkey anti-mouse antibodies). Sections
then rinsed twice with PBS-Tween and immunoreactivity was visualized by the AvidinBiotin Complex method using VIP as a substrate for the horse-radish peroxidase (VIP
impact kit; Vector Laboratories). Coronal slices from 8-OHdg vials and Control vials were
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carefully mounted on microscope slides using a paintbrush and set aside to dry. Slides were
cover slipped using DPX mountant.
2.7 Infarct Measurement
Brightfield images were taken of the sections using a 4X objective, then montaged
using advanced panoramic image stitcher called Image Composite Editor (ICE) into a
complete picture of a damaged region of the brain as indicated by a dark staining (infarct).
Area of the infarct was determined with ImageJ (Fiji open source software) from NIH.
Infarct area (mm2) was determined for every sixth slice, then multiplied by the slice
thickness (0.05 mm) and 6 to determine the complete infarct volume in mm3.
Table 6 presents an example of infarct measurement in which the infarct volume
was determined from 16 coronal brain sections collected from one animal. Slides were
numbered as they were assessed for the presence of infarcts and sections on the slide were
numbered left to right. Area of infarct was determined with Image J software, after setting
the scale. The multiplier number varied from experiment to experiment, and in this case
merely indicates that one out of every six brain coronal slices were used to measure infarcts
volume with 8-OHdG. The final summed volume of the infarct for this animal is shown in
the lower right part of the table.
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Table 6. Summary of infarct volume calculation in one animal.

Rat

Slide No.

Section No.

ID

Area

Thickness

mm2

mm

Multiplier

Volume

Final
volume
mm3

860

1

1

1.517

0.05

6

0.4551

860

1

2

1.131

0.05

6

0.3393

860

1

3

1.297

0.05

6

0.3891

860

1

4

1.897

0.05

6

0.5691

860

2

1

2.272

0.05

6

0.6816

860

2

2

1.661

0.05

6

0.4983

860

2

3

1.546

0.05

6

0.4638

860

2

4

1.089

0.05

6

0.3267

860

3

1

1.745

0.05

6

0.5235

860

3

2

1.581

0.05

6

0.4743

860

3

3

1.694

0.05

6

0.5082

860

3

4

1.613

0.05

6

0.4839

860

4

1

1.24

0.05

6

0.372

860

4

2

1.608

0.05

6

0.4824

860

4

3

1.128

0.05

6

0.3384

860

4

4

3.511

0.05

6

1.0533
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7.959

2.8 Preparing Samples for Genetic Analysis
After injecting animals with sodium pentobarbital (Euthasol; 100 mg/kg, i.p.),
animals were injected with a 1ml of Evans Blue dye directly into the ventricles of the heart
and then perfused with PBS to clear the dye. The brain is dissected, blocked and then the
coronal portion containing the infarct dropped into a beaker containing isopentane and dry
ice to freeze tissues for cryosectioning. The frozen coronal block is kept at -80 °C in a
scintillation vial until the cut on the cryostat. On the cryostat, tissue was cut from the
anterior-most end until the infarct was reached. An RNAseZap® cleaned microtome blade
and forceps were then used to remove a block of tissue surrounding the infarct. The blocks
of tissue ranged from 20-30mg in weight, are placed into pre-weighed RNase and DNase
free plastic vials for the tissue homogenization step. To isolate RNA, 600 µl of lysis buffer
(Qiagen RNeasy RLT Plus) were added to disrupt the tissue using a conventional rotor–
stator homogenizer until it is uniformly homogeneous ( about 30 seconds). Next, the lysate
was centrifuged at maximum speed for 3 minutes and the supernatant was carefully
transferred into a new microcentrifuge tube. Then, 600 µl of 70% ethanol were added to
the cleared lysate and mixed well. A 700 µl of the sample was transferred to an RNeasy
spin column placed in a 2 ml collection tube and centrifuged at 8,000 x g for 30 seconds.
The flow-through volume was discarded. Next, 700 µl of a wash buffer RW1 was added
to the RNeasy spin column and centrifuged at 8,000 x g for 30 seconds. The flow-through
volume was discarded. A 500 µl of Qiagen RPE wash buffer was added to the RNeasy spin
column and centrifuged at 8,000 x g for 30 seconds. After discarding the flow-through
volume, this step was repeated with centrifugation time of 2 min. The RNeasy spin column
was placed into a 2 ml collection tube and centrifuged at 16,000 x g for 1 minute to further
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dry the membrane, then placed into a 1.5 ml collection tube. Forty microliters of RNasefree were directly added into the spin column and centrifuged at 8,000 x g for 1 minute to
elute the RNA. The concentration of the purified RNA was determined using a NanoDrop
spectrophotometer and the RNA samples were stored at -80 degrees Celsius for future
analysis.
2.9 Gene Expression Analysis Using Real-Time PCR
RT2 PCR Array technique is a reliable tool for analyzing the expression of different
genes allowing us to detect genes of interest accurately by probing with cDNA, reversed
transcribed from the mRNA in the peri-infarct regions of rat brain using Qiagen First
Strand Kit. Both the mRNA purification kit and reverse transcription kit have a genomic
DNA elimination step to remove any false positive signals that might develop as a result
of contamination in RNA samples. Other quality control elements implanted within the
array are: housekeeping genes for data normalization, reverse-transcription controls (RTC)
for the efficiency of the first strand cDNA synthesis, and positive PCR controls to test PCR
performance. Each well has a replica on the PCR 96-well plate to assess the reproducibility
and validity of the data. Results from each sample and its replica are averaged before
running the online data analysis which automatically performs all ΔΔCt based fold-change
calculations. Average Ct values for all gene replicates were calculated first, then delta Ct
value between the gene of interest and housekeeping gene for each experiment were
calculated. Delta-delta Ct values obtained from delta Ct experiment – delta Ct control.
A comprehensive gene expression profile for different gene pathways can be
carried out in less than 6 hours using three different Qiagen kits. Animal’s tissue is first
homogenized using a rotor-stator homogenizer to prepare tissue for the RNA purification.
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The second step is to purify RNA using a spin-column method (the Qiagen Universal
RNeasy Mini Kit). RNA was converted to complementary DNA (cDNA) by performing a
reverse transcription using the First Strand Kits (contains a step for the elimination of
genomic DNA). The genomic DNA elimination mix was prepared according to the RT2
First Strand protocol and processed through a gradient thermal cycler. The next step was
to mix the cDNA with the ready-to-use RT2 SYBR® Green qPCR Mastermix and RNAse
free water; this mixture is then aliquoted (25 µl per well) across the RT2 Profiler Array.
The real-time PCR cycling program runs on the ABI 7900HT thermocycler for 40 cycles,
using absolute quantification.
Figures 15, 16 and 17 demonstrate custom RT2 PCR array layouts for M1 and M2
microglia biomarkers, RT2 Profiler synaptic plasticity PCR array and for neurotrophic
genes and their receptors array, respectively. The complete lists of gene symbols,
description of genes and their positions in each plate are described in Appendices II and
III.
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Figure 14. RT2 Profiler PCR Workflow
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Figure 15. Custom RT2 PCR Array layout for M1/M2 Microglia Biomarkers. Light
blue wells each contain a real-time PCR primer sets for the indicated
inflammatory/microglia activation related genes. All wells from column 1 to 6 are
replicated in columns 7 to 12. Dark blue wells contain a housekeeping gene panel to
normalize array data (Ppih, Actb, Hprt1, Ldha and Nono). Red wells H2 and H8
contain genomic DNA controls (GDC). Wells H3, H4, H9, and H10 include replicate
reverse-transcription controls (RTC). Wells H5, H6, H11, and H12 include replicate
positive PCR controls (PPC).
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Figure 16. The diagram illustrates the layout of the 84 different primers for rat
synaptic plasticity genes, controls for reaction quality (genomic DNA contamination,
reverse transcription, and positive PCR controls) and five housekeeping genes for
normalization.

59

Figure 17. The diagram shows the layout of the 84 different primers for neurotrophic
genes and their receptors, controls for reaction quality (genomic DNA contamination,
reverse transcription, and positive PCR controls) and five housekeeping genes for
normalization.
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2.10 Protein-Protein Interaction (PPI) Database
To investigate the relationships between the up-regulated and down-regulated
genes and the physiological significance of the interactions among them, I utilized the
Search Tool for the Retrieval of Interacting Genes (STRING) version 10.0 to predict
interaction information with high-confidence. The resource is accessible online at
http://string-db.org. STRING is a comprehensive database that provides a computational
prediction of protein-protein functional and physical associations. It is one of the widely
used PPI databases that contain interaction networks from a wide variety of organisms.
Adjustable confidence scores (low, medium or high confidence) are provided to each of
the interactions in STRING, in addition to information on protein domains, 3D structures,
and interactive network viewer that cluster networks on demand. All information can be
obtained by searching for multiple proteins by names or identifiers in the program search
engine and selecting the organism type (Rattus norvegicus strain in this study).
The current version (v10.0) of STRING database covers more than 9.6 million
proteins from over 2000 organisms ranging from Bacteria, Archaea to Homo sapiens
(Szklarczyk et al., 2011; Szklarczyk et al., 2015). STRING imports information from
various sources, including digitized experimental data from scientists and publications
such as PubMed and FlyBase (Wodak, Pu, Vlasblom, & Seraphin, 2009).
To investigate potential interactions within the genes, upregulated and downregulated genes were considered as two separate groups. If two or more genes were
identified in both the groups, they were fed into the STRING database identifier for
predicting protein-protein interaction.
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Figure 18. Screenshot of protein-protein network from the STRING website. Network
can be rearranged and clustered directly in the browser window revealing tightly
connected functional molecules with their role in different pathways. The thickness
of lines between nodes is a rough indicator of the strength of the association. Large
nodes indicate the availability of 3D protein structure information.
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2.12. Research Plans
In the first part of this study, we are examining the influence of the timing of
administration of fluoxetine after stroke onset on the final infarct size and the risk of
developing secondary hemorrhagic transformation. Since the majority of stroke patients
coming into the hospital are already on statins due to dyslipidemia, the experiment more
closely modeled clinical trials by starting all animals on 1 mg/kg simvastatin seven day
pre-stroke and continuing daily. Interesting findings in our laboratory on the effect of early
drug delivery on infarct size in female rats have prompted us to investigate the relationship
between the timing of drug administration and infarct size in male rats. Daily 5 mg/kg
fluoxetine and 20 mg/kg ascorbic acid administration were begun at three initiation time
points (6-12 hours post-stroke, 20-26 hours post-stroke and 48-54 hours post-stroke) in rats
that pre-treated with simvastatin for one week.
We also sought to improve the sensitivity of one of the behavioral tests for the
motor function: the forelimb asymmetry test. Traditionally during this test, the animal is
placed in a clear vertical tube and videotaped for 5 minutes. The number of times the animal
touches the wall with its right or left paw is quantified using slow motion video analysis.
For pre-stroke animals, we usually see around a 50:50 use of the right and left forepaw.
After the stroke surgery, we see more use of the ipsilateral paw (right paw) with inhibition
in the utilization of the left paw. This test takes a long time to complete the analysis, as
the number of wall touches must be quantified for each fore-paw, but it is a test that does
not require any training so that it could apply to all animals in the study. The manner in
which we are counting wall touches (any touch to the wall) seems to lower the sensitivity
of the test to the deficit produced. We have noticed that following a stroke; the animal
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tends not to put full weight on the left paw (does not flatten the palm against the wall). This
behavioral test is important in that it can be applied to every rat, yet with our current method
of analysis (any touch to the wall counts), it does not correlate well with functional deficits
observed with the Montoya staircase test (which shows finer motor control deficits). A
more precise approach has been proposed to evaluate another method for counting wall
touches (differentiating between a full palm touch and a fingertip touch) to see if the full
palm touches better correlates with results from the Montoya staircase test.
The second goal of this study is to determine whether physical rehabilitation might
enhance functional motor recovery in drug-treated rats versus control animals. Post-stroke
physical rehabilitation has been considered essential for enhancing functional motor
recovery (Faralli, Bigoni, Mauro, Rossi, & Carulli, 2013). Clinical studies suggest that
early rehabilitation therapy after stroke may improve physical function, increase brain
plasticity and improve the skills needed to perform activities (Feigenson, McDowell,
Meese, McCarthy, & Greenberg, 1977) and (Hayes & Carroll, 1986). A recent study on
the effects of post-stroke rehabilitation on recovery in MCAo model rat indicates that daily
rehabilitation enhances functional outcome (Sasaki et al., 2016). The degree of impairment
produced in human patients after stroke differs from experimental dysfunction in rats based
on stroke inducing procedure. The majority of acute stroke patients show severe
impairment or total loss in upper extremity movement, while rats show a little deficit of
forelimb movement in the MCAo model of focal ischemia (Kleim, Boychuk, & Adkins,
2007) . Also, the severity of rehabilitation, time of the procedure and the influence of stress
are essential factors that influence the outcome. Some of the stroke studies on rats utilized
intensive rehabilitation protocol in which the intact forelimb is constrained after the stroke
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induction surgery to force the animal to overuse the impaired forelimb for movement and
body support (Risedal, Zeng, & Johansson, 1999), (Bland et al., 2000). This type of
stressful rehabilitation led to reduced functional recovery. Since physical rehabilitation in
stroke patients involves assistance from the therapist in contrast to animal rehabilitation,
which is totally hands-off, it is crucial to choose the right rehabilitation task in rat models
to ensure that task is successful. Our method of rehabilitation using a hanging shelf filled
with peanut butter accomplished rehabilitation of the impaired limb without restraint thus
reduced stress during rehabilitation.
Finally, a newly discovered neuroprotective role of fluoxetine in suppressing
microglia-mediated inflammation in vitro (Su et al., 2015) has directed us to investigate
the genetic mechanisms for this inhibitory role aiming to explore other potential influences
of fluoxetine on modulating microglial polarization from pro-inflammatory (M1)
phenotype towards beneficial anti-inflammatory (M2) phenotype. In conjunction with
previous work in our laboratory that showed fluoxetine stimulates neurotrophic factors and
synaptic plasticity in female rats, in this study, the effects of fluoxetine on the neurotrophic
factors and synaptic plasticity in male Sprague-Dawley rats were examined.
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CHAPTER III
RESULTS

3.1 Specific Aim I
3.1.1 To examine whether administering the combination drug at an earlier time point after
the onset of stroke symptoms would reduce infarct volume.
Our previous experiments had indicated that administration of fluoxetine and
simvastatin at 20-26 hours post-stroke decreases the volume of ischemic infarcts in
Sprague-Dawley female rats (10-12 months old) (Balch et al., 2015). This current
experiment is more closely modeled on current clinical trials by starting all animals on
simvastatin 7 days pre-stroke and continuing daily in male Sprague-Dawley rats. The
purpose of this experiment is to determine the impact of the time to treatment of fluoxetine,
in combination with simvastatin, on the infarct volume and the risk of secondary
hemorrhagic transformation. Daily 5 mg/kg fluoxetine and 20 mg/kg ascorbic acid
administration were begun at three initiation time points (6-12 hours post-stroke, 20-26
hours post-stroke and 48-54 hours post-stroke). We included the 48-54 hour time-point
because this is the earliest time point used in three ongoing clinical trials (FOCUS,
AFFINITY, EFFECTS) testing fluoxetine effects on motor recovery post-stroke. Animals
were randomly assigned to either drug or control group after the surgery, but before the
baseline stroke deficit was determined using either Montoya Staircase or Forelimb
Asymmetry tests. After drug treatment had been begun, it was continued daily until post-
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stroke day 7. All animals were euthanized on post-stroke day 7, so we could see any
evidence of hemorrhagic transformation. Infarct volume was assessed at post-stroke day
seven by immunohistochemical determination of 8-hydroxy-2'deoxyguanosine (8-OHdG),
which locates nuclei that are under oxidative stress, using ImageJ software.

Table 7. Male treatment groups with different times of drug delivery. All groups were
given 1 mg/kg simvastatin beginning 7 days before stroke induction and continuing
through PSD 7. Column 2 shows any daily drug treatment for that group, with any
fluoxetine and ascorbic acid administration beginning at the times indicated in
Column 1, and continued daily until the euthanasia time-point (Column 5).
Functional tests were administered at the times indicated in Columns 3 and 4.

Group

Oral Dose

Montoya

Forelimb

Euthanasia

Staircase Asymmetry
Control (N=9)

1 mg/kg simvastatin

PSD 3-5

PSD 4

PSD 7

6-12 hrs. FSA

5 mg/kg fluoxetine + 1 mg/kg

PSD 3-5

PSD 4

PSD 7

(N=11)

simvastatin +20 mg/kg

PSD 3-5

PSD 4

PSD 7

PSD 3-5

PSD 4

PSD 7

ascorbic acid
20-26 hrs. FSA

5 mg/kg fluoxetine + 1 mg/kg

(N=9)

simvastatin + 20 mg/kg
ascorbic acid

48-54 hrs. FSA

5 mg/kg fluoxetine + 1 mg/kg

(N=10)

simvastatin +20 mg/kg
ascorbic acid
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A.

B.

Figure 19. Representative images showing 8-OHdG staining of the infarct area
indicative of oxidative DNA damage. A. This panel shows significant reduction of
infarct volume when fluoxetine and the ascorbic acid combination was administered
20-26 hours after stroke surgery in simvastatin pre-treated rats. B. Infarct size in
early drug delivery animal (6-12 hours after stroke induction) is similar to Control
and delayed treatment groups.
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In this experiment, all male Sprague-Dawley rats were on 1mg/kg simvastatin for
seven days before stroke induction and continued for seven days post-stroke, then were
euthanized. Typically, control animals had 5-13 mm3 infarct volume following endothelin1 induced stroke, when stained with 8-OHdG primary antibody (Abcam; see figure 19 for
representative images from the 20-26 hour administration (Panel A) versus early drug
delivery (Panel B). In the control group (see Table 8, Figure 19 and Figure 20), the mean
infarct volume was 8.035 ± 0.6418 mm3 SEM (N=10). Animals that received fluoxetine
and ascorbic acid beginning 6-12 hours after stroke induction showed no significant
difference in infarct volume compared to control (7.626 ± 1.009 mm3 SEM, N=11);
however, when fluoxetine delivered 20-26 hours post-stroke that resulted in significant
reduction (p=0.0366) of infarct volume (4.782 ± 0.8845 mm3 SEM, N=9). Interestingly, if
the delivery of fluoxetine was delayed to 48 hours following stroke induction, the infarct
size showed no significant change in comparison to control 8.202 ± 0.8754 mm3 SEM
(N=9).
Furthermore, brain sections in the delayed treatment group (48-54hrs) showed
evidence of hemorrhagic transformation in the peri-infarct area when stained with H&E
(see Figure 21). In figure 21, the dark blue staining was examined by pathologist Smita
Krishnamurthy, M.D. and she confirmed that the extensive staining in panels A, B, and D
is due to peripheral macrophage and lymphocyte infiltration, while panel C shows very
little infiltration. This fits in with our previous idea that we may be eliminating reperfusion
injury in this group of animals: 24 hours after stroke is when reperfusion would generally
be predicted to occur in this endothelin stroked rat. Administering the drug at this time
point appears to stop the reperfusion in compare to delaying treatment to 48 hours. To
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examine the probability of hemorrhagic transformation occurring in drug groups to the
probability of the event occurring in control group, an MD/Masters student in the lab, Neal
Verma, analyzed the relative risk of hemorrhagic transformation in these groups, and found
a relative risk (RR) of 1.04 (p-value 0.913) in the 6-12 hour administration group and 0.925
relative risk (p-value 0.845) in the 48-54 hour administration group compared to control,
while the 20-26 hour administration group had a relative risk of 0.37, with a p-value of
0.14, indicating a trend. Relative risks evaluations are usually done with group sizes of 50,
so it was very encouraging to see a statistical trend with our small group size: it suggests a
strong effect.
These results are similar to those reported in the FLAME clinical trial (Chollet et
al., 2011), where they saw no effect on infarct volume and some hemorrhagic
transformation in patients given 20 mg fluoxetine beginning two days after stroke and
continuing for 90 days. Also, we previously saw that female stroke rats just given 5 mg/kg
fluoxetine and 20 mg/kg ascorbic acid 20-26 hours after stroke and continued for 30 days,
had a roughly 11% motor recovery, as assessed by Montoya Staircase. This roughly
matched the recovery seen in the FLAME clinical trial using the Fugl Meyer Assessment
score when stroke patients were given only 20 mg fluoxetine daily (A. M. Corbett et al.,
2015). Although our dose was twice that given in the FLAME trial.
Table 8. One-way-ANOVA with Dunnett's multiple comparisons test.
Dunnett's Multiple
Comparisons Test
Control vs. 6-12hrs

Mean
Control
8.035

Mean
Test
7.626

Mean
Diff.
0.4092

95% CI of diff.

Significance

-2.518 to 3.337

No

Control vs. 20-26hrs

8.035

4.782

3.253

0.1746 to 6.331

Control vs. 48-54hrs

8.035

8.202

-0.1671

-3.245 to 2.911

Yes
p=0.0366
No
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Figure 20. Direct comparison of infarct volumes between all groups treated with
fluoxetine and ascorbic acid at different time points following stroke induction
indicates that infarct volume varies with the timing of fluoxetine delivery post-stroke.
There are no outliers at either end of the range. Each dot represents a single animal
in each group. The x-axis displays treatment groups at different time points, and the
y-axis shows the infarct volume in mm3. The broad horizontal bar indicates the group
mean and the error bars represent SEM. *p = 0.0366 using one-way ANOVA with
Dunnett’s multiple comparisons.

These results are consistent with previous findings in our lab on female rats. The
methods are similar to previous work with few exceptions: 1) in the previous work we
examined infarct volumes on day 91 after stroke induction and rats were not on simvastatin
before the surgery; 2) we added a new time-point (48-54 hours) of drug administration after
stroke, to match the earliest time point for fluoxetine delivery in human clinical trials.
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Figure 21. Representative images showing H&E stained coronal brain sections with
infarcts in male rats. (A). Control (simvastatin only) administered 7 days pre-stroke
and 7 days post-stroke shows large infarct volume with hemorrhagic transformation.
(B). Infarct size was unchanged if fluoxetine and ascorbic acid was administered 6-12
hours after stroke and had a highest relative risk of hemorrhagic transformation.
(C). Significant reduction of both infarct volume and hemorrhagic transformation
when fluoxetine and ascorbic acid combination was administered 20-26 hours after
stroke surgery. (D). The panel shows same infarct size when drug combination was
delayed 48-54 hours; a possible bleeding (hemorrhagic transformation) is marked
with an arrowhead. Scale bar is 500 micrometers.
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3.1.2 To improve the sensitivity of the Forelimb Asymmetry test by refining wall touches
into a more specified parameter that correlates better with functional tests from Montoya
staircase.
Forelimb Asymmetry analysis is routinely used in small rodents to predict
functional motor deficits caused by focal ischemic stroke; however, we found that results
of this test are not as sensitive as the Montoya Staircase test. The aim of this part is to refine
the forelimb asymmetry analysis to strengthen the sensitivity of the assessment. A
traditional Forelimb Asymmetry test, which counts all wall contacts, fails to detect
consistent functional deficits where the Montoya Staircase has identified a functional
deficit. Understanding that the hand movements in the two tests are different, with the
Montoya Staircase using finer motor control for grasping, I nevertheless wanted to
determine if some of the wall touches in the Forelimb Asymmetry test could be considered
“abnormal” when compared with pre-stroke functional analysis, and if the sensitivity of
the test would be increased if abnormal touches were not counted.

In this study in

particular, I investigated whether counting only palmar pads pressed to the wall rather than
any attempt to touch the cylinder wall (e.g. by fingertips) would allow a better correlation
with Montoya staircase results. This section deals with the functional data from the male
rat groups shown in Table 7 and also some female rats who were given 5 mg/kg fluoxetine,
1 mg/kg simvastatin and 20 mg/kg ascorbic acid beginning 20-26 hours post-stroke
compared to a vehicle control group.
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Figure 22. Rat’s left forelimb shows palmar pads and fingertips.

To evaluate if any touches to the wall were abnormal after the stroke, I needed to
determine if the normal rat pre-stroke ever touched the wall of the cylinder with only its
fingertips or if it instead used its palm pressed to the wall (see Figure 23 for different types
of wall touches). These data are detailed in Table 9, showing that there were no touches to
the wall using only fingertips with pre-stroke animals: this type of touching only occurred
after the stroke induction. This type of wall touch could then be considered abnormal, as
confirmed by the Fisher’s exact test in Table 9.
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Figure 23. Forelimb Asymmetry analysis. (A). A post-stroke animal rearing and
placing the palmar pads on the wall, which indicates its use for body support. (B).
Post-stroke animal leaning on enclosing wall using right (ipsilateral) forepaw while
attempting to touch the wall by the left (contralateral) fingertips.
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Rat
ID

901
902
903
904
905
906
907
909
910
911
912
913
915
916
917
919
921
922
923
925
927
928
929
931
932
935
937
938
939
940
941
943
944
945
946
947
950
951
953

Forelimb Asymmetry
Assessment
(Pre-Stroke)
Palmar Pads Fingertips
L
R
L
R
66
61
0
0
42
37
0
0
58
54
0
0
26
26
0
0
30
33
0
0
70
73
0
0
45
42
0
0
35
33
0
0
50
35
0
0
27
30
0
0
31
35
0
0
32
36
0
0
23
25
0
0
74
84
0
0
54
46
0
0
69
72
0
0
52
55
0
0
59
32
0
0
57
61
0
0
15
15
0
0
34
33
0
0
23
25
0
0
24
22
0
0
23
33
0
0
13
13
0
0
20
14
0
0
8
13
0
0
36
37
0
0
24
30
0
0
39
42
0
0
6
6
0
0
19
26
0
0
26
27
0
0
23
25
0
0
16
13
0
0
23
29
0
0
31
32
0
0
19
20
0
0
13
27
0
0

Forelimb Asymmetry
Assessment
(Post-Stroke Day 4)
Palmar Pads Fingertips
L
R
L
R
10
36
3
3
31
103
18
3
25
85
7
1
1
17
3
1
4
19
12
0
9
83
29
0
20
63
16
0
23
34
5
0
23
33
0
0
118
55
10
0
7
30
7
0
2
18
10
0
24
33
0
0
27
40
5
0
0
63
17
0
18
39
5
0
29
36
3
0
29
53
20
0
10
49
20
0
2
6
3
1
6
47
16
0
0
29
18
0
10
23
7
0
2
7
3
0
0
4
3
0
3
15
9
0
5
9
1
0
0
17
5
0
0
30
6
0
0
40
14
0
3
6
2
0
0
17
5
0
9
6
0
0
3
21
3
0
9
7
0
0
0
2
0
0
0
24
14
0
3
13
1
0
5
26
2
0

76

Table 9. Number
of contacts made
by animal’s left
and right forepaws
pre-stroke
compared to poststroke. Evaluating
the number of wall
contacts made by
each animal before
and after stroke
surgery indicates
that attempts to
touch the wall with
fingertips only
occur after stroke
surgery, which
strongly indicates
they are abnormal.

Table 10. This contingency table shows animals that made fingertip contacts to the
wall vs. the ones that did not (before/after stroke surgery), indicated that fingertip
contacts were only made after injury, so there is high statistical probability that they
are abnormal.

Pre-Stroke

Post-Stroke

Total

Fingertip touches

0

34

34

No fingertip touches

39

5

44

Total

39

39

78

p-value

< 0.0001 (Fishers exact test )

To refine wall touches, the numbers of ipsilateral and contralateral contacts made
by the animal were first quantified before surgery to establish the baseline, then four days
after stroke surgery to evaluate the functional deficit. We looked at the percentage of
touches to the wall by right or left paw post-stroke and divided that by their pre-stroke
performance rates. When the quotient is 1, the animal had fully regained pre-stroke
function, and when the quotient is less than 1, the animal had a functional deficit in that
limb. In this modified analysis, I focused on the contralateral side performance by counting
any touch to the wall, whether by the palm or the fingertips and compared the percentage
of deficit obtained from this quantification method to the percentage of deficit obtained
when counting touches made by animal palm (fingertip touches are not included). This
refined approach indicates that counting only the numbers of contacts made by palmar pads
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is a more sensitive behavioral analysis of functional deficit than including amounts of
touches made by both palmar pads and fingertips.
A paired t-test with Welch’s correction for unequal variances was used for
statistical comparison of the percentage of the contralateral deficit before and after stroke
using the two methods of counting. Figure 24 (B) showed a reduced functional deficit and
improved motor recovery when fingertips touches were included in the analysis, which
gave us reduced sensitivity in the assay. Counting only the palmar touches, however gave
us contralateral functional deficits that were consistent with the contralateral functional
deficits seen in the Montoya Staircase case on Post-stroke days 3, 4, and 5 (Panel A).
Again, although these tests use different muscles, this seemed to be a good initial indication
that evaluating the Forelimb Asymmetry response with palmar touches only was an
improvement.
In Table 11, Forelimb Asymmetry % contralateral deficit, calculated with either palmar
touches (middle column) or palmar and fingertip touches (final column) were compared to
the contralateral % deficit in Montoya Staircase. The female rats were included to
determine if there were any sex differences in the response. In Figure 25 we separated the
male rats and in Figure 26 we separated the female rats to perform a linear regression and
a correlation analysis to determine which Forelimb Asymmetry method of wall
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Figure 24. Percentage of the contralateral deficit in Montoya Staircase analysis versus
Forelimb Asymmetry analysis using two methods of counting the wall touches. (A).
Quantifying only palm touches in cylinder test shows a similar level of contralateral
deficit correlating with Montoya staircase results (p = 0.573, paired t-test with
Welch’s correction for unequal variances). (B). including fingertips touches with
palm contacts (in the same animal) does not accurately reflect the functional deficit
that showed by Montoya staircase results (p =0.0001). Each dot represents a single
animal. The x-axis displays functional tests (Montoya Staircase vs. forelimb
asymmetry (Palm only, A); or palm and fingertips, B). The y-axis shows the
percentage of contralateral deficit (%) in each rat measured by different analyses.
The broad horizontal bar indicates the group mean and the error bars represent
SEM.

A.

B.

Palm Only

Palm and Fingertips

Palm Only

Palm Only
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Table 11. Comparison of percentage of contralateral deficit measured by Montoya
Staircase versus Forelimb Asymmetry (palmar pads contacts and fingertip attempts
to hit the cylinder wall). Only animals that showed 20% deficit on the contralateral
side of Montoya staircase analysis were included.
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Rat’s
ID/Gender

Percentage of Contralateral Deficit
Montoya Staircase
(%)

901F
902F
903F
904F
905F
906F
907F
909F
910F
911F
912F
913F
915F
916F
917F
919F
921F
922F
923F
925M
927M
928M
929M
931M
932M
935M
937M
938M
939M
940M
941M
943M
944M
945M
946M
947M
950M
951M
953M

0.20
0.93
0.92
0.58
0.93
0.95
1.00
0.50
1.00
0.75
0.95
0.92
0.83
0.30
1.00
0.59
0.50
1.00
0.82
0.25
0.63
0.40
0.38
0.53
0.30
0.50
0.00
1.00
0.25
0.81
0.44
0.71
0.86
0.45
0.20
0.63
0.86
0.44
0.40

Forelimb
Asymmetry
(Palm touches %)
0.58
0.56
0.56
0.89
0.63
0.80
0.53
0.22
0.22
0.48
0.60
0.79
1.00
0.14
1.00
0.35
0.08
0.45
0.65
0.50
0.78
1.00
0.42
0.46
1.00
0.72
0.06
1.00
1.00
1.00
0.33
1.00
-0.22
0.74
-0.02
1.00
1.00
0.62
0.50
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Forelimb Asymmetry
(Palm and fingertip touches
%)
0.52
0.41
0.48
0.64
0.04
0.36
0.30
0.12
0.22
0.29
0.32
0.15
0.35
0.05
0.61
0.24
0.03
0.26
0.21
0.17
0.37
0.26
0.19
-0.01
0.14
0.24
-0.05
0.54
0.63
0.46
0.09
0.46
-0.22
0.54
-0.02
1.00
0.25
0.52
0.35

Figure 25. Linear regression between Montoya staircase deficit and the Forelimb
Asymmetry wall touches (palm versus palm + fingertips) in male Sprague-Dawley
rats. Comparing the overall average deficit measured by the two methods shows a
similar correlation between results of Montoya staircase and Forelimb Asymmetry
using the two counting methods of wall contacts. The Y intercept or elevation was
significantly different between the two lines (p = 0.0008). In a correlation analysis of
this data, the R-squared value for male Montoya staircase vs. Forelimb Asymmetry
palm only is R2= 0.1582 with a p-value of 0.0820, and the R-squared value Montoya
staircase vs. Forelimb Asymmetry that analyzed using both palm and fingertip
touches is R2= 0.1021 with a p-value of 0.6279.

touching correlated better with the Montoya Staircase Analysis. In Female rats, we saw a
10 fold better correlation between the palmar touches and the Montoya staircase percent
contralateral deficit. We did see a better correlation with the palmar touches in the male
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Figure 26. Linear regression between Montoya staircase deficit and the Forelimb
Asymmetry wall touch (palm versus palm + fingertips) deficits in female SpragueDawley rats. The elevations or y-intercepts were found to be significantly different
(p=0.0011). Correlation analysis of these data showed a better correlation between
results of Montoya staircase and Forelimb Asymmetry when only palm touches were
counted. The R-squared value (R2= 0.1674; p = 0.082) was about 10 fold more than
R-squared value when Forelimb Asymmetry was analyzed using both palm and
fingertip touches (R2= 0.01413; p = .6279).

rats as well, and the p-value for the R square correlation (0.0824) was remarkably similar
to that for the female rat using palm touches ( p-value of 0.082). In each case, the p-value
for the R square correlation using the palms and fingertips was much higher (p = 0.6279)
for males and females (p = 0.167). Again, since the muscles used for grasping are different
from the muscles used for pressing your hand against a wall, we did not expect a high
correlation: the value we obtained seems reasonable in this case.
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3.2 Specific Aim II
To investigate the impact of moderate rehabilitation with the impaired arm on
functional recovery with and without post-stroke drug treatment.
Adult female Sprague-Dawley rats (10-12 month old) underwent a cerebral
ischemic stroke induced by endothelin-1 and were then treated daily using a drug
combination of 5 mg/kg fluoxetine and 1 mg/kg simvastatin or a vehicle control beginning
6-12 hours after stroke induction and continued for a total of 91 days. On post-stroke day
eight, the rats were subjected to voluntary physical rehabilitation every other day for five
and half weeks (a total of 19 days rehabilitation), except when the animals were on
restricted diet for Montoya Staircase (fasted overnight, 85% of their ad libitum feed for 2
days). The animal groups in this study are laid out in Table 12. We performed Montoya
Staircase to evaluate functional recovery on post stroke days 3-5, 28-30, 58-60 and 88-90.
All animals were euthanized on post-stroke day 91.

Table 12. Treatment Groups and Rehabilitation for Female Sprague Dawley rats (1012 month)
Group

Treatment

Rehabilitation

Group I (N= 14)

Vehicle Control

No

Duration of
Treatment
90 days

Group II (N=14)

Vehicle Control

Yes

90 days

Group III (N=14)

5 mg/kg fluoxetine +
1mg/kg simvastatin
5 mg/kg fluoxetine +
1mg/kg simvastatin

No

90 days

Yes

90 days

Group IV (N=18)

In pre-stroke training, rats retrieved between 16-18 pellets per forelimb by the end
of training. In the rehabilitation assigned group, there was a significant difference

84

(p=0.002) in the performance of right and left forepaws. More pellets were retrieved using
right forepaws (ANOVA; Tukey post-hoc test) as shown in Figure 27.
Evaluating the post-stroke baseline functional deficit (Figure 28) indicates
statistically significant functional deficit (p<0.001) in post-stroke contralateral sides of
both rehabilitation and non-rehabilitation animals (approximately 55% and 66% functional
deficit, respectively) compared to the ipsilateral side, but no significant difference between
rehabilitation and non-rehabilitation baseline deficits for contralateral function. The
ipsilateral side baseline deficit (26%) of the non-rehabilitation group was found to be
significantly different from the rehabilitation group (3%) (p<0.001). This may have been
caused by slight differences in the depth of endothelin-1 injection in the stroke induction
surgeries, causing the infarct to extend into the corpus callosum.
By examining the influence of physical rehabilitation on contralateral functional
recovery (Figure 29), we noticed that the percentage of contralateral functional recovery
(26%) in the control rehabilitation group is enhanced compared to the non-rehabilitation
group (8.6%), (p =0.014); however, there was no difference in the percentage of
contralateral functional recovery between the fluoxetine & simvastatin (FS) rehabilitation
group and the FS non-rehabilitation group, where both are showing 34% contralateral
recovery (p = 0.98). We did note that the drug plus rehabilitation group reached its 34%
recovery in 30 days, while the drug only group took the entire 90 days to reach 34%
recovery, showing a steady increase each month. Overall, there is a significant difference
between drug-treated groups and control groups (p =0.037) and a significant difference
between non-rehabilitation FS group and non-rehabilitation control group (p =0.014) as
analyzed with two-way ANOVA.

85

Both control and drug non-rehabilitation groups show about 23% of ipsilateral
functional recovery, which was statistically significant (p<0.05) compared to the ipsilateral
functional recovery in control and drug rehabilitation groups (~-0.1%) (Figure 30). Of
course, the rehabilitation groups did not show an ipsilateral deficit in their baseline deficit
following stroke surgery (see Figure 28), so it is not surprising there was no recovery.
Overall, these results suggest that the post-stroke drug combination may allow for
functional motor recovery in individuals for whom physical rehabilitation may not be
available.
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Figure 27. Montoya Staircase Pre-stroke Training. The y-axis depicts the number of
pellets retrieved in each group using contralateral (blue bar) or ipsilateral (red bar)
forelimb before stroke induction. The x-axis shows the rehabilitation assigned group
vs. non-rehabilitation. The graph indicates a significant difference (two-way ANOVA,
p=0.002; Tukey post-hoc test) between ipsilateral and contralateral forepaw
performance among the rehabilitation group, but not the non-rehabilitation group.
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Figure 28. Montoya Staircase Post-Stroke Baseline Functional Deficit. The y-axis
depicts functional deficit in contralateral (blue bar) or ipsilateral (red bar) forelimb.
The x-axis shows the rehabilitation assigned group vs. non-rehabilitation. The graph
indicates a significant functional deficit (p<0.001) in post-stroke contralateral sides of
both rehabilitation and non-rehabilitation groups compared to ipsilateral sides. The
non-rehabilitation group was significantly different from the rehabilitation group
(p<0.001).
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Figure 29. Effect of Physical Rehabilitation on Contralateral Functional Recovery.
Yellow bars denote control groups, and green bars denote FS drug treated groups.
Rehabilitation groups are indicated by hatched bars, and non-rehabilitation groups
are indicated by solid bars. The graph depicts significant difference between drugtreated groups and control groups (p =0.037), and a significant difference between
non-rehabilitation FS group (solid green bar) and non-rehabilitation control group (
solid yellow bar) (p =0.014).
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Figure 30. Effect of Physical Rehabilitation on Ipsilateral Functional Recovery. Both
control and drug non-rehabilitation groups show about 23% of ipsilateral functional
recovery, which was statistically significant (p<0.05) compared to the ipsilateral
functional recovery in control and drug rehabilitation groups. The baseline ipsilateral
functional deficit in the non-rehabilitation group explains the apparent significant
recovery when comparing to rehabilitation group that did not show as much
ipsilateral deficit at the baseline (Figure 30).
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3.3 Specific Aim III
To explore sex-dependent changes in gene expression of inflammation and
polarization markers expressed by microglia in the peri-infarct zone in response to
combination drug treatment. Neurotrophic factors and synaptic plasticity genes will also
be examined in male rats.
The animal groups used in this study are shown in Table 13, with each male group
having an N of 6 pre-stroke and each female group having an N of 6 pre-stroke. All animals
except the control group, were on simvastatin beginning 7 days pre-stroke and continued
daily throughout the study. The functional tests used are shown in the table and were
analyzed in the Specific Aim 1. Animals were euthanized on post-stroke day 7, perfused
with phosphate-buffered saline, then the brain dissected, blocked and quick frozen in
isopentene and dry ice. Peri-infarct region was excised on the cryostat, mRNA prepared,
Table 13. Male and Female Sprague-Dawley rats: Control group received the vehicle.
Simvastatin and FSA groups were on 1mg/kg Simvastatin for seven days before
stroke induction and continued for six days post-stroke, then euthanized. PSD refers
to Post-Stroke Day. All treatment started at 20-26 hours after stroke. There was no
Female Simvastatin only group.
Group

Oral Dose

Montoya

Forelimb

Euthanasia

Staircase Asymmetry
Male and Female Control
Group (N= 6)
Male Simvastatin Group
(N= 6)
Male and Female
FSA Group (N= 6)

Vehicle

PSD 3-5

PSD 4

PSD 7

1 mg/kg Simvastatin

PSD 3-5

PSD 4

PSD 7

5 mg/kg fluoxetine
+ 1 mg/kg
simvastatin
+ 20 mg/kg Vit C

PSD 3-5

PSD 4

PSD 7

and reverse transcribed to cDNA with the Qiagen First Strand Kit. cDNA was then applied
to custom and purchased micro-array real time PCR microarray plates for analysis of gene
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expression differences. All samples in data analysis passed the quality control tests for
PCR array reproducibility, reverse transcription efficiency, and genomic DNA
contamination test. Hypoxanthine phosphoribosyl transferase-1 (Hprt1) and lactate
dehydrogenase A (Ldha) have been chosen from the housekeeping gene panel for
normalization. Other HK genes such as Ppih, Actb and Nono, were not included since they
show small variations between the plates.
Data were analyzed, and statistical significance was assessed by using the online
software at (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). This online
tool does statistical analysis by calculating the p-values and fold changes using a Student’s
t-test (two-tail distribution and equal variances between the two samples) based on the
Livak method in which, Ct value of the target gene normalized to Ct value of the reference
gene in each experiment to obtain ∆Ct. Then ∆Ct of the Test Sample normalized to ∆Ct of
the Control Sample to obtain ∆∆Ct. The Fold Changes in expression is calculated as 2^∆∆Ct, and the Fold Regulation is the negative inverse of the fold change.

3.3.1 Results of Profiling Microglia Markers in FSA treated Male Rats vs. Control

RT2 PCR analysis data was presented as fold-change and fold regulations, where
fold-change 2^(- Delta Delta Ct) is the normalized gene expression 2^(- Delta Ct) in the Test Sample
divided the normalized gene expression 2^(- Delta Ct) in the Control Sample.
Fold-Regulation represents fold-change results in a biologically meaningful way.
Fold-change values greater than 1 indicate a positive or an up-regulation, and the foldregulation is equal to the fold-change. Fold-change values less than 1 indicate a negative
or down-regulation, and the fold-regulation is the negative inverse of the fold-change. The
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lists of genes that are presented in result tables were chosen based on fold upregulation >2
or fold down-regulation <-2. Data was sorted by lowest to highest p-value. The full lists of
all genes including the ones that did not show a significant change are shown in Apendix
VII with fold-change and fold-regulation values greater than 2 are indicated in red; foldchange values less than 0.5 and fold-regulation values less than -2 are indicated in blue.
Table 14 represents significantly up-regulated genes in the FSA treatment group
versus control in male Sprague-Dawely rats. Signal Transducer and Activator of
Transcription Stat4 and Chemokine (C-C motif) ligand 11 Ccl11 show fold regulation of
3.74 and 2.08 (p= 0.0323 and 0.0413, respectively). STAT4 protein is involved in both
classic and alternative immune responses; it binds to specific regions of DNA to promote
T cell activation and proliferation as well as helps in cytokine production. The molecular
mechanisms by which STAT4 modulates the immune system are unclear (Wurster, Tanaka,
& Grusby, 2000). Chemokine (C-C motif) ligand 11 Ccl11 is associated with aging in mice
and humans (Villeda et al., 2011). Brain-derived neurotrophic factor Bdnf was highly
Table 14. Genes up-regulated in FSA treated male rats vs. control group with a fold
regulation >2. Ccl11 and Stat4 are associated with M1 type microglia, and Bdnf is
associated with M2a and M2c type microglia.
Upregulated
Genes
Ccl11
Stat4

Bdnf

Description

Role of the
gene

p-value

Chemokine (C-C
motif) ligand 11
Signal transducer
and activator of
transcription 4
Brain-derived
neurotrophic factor

M1 marker

0.0323

3.74

3.74

M1 marker

0.0413

2.08

2.08

M2a and M2c
marker /
growth factor

0.089

3.85

3.85
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Fold
Fold
Change Regulation

upregulated in male FSA treated animals (fold regulation 3.85) with a trend toward
significance (p =0.089) compared to control group. BDNF has been found to regulate
neuronal activity and enhance neurogenesis (Zigova, Pencea, Wiegand, & Luskin, 1998)
and we believe this growth factor is contributing to both our functional recovery and
smaller infarct size. Our findings on the down-regulated genes in FSA-treated male rats
and the corresponding fold regulation and p-values are summarized below in Table 15. The
only gene that was down-regulated and shows trend towards significance (p=0.094) is the
inducible nitric oxide synthase 2 (Nos2). This gene is associated with inflammatory M1
microglia and is believed to cause most of the damage following stroke.

Table 15. Down-regulated genes in FSA treated male rats with a fold regulation ≤-2.0
Down-regulated

Description

Role of
the gene

p-value

Fold
Change

Fold
Regulation

Nitric oxide
synthase 2,
inducible

M1
marker

0.094

0.50

-2.0

Genes
Nos2

We used the protein-protein interaction (PPI) information reported in STRING
software (version 10.0) to predict interactions between genes in certain pathways. We first
examined the interaction of the highly up-/down-regulated genes with tightly stringent
approach, followed by a loose stringent approach. The networks were identified from a list
of pathways based on the count of gene involved and a False Discovery Rate (FDR)
threshold less than 0.05. Complete lists of differentially expressed genes are provided in
Appendix VII.
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3.3.2 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:
Upregulated Microglia Genes in FSA-treated Male Rats vs. Control

PPI Analysis: Network does not have significantly more interactions than expected. This
means that current set of proteins is either rather small (i.e. less than 5 proteins or so) or
that it is essentially a random collection of proteins that are not very well connected (see
Figure 31). This does not necessarily mean that it is not a biologically meaningful selection

Figure 31. Predicted protein-protein interaction network (PPI) of the up-regulated
genes in male FSA treatment group created by STRING 10.0 (tight stringency)
(Threshold: 0.4, medium confidence).

of proteins, it could simply be that these proteins have not been studied very much and that
their interactions might not yet be known to STRING. All genes that belong to same
pathway are represented in red highlighted nodes.
Both Ccl11 and Stat4 are M1 microglia biomarkers that are involved in chronic
inflammatory response. Bdnf gene, however, is an M2 biomarker and essential contributor
in neurogenesis. The large nodes suggest that some 3D structure is known or predicted.
The very thin line between Ccl11 and Stat4 indicates weak interactions between the two
molecules.
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Figure 32. Predicted protein-protein interaction network (PPI) of up-regulated genes
in male FSA treatment group (loose stringency) shows 5 genes involved in
inflammatory response and positive regulation of cell communication. (Threshold:
0.4, medium confidence).

In Figure 32, we examined protein-protein interaction of the upregulated genes in Male
FSA versus control with loose stringency. Here we see growth factors or their receptors
up-regulated (Bdnf, Fgf9 and Npy2r) with upregulation of Stat3, a M2 microglial marker.
The network shows interaction between Stat4, Ccl11 (M1 markers) and Stat3 (M2 marker)
because these shifts are fluid rather than absolute, retaining some markers as the shift
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occurs. We begin to see interactions between the neuropeptide Y receptor 2 and Gal
receptor1, and also see some signs of stress (upregulated corticotropin-releasing hormone
releasing hormone and its binding protein), but the binding protein may actually be
reducing the stress effect by preventing Crh binding to its receptor.

Figure 33. Predicted protein-protein interaction network (PPI) of down-regulated
genes in male FSA treatment group (loose stringency) shows a large count of genes
involved in cytokine-cytokine receptor interaction.
confidence).
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(Threshold: 0.4, medium

In Figure 33, we see a general downregulation of inflammatory factors (Cd40, Il6, Stat1,
Nos2, Tnf) but we also see some beginning downregulation of some anti-inflammatory
factors (Tgfb, Il10ra, Arg1(M2 microglia marker)). We see downregulation of Crh
receptors and downregulation of some growth factors and neuroplasticity markers.

3.3.3 Results of Profiling Microglia Markers in FSA treated Female vs. Control

Table 16. Up-regulated genes with fold regulation >2 in female rats treated with FSA
vs. control.
Upregulated
Genes
Sox2
Crhr1
Camk2g

Crh

Crhbp

Description

Role of the
gene

p-value

Fold
Change

Fold
Regulation

SRY (sex determining
region Y)-box 2
Corticotropin releasing
hormone receptor 1
Calcium/calmodulindependent protein kinase II
gamma
Corticotropin releasing
hormone

transcription
factor
receptor in
rat microglia
CREB
cofactor

0.047

2.5115

2.5115

0.103

2.4755

2.4755

0.125

2.1039

2.1039

Neuropeptide
involved in
microglia
activation
Neuropeptide

0.147

2.3538

2.3538

0.215

2.2195

2.2195

Neuronal
apoptosis
Apoptotic
factor

0.310

2.0208

2.0208

0.412

2.1142

2.1142

Cbln1

Corticotropin releasing
hormone binding protein
Cerebellin 1 precursor

Nell1

NEL-like 1

Table 16 show a significant upregulation of Sox2 in female rats, which is a
transcription factor important for maintaining self-renewal of undifferentiated embryonic
stem cells. Sox2 plays a vital role in maintenance of neural stem cells. Other upregulated
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genes that show trend toward significance are Crhr1, Camk2g, Crh, Crhbp, Cbln1 and
Nell1.
Crhr1 gene encodes corticotropin releasing hormone receptor-1 (CRH-R1). Both
in vitro studies on embryonic rat microglia culture (W. Wang, Ji, Riopelle, & Dow, 2002),
and in vivo studies (Stevens et al., 2003) found that CRH-R1 and CRH-R2 receptors are
expressed on microglia in rodent’s brain with CRH-R1 being the predominant receptor
expressed in rat brain microglia. These findings suggest that microglia may play a role in
mediating effects of corticotropin releasing hormone in brain under normal and
pathological conditions.
Table 17 indicates a reasonable trend of down-regulation of Arginase Arg1, which
is an M2a and M2c biomarker that involved in cellular response to hydrogen peroxide,
tissue remodeling, response to toxic substance and response to wounding (Kolluru, Bir, &
Kevil, 2012).

Table 17. Down-regulated genes in female rats treated with FSA
Down-regulated
Genes
Arg1

Description
Arginase

Role of the
gene
M2a, M2c
marker

p-value
0.155

Fold
Fold
Change Regulation
0.3795
-2.6353

3.3.4 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:
Up-regulated Microglia Genes in FSA-treated Female Rats vs. Control
PPI Analysis: The network has significantly more interactions than expected. Proteins
have more interactions among themselves than what would be expected for a random set
of proteins of similar size, drawn from the genome. Such an enrichment indicates that the
proteins are at least partially biologically connected, as a group.
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For tight clustering using only the upregulated genes from Table 16, the predicted
graph shows the highest number of genes are involved in two networks consisting of 6 and
4 genes. These networks are: single-organism cellular process and regulation of synapse
structure or activity (Figure 34 A and B).

A.

B.

Figure 34. PPI analysis of up-regulated genes in female FSA treatment group (tight
stringency). (A). Genes involved in single-organism cellular process. (B). Genes play
role in regulation of synapse structure or activity. (Threshold: 0.4, medium
confidence).
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Figure 35. PPI analysis of up-regulated genes in female FSA treatment group (loose
stringency) shows 19 microglia genes are involved in positive regulation of cell
communication.

101

In Figure 35, we see interactions that may have occurred if we had used a higher N in
our gene analysis to obtain lower p values. We see a stress network (Crh receptors and
binding protein) connected to synaptic plasticity network (Creb1, Camk2a, Camk2g, Bdnf)
and also see more growth factors upregulated. This network is strikingly more complex
than that seen in male rats with the same drug treatment.

3.3.5 Results of Profiling Microglia Markers in Simvastatin-treated Male Rats vs.
Control
Testing samples from male rats pre-treated with simvastatin for 7 days before stroke
surgery, and 6 days after stroke induction shows that Chemokine (C-C motif) ligand 11
(Ccl11), which is associated with M1 microglia, is significantly up-regulated as seen in
FSA treated male rats but not FSA treated females. In addition, both cerebellin 1 precursor
and Brain-derived neurotrophic factor were highly expressed.

Table 18. Up-regulated genes in male rats treated with simvastatin compared to
control.
Upregulated
Genes
Ccl11
Cbln1

Bdnf

Description

Role of the
gene

p-value

Chemokine (C-C
motif) ligand 11
Cerebellin 1 precursor

M1 marker

0.022319

2.3405

2.3405

Regulates
synapse
function
M2a and
M2c
marker/
growth
factor

0.185183

2.0057

2.0057

0.200537

3.0055

3.0055

Brain-derived
neurotrophic factor
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Fold
Fold
Change Regulation

In contrast to FSA treated males, none of the genes in simvastatin treatment group
was significantly down-regulated to -2. This suggests a possible essential role of fluoxetine
as an anti-inflammatory agent inhibiting the inducible nitric oxide synthase 2 (Nos2), which
associated with inflammatory M1 microglia.
3.3.6 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:
Up-regulated Microglia Genes in Simvastatin-treated Male Rats vs. Control

PPI Analysis: As seen in FSA male groups, network does not have significantly more
interactions than expected. Although the upregulated genes are not directly connected to
each other, the STRING system proposed that all of these genes are involved in positive
regulation of cellular component biogenesis and both Bdnf and Cbln1 contribute to positive
regulation of synapse assembly.

Figure 36. PPI analysis of up-regulated genes in male simvastatin treatment group.
(Tight stringency) (Threshold: 0.4, medium confidence).

Figure 36 shows the protein-protein interaction analysis with loose stringency to
both upregulated and down-regulated genes displays 16 up-regulated genes that are
connected in positive regulation of signal transduction. We see upregulation of growth
factors and their receptors (Bdnf, Cntf, receptors for neuropeptide Y) and synaptic plasticity
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genes. Interestingly, we see association of the Stat genes that are associated with the
different M1 and M2 microglial subtypes, as well as other associated markers, again
suggesting a fluid transition from one microglial subtype to another. These genes seem to
be predominately anti-inflammatory. On the other hand, three of the down-regulated genes
(Vegfa, Nos2 and il6) appear to be involved in hypoxia-inducible factor (HIF-1) signaling
pathway that mediates the cellular oxygen signaling pathway, and plays a multifaceted role
of HIF-1 in outcomes of ischemic stroke (Kalakech et al., 2013), (Sharp, Bergeron, &
Bernaudin, 2001) .
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A.

B.

Figure 37. PPI analysis of up-regulated genes in male simvastatin treatment group
(A); and down-regulated genes (B) (loose stringency). (Threshold: 0.4, medium
confidence).
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3.3.7 Comparing the Expression of Microglia Markers in FSA treated Female Rats to
FSA treated Males
Examining changes in gene expression patterns in female rats in relation to same
age male rats that received same drug combination treatment (used as control in this
analysis) showed a tendency towards statistical significance in the expression of a potent
neurotrophic factor, GDNF family receptor alpha 3 (Gfra3), with a 6 fold increase. This
protein play key role in the control of neuron survival and differentiation. Other upregulated genes in response to the FSA treatment in female rats are: cluster of
differentiation (Cd163 gene), which is an M2 microglia marker that is expressed when
microglia is recruited to sites of ischemia (Cherry, Olschowka, & O'Banion, 2014). CD163
protein functions in hemoglobin scavenging (Kowal et al., 2011), and it has been used in
experimental studies to identify M2 microglia in rat traumatic brain injury (Z. Zhang,
Zhang, Wu, & Schluesener, 2012). Moreover, multiple pro-inflammatory biomarkers of
M1 microglia appear to be up-regulated in females compared than male rats, which include
Il1b, Nos2, Tnf, Stat1, il10ra and Il6 cytokines.
Although there was no significant difference in gene expression between the two
tested genders, this pattern of response to the drug treatment in female rats may promote
future studies to build on these findings and determine whether the two genders are
significantly different from one another. Significant variation could be seen after increasing
the number of experimental animals.
Gene regulation pattern in female FSA treated animals vs. male FSA treated animal
is represented in Table 19.
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Table 19. Up-regulated genes in female FSA treated group compared to male FSA
treated rats.

Upregulated
Genes
Gfra3
Cd163
Cntf

Il1b
Nos2
Tnf
Tgfb1
Cxcr4
Stat1

il10ra
Cd40

Gmfg
Il6

Description

Role of the
gene

p-value

Fold
Change

Fold
Regulation

GDNF family
receptor alpha 3
CD163 molecule
Ciliary neurotrophic
factor

Neurogenesis

0.084574

5.8624

5.8624

Cytokine
Neurotrophic
factor/ Cell
differentiation
Cytokine
M1 marker

0.089223
0.105728

3.0674
2.2289

3.0674
2.2289

0.150449
0.174178

3.2735
2.371

3.2735
2.371

Cytokine / M1
marker
Growth factor

0.273191

3.012

3.012

0.295521

2.6995

2.6995

Cytokine / M1
marker
M1 marker

0.346437

3.4937

3.4937

0.352873

2.3304

2.3304

Cytokine / M1
marker
Apoptotic
factor

0.464164

2.0297

2.0297

0.487533

2.4509

2.4509

Growth factor

0.582022

2.2929

2.2929

Cytokine

0.639032

2.3906

2.3906

Interleukin 1 beta
Nitric oxide synthase
2, inducible
Tumor necrosis
factor
Transforming growth
factor, beta 1
Chemokine (C-X-C
motif) receptor 4
Signal transducer and
activator of
transcription 1
Interleukin 10
receptor, alpha
CD40 molecule, TNF
receptor superfamily
member 5
Glia maturation
factor, gamma
Interleukin 6
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3.3.8 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:
Up-regulated Microglia Genes in Female FSA vs. Male FSA Group

PPI Analysis: Network has significantly more interactions than expected. Figure 38 shows
six genes in the tight stringency analysis appear to influence positive regulation of response
to external stimulus. These are the neurotrophic factor ciliary neurotrophic factor (Cntf),
M1 microglia markers; interleukin 1 beta (Ilb), Tumor necrosis factor (Tnf), Interleukin 6
(Il6) and Chemokine (C-X-C motif) receptor 4 (Cxcr4) (red highlighted nodes in Figure
38). In the loose stringency prediction, half of all upregulated genes are involved in signal
transduction and cell communication (Figure 39).

Figure 38. PPI analysis of up-regulated genes in female FSA treatment group
compared to male FSA group (tight stringency). (Threshold: 0.4, medium
confidence).
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Figure 39. PPI analysis of up-regulated genes in female FSA treatment group
compared to male FSA group (loose stringency). Graph indicates that (Threshold:
0.4, medium confidence).
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3.3.9 Comparing the Expression of Microglia Markers in Female Control against
Male Control Group
Profiling gene expression in female control group against male control (Table 20)
shows that Sox2 is the only significant down-regulated gene with a p-value 0.046. A group
of 10 other genes were down-regulated with at least a -2 fold regulation. This may indicate
a sex-dependent difference in gene expression pattern in response to endothelin induced
stroke. The down-regulated genes are presented in the table below and their predicted
interactions are demonstrated in Figures 40 and 41.
Table 20. Down-regulated genes in control female rats compared to control male
rats.
Downregulated
Genes
Sox2
Cntfr

Camk2g

Fgf9
Npy2r
Crhr1
Npy1r
Cbln1
Arg1
Camk2a

Nell1

Description

Role of the
gene

p-value

SRY (sex determining
region Y)-box 2
Ciliary neurotrophic factor

Transcription
factor

0.046

0.403

-2.4814

Neurotrophic
factor/ Cell
differentiation
CREB cofactor

0.074

0.4995

-2.0022

0.130

0.4639

-2.1558

Cell
differentiation
Neuropeptide

0.1307

0.4431

-2.2566

0.151

0.4974

-2.0105

CRH receptor

0.172

0.4365

-2.2911

Neuropeptide

0.268

0.4962

-2.0152

M2 marker

0.286
0.343
0.415

0.4205
2.6161
0.4426

-2.3784
2.6161
-2.2593

0.443

0.4082

-2.4496

Calcium/calmodulindependent protein kinase II
gamma
Fibroblast growth factor 9
Neuropeptide Y receptor
Y2
Corticotropin releasing
hormone receptor 1
Neuropeptide Y receptor
Y1
Cerebellin 1 precursor
Arginase
Calcium/calmodulindependent protein kinase II
alpha
NEL-like 1

Synaptic
plasticity

Apoptotic
factor
110

Fold
Fold
Change Regulation

3.3.10 Analysis of Protein-Protein Interaction (PPI) in Microglia Markers:
Down-regulated Microglia Genes in Female Control vs. Male Control Group

PPI Analysis: The network has significantly more interactions than expected. In Figure
40, regulation of synapse structure or activity is the only predicted biological pathway in
which 4 genes are involved. These genes are (Crhr1, Camk2a, Camk2g and Cbln1). Underexpression of these important genes in control untreated female rats when compared to
control males worth further investigation. The loose stringency analysis in Figure 41 shows
that genes are primarily involved in signal transduction and cellular response to
endogenous stimulus and cell differentiation.

Figure 40. PPI analysis of down-regulated genes in female control group compared
to male control group (tight stringency). (Threshold: 0.4, medium confidence).
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Figure 41. PPI analysis of down-regulated genes in female control group compared
to male control group (loose stringency). (Threshold: 0.4, medium confidence).
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3.3.11 Results for Neurotrophic Gene Profiling in Male Rats
Gene analysis of neurotrophic factors and their receptors shows upregulation of
multiple growth factors and their receptors in Table 22 and downregulation of genes in
Table 23. Male (10-12 months) Sprague-Dawley rats that were treated with FSA for 7 days
after stroke and were compared to vehicle control in this gene expression analysis
according to the groups are listed in Table 22.

Table 21. Treatment groups for genetic analysis of neurotrophic factors

RT-qPCR Array

Control Group

FSA Group

Neurotrophins and Receptors

N=6

N=5

In Table 23, one of the markedly up-regulated genes is orexin (also known as
hypocretin HcRt) with a trend towards significance in FSA treated group of male SpragueDawley rats. This was similar to previous results in female rats using this same microarray
plate. In the current study on male FSA treated vs. control, orexin (HcRt) shows about 10
fold of increase (9.92). Our previous work on female rats (10-12 month) treated with the
same dose of FSA for 10 days after stroke showed that HcRt was upregulated to 2.06 fold.
Another experiment in our lab on female 10-12 month rats using fluoxetine and simvastatin
(FS) without ascorbic acid for 10 days treatment indicates that orexin receptors Hctr1 and
Hctr2 are up-regulated to 2.07 and 2.93, respectively ( p <0.05). This suggests that males
and females may require different drug combinations for optimal recovery after stroke.
A summary of the main orexinergic pathways and receptor mRNA distribution in
the rat brain is illustrated in Figure 42. Note particularly that the orexin receptors are in the
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cortex itself, and are thought to increase Bdnf when activated. In human stroke patients,
decrease in orexin in the blood following stroke has been observed. This upregulation of
receptors that we see may help counter the drop of orexin in this region, helping more of
the cortex survive. Other potential players in the possible neuroprotective role of the drug
combination are listed below in Table 22 and Table 23.

Table 22. Neurotrophic Factors and Receptors: Gene profiling in male SpragueDawley rats shows up-regulated genes in FSA treated group vs. control group.
Upregulated
Genes
Nr1i2

HcRt
Grpr
Bdnf

Description

Role of the
gene

p-value

Fold
Change

Fold
Regulation

Nuclear receptor
subfamily 1, group
I, member 2
Orexin/Hypocretin
Gastrin releasing
peptide receptor
Brain-derived
neurotrophic factor

Transcription
factor

0.039

3.77

3.77

Neuropeptide
Neuropeptide

0.128
0.132

9.92
2.24

9.92
2.24

M2a and M2c
marker/
growth factor

0.275

3.97

3.97
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Table 23. Neurotrophic Factors and Receptors: Gene profiling in male SpragueDawley rats shows down-regulated genes in FSA treated group vs. control group.

Downregulated
Genes
Fas

Description

Il1b

Fas (TNF receptor
superfamily, member
6)
Interleukin 1 beta

Il10

Interleukin 10

Lif
Hspb1

Leukemia inhibitory
factor
Heat shock protein 1

Il6

Interleukin 6

Cxcr4

Chemokine (C-X-C
motif) receptor 4
Myelocytomatosis
oncogene

Myc

Role of p-value
the gene
Apoptotic 0.031
factor

Fold
Change
0.40

Fold
Regulation
-2.47

M1
marker
M1
marker
Cytokine

0.032

0.38

-2.57

0.059

0.45

-2.21

0.149

0.28

-3.52

Apoptotic
factor
M1
marker
Cytokine

0.160

0.35

-2.79

0.210

0.36

-2.74

0.260

0.43

-2.27

Apoptotic
factor

0.490

0.49

-2.03
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Figure 42. The schematic diagram illustrates the majority of orexinergic pathways
and locations in brain. The level of expression varies between areas. CA1–3 = areas
of hippocampus; CC = cingulate cortex; CMN = centromedial nucleus; DRN = dorsal
raphe; LC = locus coeruleus; MRN = median raphe nucleus; NST = nucleus of solitary
tract; olfB = olfactory bulb; olfT = olfactory tubercle; PVN = paraventricular
nucleus; NRM = nucleus raphe magnus; RO = nucleus raphe obscurus; SCN =
suprachiasmatic nucleus; SON = supraoptic nucleus; STN = spinal trigeminal
nucleus; TMN = tuberomamillary nucleus; VAMN = ventral anteromedial nuclei.
Adapted from The Hypothalamic Orexinergic System: Pain and Primary Headaches
(Holland & Goadsby, 2007).
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3.3.12 Analysis of Protein-Protein Interaction (PPI) within Neurotrophic Genes in
Male Rats

PPI Analysis: The tight stringency analysis of upregulated genes for Male FSA versus
control is shown in Figure 43. The network does not have significantly more interactions
than expected. This could be explained by the small number of interacting proteins or
because it is essentially a random collection of proteins that are not very well connected.
Again, this does not necessarily mean that it is not a biologically meaningful selection of
proteins, it could be that these proteins have not been studied very much and that their
interactions might not yet be known to STRING.
The loose stringency analysis of the upregulated genes in Figure 45 indicates that the
upregulated HcRt and Bdnf genes networked through the neuropeptide Y receptors.

Figure 43. PPI analysis of up-regulated neurotrophic genes in male FSA group
compared to male control group (tight stringency). (Threshold: 0.4, medium
confidence).
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On the other hand, PPI prediction shows that down-regulated neurotrophic factors
are part of regulatory pathway of programmed cell death (Figure 44, A) and inflammatory
immune response process (Figure 44, B). Loose stringency (Figure 46) showed more
network connections

A.

B.

Figure 44. PPI analysis of down-regulated neurotrophic genes in male FSA group
compared to male control group (tight stringency). A. Genes that involved in
regulation of apoptosis; B. Genes that involved in immune response. (Threshold: 0.4,
medium confidence).
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Figure 45. PPI analysis of up-regulated neurotrophic genes in male FSA group
compared to male control group (loose stringency). (Threshold: 0.4, medium
confidence).
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Figure 46. PPI analysis of down-regulated neurotrophic genes in male FSA group
compared to male control group (loose stringency). (Threshold: 0.4, medium
confidence).
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3.3.13 Results for Synaptic Plasticity Gene Profiling in Male Rats

Table 24 shows the number of animals used in RT-qPCR analysis of synaptic
plasticity gene upregulation in male (10-12 months) Sprague-Dawley rats that treated with
FSA for 7 days after stroke were compared to vehicle control.

Table 24. Treatment groups for genetic analysis of synaptic plasticity factors
RT-qPCR Array

Control Group

FSA Group

Synaptic Plasticity

N=6

N=5

Profiling of synaptic plasticity genes of FSA-treated male animals in Table 25
(upregulated genes) shows increase in a cell adhesion gene, Protocadherin 8 (Pcdh8) that
may be confirmed by increasing number of animals. The results of profiling synaptic
plasticity genes were uploaded to STRING program and investigated for any proteinprotein interactions under loose and stringent clustering settings.

Table 25. Synaptic Plasticity Gene Profiling in Male Sprague-Dawley rats: Table
shows up-regulated gene in FSA treated group vs. Control group.
UpDescription
Role of the
p-value
Fold
Fold
regulated
gene
Change
Regulation
Genes
Pcdh8
Protocadherin 8
Cell
0.218854
2.851
2.851
adhesion

Table 25 shows the downregulated genes in Male FSA treated group versus control when
using the Synaptic Plasticity RT PCR microarray plate.

Interestingly, we see

downregulation of matrix metallopeptidase 9, which is thought to be involved is
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hemorrhagic transformation after stroke. The FSA treated rats had a lower relative risk of
hemorrhagic transfomation compared to controls.

Table 26. Synaptic Plasticity Gene Profiling in Male Sprague-Dawley rats: Table
shows down-regulated genes in FSA treated group vs. Control group.
Downregulated
Genes
Mmp9

Cebpd

Igf1

Description

Matrix metallopeptidase 9

CCAAT/enhancer binding
protein (C/EBP), delta

Insulin-like growth factor 1

Role of the
gene

p-value

Immediate- 0.177072
Early
Response
Gene
Immediate- 0.186163

Fold
Change

Fold
Regulation

0.4552

-2.1968

0.3841

-2.6035

0.4222

-2.3683

Early
Response
Gene

Long Term 0.401632
Depression
(LTD)
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3.3.14 Analysis of Protein-Protein Interaction (PPI) within Synaptic Plasticity Genes
in Male Rats

PPI Analysis: In Figure 47, the network does not have significantly more interactions
than expected due to the number of tested genes or the lack of information about their
interactions. The PPI prediction suggests that two of the down-regulated genes, Igf1 and
Mmp9, are involved in transcriptional misregulation in cancer, but Mmp9 is also associated
with damage in stroke. As shown in a previous study on adult male mice (J. Y. Lee et al.,
2012), fluoxetine in the drug combination appears to down-regulate matrix metalloprotease
gene (Mmp9) which responsible for degrading the extracellular matrix proteins and
involved in blood-brain-barrier damage after ischemic stroke.

Figure 47. PPI analysis of down-regulated synaptic plasticity genes in male FSA
group compared to male control group (tight stringency).

The backbone network in Figure 48 (loose stringency of upregulated genes)
consists of 29 nodes of which 20 genes (red nodes) are involved in positive regulation of
cellular process with medium to high interactions. Upregulating of these genes reveals a
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positive role of the FSA drug combination in synaptic plasticity in male rats as seen before
in females. These genes in a different network pattern are involved in learning,
neurogenesis, protein binding, and regulation of apoptotic process, cell communication,
and signal transduction, cellular response to stimulus and cellular components of neuron
projections.

Figure 48. PPI analysis of up-regulated synaptic plasticity genes in male FSA group
compared to male control group (loose stringency). The 3D structure of the majority
of the clustered proteins is known from the literature.
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One interesting gene family network in the down-regulated genes (although they
are not significant), is their clustering in glutamatergic synapse pathway representing the
metabotropic glutamate receptors. This includes Grm1, Grm2, Grm3, Grm5, and Grm8.
Glutamate is a key excitatory neurotransmitter that thought to mediate neuronal damage
after cerebral ischemia by acting upon these receptors (J. M. Lee, Grabb, Zipfel, & Choi,
2000).

Figure 49. PPI analysis of down-regulated synaptic plasticity genes in male FSA
group compared to male control group (loose stringency).

125

CHAPTER IV
DISCUSSION

Stroke is a cerebrovascular accident that occurs when the normal blood supply to
the brain is interrupted. With the limited availability of pharmacologic therapy to treat
stroke and the increase in number of people having stroke along with the cost of treatment
that is projected to more than double by 2030, there remains a pressing need for finding an
appropriate post-stroke drug or drug combination that can prevent long-term disability and
save lives.
Preclinical stroke research
Despite the remarkable investments in advancing translational research; numerous
pre-clinical stroke studies failed in translating their outcomes into human clinical trials.
Some reasons that explain this failure are related to poor experimental design in which
inappropriate animal models employed did not sufficiently simulate the clinical condition
in humans. The lack of efficient methodologies and accurate data analysis, blinding and
randomization of experimental data are essential factors that contribute to this unsuccessful
translation. Also, publication bias and funding resources could hugely influence the
reliability of studies. We considered a combination of innovative approaches to closely
mirror what happens in the clinic and bridge the gap between the two sides of translational
research. By optimizing the pre-clinical studies design, we aimed at developing the most

126

appropriate animal model and methodologies to increase the translational capability of the
stroke model.
Pre-clinical studies in other laboratories have looked at fluoxetine administration
in animals after stroke induction, or traumatic brain injury, and many have failed to see any
positive effect of the fluoxetine (Couillard-Despres et al., 2009; Y. Wang et al., 2011;
Windle & Corbett, 2005). In several of these studies, neurogenesis is examined primarily
in the dentate gyrus, with only cursory examination of neurogenesis in lateral ventricles
that are very posterior in the brain (to the side of the hippocampus). Also, the delivery
method for fluoxetine is one which would induce stress in the animal (surgical implantation
of an osmotic pump delivering fluoxetine, daily intraperitoneal injections of fluoxetine,
oral gavage of fluoxetine, etc.). We have seen increases in neurogenesis in older (10-12
month) rats in the subventricular zone (SVZ) of the anterior lateral ventricles in the
presence of fluoxetine when it is given with voluntary oral administration, thus eliminating
any stress with the administration of the drug. We also see functional recovery, which
correlates well with what is being observed in clinical trials of the drug in stroke patients
(Chollet et al., 2011; Gaillard & Mir, 2011) or traumatic brain injury patients (Horsfield et
al., 2002). Since stress has an inhibitory effect on neurogenesis and fluoxetine can induce
neurogenesis (Dwivedi, Rizavi, & Pandey, 2006; Hitoshi et al., 2007), we believe that care
must be taken to eliminate stress when administering the fluoxetine to animal models of
disease, which our drug delivery system accomplishes (A. Corbett et al., 2012).
Animal models are designed to provide therapeutic relevance to human research,
however, there is an ongoing disconnect between animal studies and human clinical trials
that can be mainly attributed to either employing improper animal age or sex preference.
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Gender bias exists in animal stroke models, in which male models are usually employed in
pre-clinical studies (Dietz, 2006). Consistency with using methods that have been shown
to induce deficits in an animal model similar to human stroke patients and using a reliable
method of drug delivery and suitable functional evaluation techniques are fundamental
factors of sound pre-clinical research. In addition, randomization and blinding of the
experimenter to treatment conditions are crucial to eliminate bias.
Since the majority of pre-clinical stroke studies conducted on young rats, they often
show spontaneous recovery after focal ischemia. To better correlate with the human stroke
population, animal models need to be middle-aged or older. We use adult male and female
Sprague-Dawley rats at 10-12 months of age as an animal model of stroke because of their
age correlates with middle age human, and their blood vessel collateralization is similar to
the human population. We are assessing differences between females and males, as
diversity in the response to stroke is clinically relevant. Moreover, we suggest further
experimentation in a variety of species such as rabbits and guinea pigs and even larger
animal models to confirm any findings.
Appropriate Timing of Drug Administration
Fluoxetine, simvastatin and ascorbic acid combination that was developed in our
lab might be a potential therapeutic intervention to complement the limited availability of
thrombolytic therapy rt-PA, and improve functional motor recovery after ischemic stroke.
Given the results of a previous study in our lab on adult (10-12 month) female SpragueDawley rats (Balch et al., 2015), it appears that delivering fluoxetine 20-26 hours after
stroke induction not only promotes functional motor recovery but also reduces the infarct
volume significantly compared to giving the fluoxetine within 6-12 hours of stroke
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induction. Moreover, administrating the fluoxetine early (6-12hrs) led to developing a
secondary hemorrhagic stroke in female rats.
The current work has emphasized the importance of timing in the delivery of the
fluoxetine to a male rat model of ischemic stroke already on simvastatin. Studying the
effect of fluoxetine in an animal model of stroke where the rats were already on statins,
7days before stroke induction, correlates better with what is seen during clinical trials with
fluoxetine, as almost a third of the clinical trial patient are on statins. The finding of this
study in adult (10-12 month) male Sparague-Dawley rats suggests that functional outcome
might be substantially enhanced by administering fluoxetine within 20-26 hours of a stroke
rather than having the first delivery at 48-54 hours after stroke. Findings of this study are
similar to those of females and showed signs of hemorrhagic transformation at both the
early time point of drug administratinon (6-12 hrs), and delayed time (48-54 hrs) following
stroke. However, any hemorrhagic transformation in male rats were in the reperfusion
injury region, extending from the original site of injection and no isolated hemorrhagic
infarcts were seen in the males, in direct contrast to the females.
Refining the Functional Assessment of Stroke
Finding appropriate tests to assess functional outcome in preclinical studies of
stroke is imperative. Due to the range of different deficits that accompany stroke, a variety
of functional tests that are sensitive to the extent of damage, location of the stroke, and
beneficial treatment should be applied. Although there are multiple functional tests, I only
covered the most commonly performed functional assessments of motor function in the
rodent stroke model (Montoya staircase and forelimb asymmetry test). Montoya staircase
is considered more sensitive and able to detect even moderate functional impairments
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following stroke, due to the fine motor control involved in grasping and holding onto a
small object. The forelimb asymmetry analysis has the advantages over Montoya’s test in
that no pre-training of the animals is required, and no expensive apparatus is needed.
However, a more accurate approach is required to adequately assess functional deficit and
recovery using this cylinder test. Behavioral studies traditionally count every touch made
by the animal to the wall. I analyzed pre-stroke versus post-stroke wall touches and found
that fingertip touches to the wall were only seen post-stroke, so are likely to be abnormal
touching seen only after injury.

In my approach, I calculated the percentage of deficit

obtained from counting palm touches versus palm and fingertip touches and compared the
outcome to the results obtained from Montoya staircase analysis. The results showed that
in female rats there was a slightly better correlation between the results of Montoya
staircase and the forelimb asymmetry analyses when only palm touches were counted.
These findings might provide evidence of an increased sensitivity of the Forelimb
Asymmetry test through the use of the modified counting method (palm only counted as a
normal touch), which needs further confirmation with a larger number of experimental
animals. By evaluating the available functional assessments in clinical trials, the outcomes
of both Forelimb Asymmetry test and Montoya Staircase can be translated over to human
clinical trial studies, with similarities in both the Fugl-Meyer Assessment and the Modified
Rankin Score.
Infarct Volumes in Female Sprague-Dawley Rats
The previous work in our lab to evaluate infarct volume in 10-12 month female
Sprague-Dawley rats were conducted by using a Cresyl Violet (Nissl) stain, in which slides
of coronal sections of the brain were stained, cleared and dehydrated using a series of timed
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washes. After the stained tissue was dry, cover slips were placed over the tissue using a
permanent mordant DPX (Balch, 2014).
Table 27. Female treatment groups with different times of drug delivery. Combined
medications (5 mg/kg fluoxetine and 1 mg/kg simvastatin) were orally administered either
beginning 6-12 hours or 20-26 hours after stroke induction and continued daily for 90 days.
Infarct volumes were assessed at post-stroke day 91 using Nissl stained coronal brain
sections (representative sections shown in Figure 50).
Group

Oral Dose

Montoya

Forelimb

Euthanasia

Staircase Asymmetry
6-12 hrs. Control
(N=8)
6-12 hrs. FS
(N=11)

None

PSD 3-5

PSD 4

PSD 91

1 mg/kg statin
5 mg/kg fluoxetine

PSD 3-5

PSD 4

PSD 91

20-26 hrs. Control
(N=8)

None

PSD 3-5

PSD 4

PSD 91

20-26 hrs. FS
(N=6)

1 mg/kg statin
5 mg/kg fluoxetine

PSD 3-5

PSD 4

PSD 91

In Figure 50, I put together the montages for the Nissl stained brain sections
(representative figures) used in this publication in which I was a co-first author (Balch et
al., 2015). This work showed some similar changes to that seen in my work on the male
rats. In particular, notice that in panel A and C, which are control animals for 6-12 hour
and 20-26 hour administration respectively, you can clearly see the injection site for the
endothelin at the top of the cortex, and to the right of this site there is extensive damage
which is likely caused by reperfusion injury. Inflammatory microglia are thought to be
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involved in both making the blood brain barrier permeable after stroke and allowing
infiltration of peripheral macrophages and lymphocytes, which cause most of the damage
in reperfusion injury. Note that in Panels B and D, where drug treatment with fluoxetine
and simvastatin has occurred, we do not see the extensive reperfusion damage associated
with the injection site, although the 6-12 hour drug administration rats do have evidence of
secondary bleeding.

Figure 50: Representative Nissl stained coronal sections showing infarcts from female
stroke rats (control versus fluoxetine, simvastatin treated) at two different administration
time-points. These rats received fluoxetine (5 mg/kg) and simvastatin (1 mg/kg) at either
6-12 hours after stroke (Panel B) or 20-26 hours after stroke (Panel D). Control rats are in
panels A and C for 6-12 hours after stroke and 20-26 hours after stroke respectively. The
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lower infarct on Panel B, with fluoxetine and simvastatin given after 6-12 hours, represents
a secondary hemorrhagic infarct, totally dissociated from the original infarct site: these
were only seen in female rats, although male rats did show hemorrhagic transformation
within the reperfusion injury. Rats were euthanized 90 days post-stroke. The scale bar
indicates 500 micrometers.

Figure 51. Infarct volumes vary with timing of fluoxetine and simvastatin delivery after
ischemic stroke. (A). in delayed drug delivery time (20-26 hrs. post-stroke), a strong trend
of volume reduction was seen using t-test with Welch’s correction for the drug group,
but missed a significant difference (3 ± 0.3447 mm3 SEM, p =0.0563). (B). Infarct volumes
in early drug delivery time (6-12 hrs. post-stroke) showed no statistical difference
(p=0.1347) when compared to vehicle control using t-test with Welch’s correction for the
drug group. (C). Direct comparison of infarct volumes between early and delayed treatment
groups that indicates significant difference using t-test with Welch’s correction (15.4 ±
4.260 mm3 SEM, p =0.0157), with the earlier delivery time producing a much larger infarct.
Each dot represents an animal in each group. The x-axis displays treatment groups, and
the y-axis shows the infarct volume in mm3. The broad horizontal bar indicates the
group mean and the error bars represent SEM, with individual infarct volumes given by
closed symbols clustered around means.
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Impact of Physical Rehabilitation on Motor Recovery
Another limitation for a successful translation between experimental studies and
clinical research is the usefulness of the rehabilitation procedure and time. Appropriate and
adequate physical rehabilitation is essential to ensuring effective improvement of poststroke motor recovery in a rodent model. To obtain reliable data, the chosen method of
physical rehabilitation we utilized was performed with minimum stress and anxiety to the
animals. Our findings indicate that the drug combination (fluoxetine and simvastatin)
treatment in female Sprague-Dawley rats achieved slightly greater motor functional
recovery in rehabilitated animals compared to rehabilitated vehicle-treated animals.
Rehabilitation did not improve the overall functional recovery seen in the drug treated
animals, but it did seem to speed the overall recovery, with drug combination only
providing a slower steady progression. This drug treatment, however, may provide
adequate recovery for human stroke patients who cannot participate in physical
rehabilitation.
The Anti-inflammatory Role of the Drug Combination
The combination therapy of fluoxetine and simvastatin reveals promising signs of
a neuroprotective role in inflammation through inducing anti-inflammatory markers and
suppressing the pro-inflammatory ones. Studies have shown that activated microglia can
act as a double-edged sword to detrimentally intensify neurotoxicity when inflammatory
markers are high (Levesque et al., 2010), (Harry & Kraft, 2008), or potentially promoting
neuronal regeneration and recovery when they are changed into M2 type microglia (Diestel
et al., 2010), (McPherson, Kraft, & Harry, 2011). These contradictory effects come from
diverse experimental sets of in vitro and in vivo models that vary in terms of the activation
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stimulus, timing of microglial activation, sex and age of animals (Luo & Chen, 2012). Our
preliminary data has indicated that at post-stroke day 7, the microglia is primarily in the
M2 form, however, as a recent review of neuroinflammation indicates that microglia
undergoes a broad range of morphological transformations in a time-dependent fashion
(Fumagalli, Perego, Pischiutta, Zanier, & De Simoni, 2015), microglia express M1 markers
in the very early phases after injury followed by recruitment of macrophages and
expression of M2 markers by both myeloid populations. The peak of M2 marker expression
rapidly disappears and is followed by another upregulation of M1 markers that persists
longer. The cells also undergo morphological changes from sprouting ramified cells soon
after brain injury to non-branching phenotype followed by phagocytic ameboid shape few
days after the initial brain insult (Xiang, Haroutunian, Ho, Purohit, & Pasinetti, 2006).
Our customized array contains microglia markers to pro-inflammatory M1 and antiinflammatory M2 subtypes that have been discussed in literature; however, we do not know
whether these markers are sufficient to distinguish between the different types of microglia
in our animal models. There are some troubling signs, like up-regulation of some markers
and down-regulation of other markers for the same microglial subtype, which require
further investigation. As it has been previously reported, after focal cerebral ischemia,
microglia are activated rapidly in response to brain damage and their proliferation peaks
within 2 to 3 days of ischemia onset (Lalancette-Hebert, Gowing, Simard, Weng, & Kriz,
2007). We might miss the opportunity to explore the early stage changes in microglia
activity by delaying the evaluation of microglia markers to post-stroke day 7. In future
studies, we will need to test an earlier time point, perhaps 48 to 72 hours post-stroke to see
any potential differences in the M1 and M2 microglial subtypes.
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There is a possibility that expression of microglia markers may vary with animal’s
age and sex. Our findings indicate variable effects of the drug combination on gene
expression by microglial subtypes in male and female animals. For example; treating male
rats with the combination drug significantly led to significant up-regulation of two proinflammatory markers of M1 microglia, Ccl11 and Stat4, while also showing reduced
expression of a tryptophan metabolism effector molecule Nos2, which is another M1 proinflammatory marker. Female rats, on the other hand, show a different pattern of response
to drug treatment; the significant up-regulation of the sex determining region Y-box 2
(Sox2) gene in female rats may provide a sign of a sex-dependent role of the drug on
microglial gene upregulation. The SOX2 transcription factor is critical for maintaining selfrenewal of embryonic and neural stem cells (Rizzino, 2009). The drug combination
exhibits a trend of up-regulation of the anti-inflammatory marker of M2a and M2c
microglia, Bdnf, with a 3.85 fold change in male rats; whereas when female rats treated
with the same combination drug the fold change of Bdnf was 1.99. These findings suggest
a possible sex-dependent effect of the medicine that needs to be confirmed by increasing
the number of tested animals.
Interestingly, prior and post-treatment of male Sprague-Dawley rats with
simvastatin only demonstrates that simvastatin by itself has no inhibitory effect on proinflammatory cytokines as fluoxetine does. This outcome proposes a vital role of fluoxetine
in the FSA drug combination in down-regulating the pro-inflammatory genes.
Effects of the Drug Combination on Neurotrophic Factors and Synaptic Plasticity
Our results imply a positive effect of the drug combination in stimulating
neurotrophic factors and synaptic plasticity genes. The sex-specific pattern of gene
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expression varies between male and female rats receiving the same dose of fluoxetine,
simvastatin, and ascorbic acid treatment at the same time.
An interesting finding in neurotrophic factors expression profile indicates
remarkable upregulation of orexin/hypocretin (HCRT) protein in male drug treatment
group of rats, with a trend toward significance (9.92 fold regulation). These results were
similar to what we have seen before in female rats. Our previous work on adult female rats
treated with the same dose of drug combination for 10 days after stroke showed that orexin
was upregulated to 2.06 fold, while another experiment that used fluoxetine and
simvastatin (FS) only for the same amount of time in adult female rats showed significant
upregulation of Hctr1 (2.07) and Hctr2 (2.93); p <0.05. In light of these findings,
endogenous HcRt may mediate the neuroprotective effect of the FSA drug combination
and contribute to its beneficial role in motor recovery in male rats. The exact mechanisms
of action of HcRt though are not clear. In Figure 45 of protein-protein interaction network,
it appears that the orexin pathway ( Hcrt and Hcrtr1 and Hcrtr2) would work through
neuropeptide Y Npy and its receptor Npy1r, that are known for their significant role in
hippocampal learning and memory (Howell et al., 2003), to boost synaptic plasticity.
Further studies are required to elucidate these mechanisms.
Another critical finding was the down-regulation of matrix metalloprotease gene
(Mmp9) in male rats treated with FSA combination. This gene encodes a protein that is
responsible for degrading the extracellular matrix proteins and involved in blood-brainbarrier damage after ischemic stroke. A previous in vivo study on adult mice from another
laboratory demonstrated an inhibitory role of fluoxetine in Mmp9 regulation.
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A significant down-regulation of the apoptotic gene, Fas (TNF receptor
superfamily, member 6) in adult male rats treated with FSA in compare to control animals
(p=0.031) provide preliminary evidence of possible anti-apoptotic role of the drug
combination in suppressing this gene that is involved in negative regulation of cell death,
apoptotic process and TNF signaling pathway.
Utilizing the STRING software to predict protein-protein interactions and
demonstrate how genes cluster in individual pathways, enables a previously unobtainable
level of visualization of the regulated genes in the pathophysiology of stroke. The predicted
analyses depict gene networks that interact mainly in signal transduction, cell-cell
signaling, regulation of multicellular organismal process, cellular response to stimulus,
nervous system development, cell differentiation and proliferation, positive regulation of
biological process and receptor binding. Up-regulating of these genes in response to FSA
drug treatment may indicate a potential role of the drug in inducing neurotrophic factors
critical for neurogenesis and motor recovery after stroke.
To better understand mechanisms that promote recovery after ischemic stroke and
to evaluate the effect of pharmacologic interventions, future studies should continue to
investigate the relationship between molecular data (neurotrophic factors and brain tissue
plasticity), histopathological analysis (infarct volume and hemorrhagic transformation) as
well as behavioral outcome; with emphasis on investigating early genetic changes in
different sexes for their effect long-term functional recovery. These data suggest that
different slightly drug treatments for males and females may optimize functional recovery
following stroke.
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CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS
1). Giving Fluoxetine 20-26 hours after stroke induction not only promotes functional
motor recovery but also reduces the infarct volume significantly compared to giving the
Fluoxetine within 6-12hrs of stroke induction. Waiting for 48hours before giving the
treatment did not have any beneficial effect on infarct size.
2). Counting only the numbers of touches made by palmar pads is a more sensitive
behavioral analysis of functional deficit than including amounts of contacts made by both
palmar pads and fingertips.
3). Rehabilitation speeds recovery post-stroke when there is drug treatment, but we are able
to achieve the same level of recovery with our drug treatment without rehabilitation.
4) We see differences in the upregulation and down regulation of genes in female rats
compared to male rats following stroke, with better recovery seen with a slightly different
drug combination.
5). Gene analysis shows upregulation of neurotrophic factors and synaptic plasticity genes
in FSA males, pointing to a possibly important upregulation of orexin receptors, which
may play a key role in cortical recovery in both males and females.
6) Preliminary data suggested that at post-stroke day 7, the microglia is primarily in the
M2 form, but the control rats also showed the same markers. We will need to test an earlier
time point, perhaps post-stroke day 3 to see potential differences in the M1 and M2
microglial subtypes in female and male rats.
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APPENDIX II
Gene table shows gene position, symbol and description for M1 and M2 microglia
biomarkers.

A01 Bdnf Brain-derived neurotrophic factor
A02 Arg1 Arginase
A03 Camk2a Calcium/calmodulin-dependent protein kinase II alpha
A04 Camk2g Calcium/calmodulin-dependent protein kinase II gamma
A05 Cbln1 Cerebellin 1 precursor
A06 Ccl11 Chemokine (C-C motif) ligand 11
A07 Bdnf Brain-derived neurotrophic factor
A08 Arg1 Arginase
A09 Camk2a Calcium/calmodulin-dependent protein kinase II alpha
A10 Camk2g Calcium/calmodulin-dependent protein kinase II gamma
A11 Cbln1 Cerebellin 1 precursor
A12 Ccl11 Chemokine (C-C motif) ligand 11
B01 Cd163 CD163 molecule
B02 Cd40 CD40 molecule, TNF receptor superfamily member 5
B03 Cntf Ciliary neurotrophic factor
B04 Cntfr Ciliary neurotrophic factor receptor
B05 Creb1 CAMP responsive element binding protein 1
B06 Crh Corticotropin releasing hormone
B07 Cd163 CD163 molecule
B08 Cd40 CD40 molecule, TNF receptor superfamily member 5
B09 Cntf Ciliary neurotrophic factor
B10 Cntfr Ciliary neurotrophic factor receptor
B11 Creb1 CAMP responsive element binding protein 1
B12 Crh Corticotropin releasing hormone
C01 Crhbp Corticotropin releasing hormone binding protein
C02 Crhr1 Corticotropin releasing hormone receptor 1
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C03 Crhr2 Corticotropin releasing hormone receptor 2
C04 Cxcr4 Chemokine (C-X-C motif) receptor 4
C05 Fgf9 Fibroblast growth factor 9
C06 Fos FBJ osteosarcoma oncogene
C07 Crhbp Corticotropin releasing hormone binding protein
C08 Crhr1 Corticotropin releasing hormone receptor 1
C09 Crhr2 Corticotropin releasing hormone receptor 2
C10 Cxcr4 Chemokine (C-X-C motif) receptor 4
C11 Fgf9 Fibroblast growth factor 9
C12 Fos FBJ osteosarcoma oncogene
D01 Galr1 Galanin receptor 1
D02 Gfra3 GDNF family receptor alpha 3
D03 Gmfg Glia maturation factor, gamma
D04 Il1b Interleukin 1 beta
D05 il10ra Interleukin 10 receptor, alpha
D06 Il6 Interleukin 6
D07 Galr1 Galanin receptor 1
D08 Gfra3 GDNF family receptor alpha 3
D09 Gmfg Glia maturation factor, gamma
D10 Il1b Interleukin 1 beta
D11 il10ra Interleukin 10 receptor, alpha
D12 Il6 Interleukin 6
E01 Nos2 Nitric oxide synthase 2, inducible
E02 Nell1 NEL-like 1
E03 Npy1r Neuropeptide Y receptor Y1
E04 Npy2r Neuropeptide Y receptor Y2
E05 Sox2 SRY (sex determining region Y)-box 2
E06 Stat1 Signal transducer and activator of transcription 1
E07 Nos2 Nitric oxide synthase 2, inducible
E08 Nell1 NEL-like 1
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E09 Npy1r Neuropeptide Y receptor Y1
E10 Npy2r Neuropeptide Y receptor Y2
E11 Sox2 SRY (sex determining region Y)-box 2
E12 Stat1 Signal transducer and activator of transcription 1
F01 Stat3 Signal transducer and activator of transcription 3
F02 Stat4 Signal transducer and activator of transcription 4
F03 Stat6 Signal transducer and activator of transcription 6
F04 Tgfb1 Transforming growth factor, beta 1
F05 Tnf Tumor necrosis factor (TNF superfamily, member 2)
F06 Plat Plasminogen activator, tissue
F07 Stat3 Signal transducer and activator of transcription 3
F08 Stat4 Signal transducer and activator of transcription 4
F09 Stat6 Signal transducer and activator of transcription 6
F10 Tgfb1 Transforming growth factor, beta 1
F11 Tnf Tumor necrosis factor (TNF superfamily, member 2)
F12 Plat Plasminogen activator, tissue
G01 Grip1 Glutamate receptor interacting protein 1
G02 Vegfa Vascular endothelial growth factor A
G03 Ppih Peptidylprolyl isomerase H (cyclophilin H)
G04 Actb Actin, beta
G05 Hprt1 Hypoxanthine phosphoribosyltransferase 1
G06 Ldha Lactate dehydrogenase A
G07 Grip1 Glutamate receptor interacting protein 1
G08 Vegfa Vascular endothelial growth factor A
G09 Ppih Peptidylprolyl isomerase H (cyclophilin H)
G10 Actb Actin, beta
G11 Hprt1 Hypoxanthine phosphoribosyltransferase 1
G12 Ldha Lactate dehydrogenase A
H01 Nono Non-POU domain containing, octamer-binding
H02 GDC Genomic DNA control
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H03 RTC Reverse-transcription control
H04 RTC Reverse-transcription control
H05 PPC Positive PCR control
H06 PPC Positive PCR control
H07 Nono Non-POU domain containing, octamer-binding
H08 GDC Genomic DNA control
H09 RTC Reverse-transcription control
H10 RTC Reverse-transcription control
H11 PPC Positive PCR control
H12 PPC Positive PCR control
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APPENDIX III
Gene table shows gene position, symbol and description for neurotrophins and
receptors RT² Profiler PCR Array
A01 Adcyap1r1 Adenylate cyclase activating polypeptide 1 receptor 1
A02 Artn Artemin
A03 Bax Bcl2-associated X protein
A04 Bcl2 B-cell CLL/lymphoma 2
A05 Bdnf Brain-derived neurotrophic factor
A06 Cbln1 Cerebellin 1 precursor
A07 Cckar Cholecystokinin A receptor
A08 Cd40 CD40 molecule, TNF receptor superfamily member 5
A09 Cntf Ciliary neurotrophic factor
A10 Cntfr Ciliary neurotrophic factor receptor
A11 Crh Corticotropin releasing hormone
A12 Crhbp Corticotropin releasing hormone binding protein
B01 Crhr1 Corticotropin releasing hormone receptor 1
B02 Crhr2 Corticotropin releasing hormone receptor 2
B03 Cx3cr1 Chemokine (C-X3-C motif) receptor 1
B04 Cxcr4 Chemokine (C-X-C motif) receptor 4
B05 Fas Fas (TNF receptor superfamily, member 6)
B06 Fgf2 Fibroblast growth factor 2
Fgf9 Fibroblast growth factor 9
B08 Fgfr1 Fibroblast growth factor receptor 1
B09 Fos FBJ osteosarcoma oncogene
B10 Frs2 Fibroblast growth factor receptor substrate 2
B11 Frs3 Fibroblast growth factor receptor substrate 3
B12 Fus Fusion (involved in t(12;16) in malignant liposarcoma) (human)
C01 Galr1 Galanin receptor 1
C02 Galr2 Galanin receptor 2
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C03 Gdnf Glial cell derived neurotrophic factor
C04 Gfra1 GDNF family receptor alpha 1
C05 Gfra2 GDNF family receptor alpha 2
C06 Gfra3 GDNF family receptor alpha 3
C07 Gmfb Glia maturation factor, beta
C08 Gmfg Glia maturation factor, gamma
C09 Grpr Gastrin releasing peptide receptor
C10 HcRt Hypocretin
C11 Hcrtr1 Hypocretin (orexin) receptor 1
C12 Hcrtr2 Hypocretin (orexin) receptor 2
D01 Hspb1 Heat shock protein 1
D02 Il10 Interleukin 10
D03 Il10ra Interleukin 10 receptor, alpha
D04 Il1b Interleukin 1 beta
D05 Il1r1 Interleukin 1 receptor, type I
D06 Il6 Interleukin 6
D07 Il6r Interleukin 6 receptor
D08 Il6st Interleukin 6 signal transducer
D09 Lif Leukemia inhibitory factor
D10 Lifr Leukemia inhibitory factor receptor alpha
D11 Maged1 Melanoma antigen, family D, 1
D12 Mc2r Melanocortin 2 receptor
E01 Mt3 Metallothionein 3
E02 Myc Myelocytomatosis oncogene
E03 Nell1 NEL-like 1
E04 Nf1 Neurofibromin 1
E05 Ngf Nerve growth factor (beta polypeptide)
E06 Ngfr Nerve growth factor receptor (TNFR superfamily, member 16)
E07 Ngfrap1 Nerve growth factor receptor (TNFRSF16) associated protein 1
E08 Npffr2 Neuropeptide FF receptor 2
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E09 Npy Neuropeptide Y
E10 Npy1r Neuropeptide Y receptor Y1
E11 Npy2r Neuropeptide Y receptor Y2
E12 Nr1i2 Nuclear receptor subfamily 1, group I, member 2
F01 Nrg1 Neuregulin 1
F02 Nrg2 Neuregulin 2
F03 Ntf3 Neurotrophin 3
F04 Ntf4 Neurotrophin 4
F05 Ntrk1 Neurotrophic tyrosine kinase, receptor, type 1
F06 Ntrk2 Neurotrophic tyrosine kinase, receptor, type 2
F07 Ntsr1 Neurotensin receptor 1
F08 Ppyr1 Pancreatic polypeptide receptor 1
F09 Pspn Persephin
F10 Ptger2 Prostaglandin E receptor 2 (subtype EP2)
F11 Stat1 Signal transducer and activator of transcription 1
F12 Stat2 Signal transducer and activator of transcription 2
G01 Stat3 Signal transducer and activator of transcription 3
G02 Stat4 Signal transducer and activator of transcription 4
G03 Tacr1 Tachykinin receptor 1
G04 Tfg Trk-fused gene
G05 Tgfa Transforming growth factor alpha
G06 Tgfb1 Transforming growth factor, beta 1
G07 Tgfb1i1 Transforming growth factor beta 1 induced transcript 1
G08 Tp53 Tumor protein p53
G09 Ucn Urocortin
G10 Vgf VGF nerve growth factor inducible
G11 Zfp110 Zinc finger protein 110
G12 Zfp91 Zinc finger protein 91
H01 Actb Actin, beta
H02 B2m Beta-2 microglobulin

172

H03 Hprt1 Hypoxanthine phosphoribosyltransferase 1
H04 Ldha Lactate dehydrogenase A
H05 Rplp1 Ribosomal protein, large, P1
H06 RGDC Rat Genomic DNA Contamination
H07 RTC Reverse Transcription Control
H08 RTC Reverse Transcription Control
H09 RTC Reverse Transcription Control
H10 PPC Positive PCR Control
H11 PPC Positive PCR Control
H12 PPC Positive PCR Control
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APPENDIX IV
Gene table shows gene position, symbol and description for synaptic plasticity RT²
Profiler PCR Array.
A01 Adam10 ADAM metallopeptidase domain 10
A02 Adcy1 Adenylate cyclase 1 (brain)
A03 Adcy8 Adenylate cyclase 8 (brain)
A04 Akt1 V-akt murine thymoma viral oncogene homolog 1
A05 Arc Activity-regulated cytoskeleton-associated protein
A06 Bdnf Brain-derived neurotrophic factor
A07 Camk2a Calcium/calmodulin-dependent protein kinase II alpha
A08 Camk2g Calcium/calmodulin-dependent protein kinase II gamma
A09 Cdh2 Cadherin 2
A10 Cebpb CCAAT/enhancer binding protein (C/EBP), beta
A11 Cebpd CCAAT/enhancer binding protein (C/EBP), delta
A12 Cnr1 Cannabinoid receptor 1 (brain)
B01 Creb1 CAMP responsive element binding protein 1
B02 Crem CAMP responsive element modulator
B03 Dlg4 Discs, large homolog 4 (Drosophila)
B04 Egr1 Early growth response 1
B05 Egr2 Early growth response 2
B06 Egr3 Early growth response 3
B07 Egr4 Early growth response 4
B08 Ephb2 Eph receptor B2
B09 Fos FBJ osteosarcoma oncogene
B10 Gabra5 Gamma-aminobutyric acid (GABA) A receptor, alpha 5
B11 Gnai1 Guanine nucleotide binding protein (G protein), alpha inhibiting 1
B12 Gria1 Glutamate receptor, ionotropic, AMPA 1
C01 Gria2 Glutamate receptor, ionotropic, AMPA 2
C02 Gria3 Glutamate receptor, ionotrophic, AMPA 3
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C03 Gria4 Glutamate receptor, ionotrophic, AMPA 4
C04 Grin1 Glutamate receptor, ionotropic, N-methyl D-aspartate 1
C05 Grin2a Glutamate receptor, ionotropic, N-methyl D-aspartate 2A
C06 Grin2b Glutamate receptor, ionotropic, N-methyl D-aspartate 2B
C07 Grin2c Glutamate receptor, ionotropic, N-methyl D-aspartate 2C
C08 Grin2d Glutamate receptor, ionotropic, N-methyl D-aspartate 2D
C09 Grip1 Glutamate receptor interacting protein 1
C10 Grm1 Glutamate receptor, metabotropic 1
C11 Grm2 Glutamate receptor, metabotropic 2
C12 Grm3 Glutamate receptor, metabotropic 3
D01 Grm4 Glutamate receptor, metabotropic 4
D02 Grm5 Glutamate receptor, metabotropic 5
D03 Grm7 Glutamate receptor, metabotropic 7
D04 Grm8 Glutamate receptor, metabotropic 8
D05 Homer1 Homer homolog 1 (Drosophila)
D06 Igf1 Insulin-like growth factor 1
D07 Inhba Inhibin beta-A
D08 Jun Jun oncogene
D09 Junb Jun B proto-oncogene
D10 Kruppel-like factor 10
D11 Mapk1 Mitogen activated protein kinase 1
D12 Mmp9 Matrix metallopeptidase 9
E01 Ncam1 Neural cell adhesion molecule 1
E02 Nfkb1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
E03 Nfkbib Nuclear factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, beta
E04 Ngf Nerve growth factor (beta polypeptide)
E05 Ngfr Nerve growth factor receptor (TNFR superfamily, member 16)
E06 Nos1 Nitric oxide synthase 1, neuronal
E07 Nptx2 Neuronal pentraxin 2
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E08 Nr4a1 Nuclear receptor subfamily 4, group A, member 1
E09 Ntf3 Neurotrophin 3
E10 Ntf4 Neurotrophin 4
E11 Ntrk2 Neurotrophic tyrosine kinase, receptor, type 2
E12 Pcdh8 Protocadherin 8
F01 Pick1 Protein interacting with PRKCA 1
F02 Pim1 Pim-1 oncogene
F03 Plat Plasminogen activator, tissue
F04 Plcg1 Phospholipase C, gamma 1
F05 Ppp1ca Protein phosphatase 1, catalytic subunit, alpha isoform
F06 Ppp1cc Protein phosphatase 1, catalytic subunit, gamma isoform
F07 Ppp1r14a Protein phosphatase 1, regulatory (inhibitor) subunit 14A
F08 Ppp2ca Protein phosphatase 2, catalytic subunit, alpha isoform
F09 Ppp3ca Protein phosphatase 3, catalytic subunit, alpha isoform
F10 Prkca Protein kinase C, alpha
F11 Prkcg Protein kinase C, gamma
F12 Prkg1 Protein kinase, cGMP-dependent, type 1
G01 Rab3a RAB3A, member RAS oncogene family
G02 Rela V-rel reticuloendotheliosis viral oncogene homolog A (avian)
G03 Reln Reelin
G04 RGD1562511 Similar to MmKIF17
G05 Rgs2 Regulator of G-protein signaling 2
G06 Rheb Ras homolog enriched in brain
G07 Sirt1 Sirtuin (silent mating type information regulation 2 homolog) 1 (S.
cerevisiae)
G08 Srf Serum response factor (c-fos serum response element-binding transcription
factor)
G09 Synpo Synaptopodin
G10 Timp1 TIMP metallopeptidase inhibitor 1 theta polypeptide
H01 Actb Actin, beta

176

H02 B2m Beta-2 microglobulin
H03 Hprt1 Hypoxanthine phosphoribosyltransferase 1
H04 Ldha Lactate dehydrogenase A
H05 Rplp1 Ribosomal protein, large, P1
H06 RGDC Rat Genomic DNA Contamination
H07 RTC Reverse Transcription Control
H08 RTC Reverse Transcription Control
H09 RTC Reverse Transcription Control
H10 PPC Positive PCR Control
H11 PPC Positive PCR Control
H12 PPC Positive PCR Control
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APPENDIX V
Neurotrophins & Receptors PCR Array: Functional Gene Grouping
Neuropeptides and Receptors:
Adcyap1r1, Artn, Bdnf, Cntf, Cntfr, Crh, Crhbp, Crhr1, Crhr2, Frs2, Frs3, Gdnf, Gfra1,
Gfra2, Gfra3, Gmfb, Gmfg, Hcrtr1, Hcrtr2, Mt3, Ngf, Ngfr, Ngfrap1, Nr1i2, Nrg1 (Hgl),
Nrg2, Ntf3, Ntf4, Ntrk1, Ntrk2, Pspn, Ptger2, Tfg, Cd40 (Tnfrsf5), Fas (Tnfrsf6), Ucn,
Vgf, Zfp110, Zfp91.
Neuropeptides and Receptors:
Galanin Receptors: Galr1, Galr2.
Neuropeptide Y Receptors: Npy1r, Npy2r, Npy4r.
Other Neuropeptides and Receptors: Cckar, Grpr, Npffr2 (Gpr74), Ntsr1, HcRt, Mc2r,
Npy, Nrg1 (Hgl), Tacr1.
Neurogenesis:
Central Nervous System Development: Cxcr4, Fgfr1, Ngfr, Ntf3.
Peripheral Nervous System Development: Artn, Gdnf, Gfra3, Ngf, Nrg1 (Hgl), Ntf3.
Axon Guidance: Artn, Gfra3, Ngfr.
Gliogenesis: Fgf2 (bFGF), Nrg1 (Hgl), Ntf3.
Dendrite Morphogenesis: Bdnf, Mt3.
Other Neurogenesis Genes: Bax, Fos, Cbln1, Galr2, Gfra1, Gfra2, Nell1, Ntf4, Ntrk1,
Ntrk2.
Cell Growth and Differentiation:
Growth Factors and Receptors: Artn, Bdnf, Fgf2 (bFGF), Fgf9, Fgfr1, Gdnf, Gmfb, Gmfg,
Il10, Il1b, Il6, Lif, Mt3, Ngf, Nrg2, Ntf3, Ntf4, Pspn, Tgfa, Tgfb1, Tgfb1i1, Tp53, Vgf.
Cell Cycle: Fgf2 (bFGF), Fgf9, Il1b, Ntrk1, Tgfa, Tgfb1, Tp53.
Cell Proliferation: Bax, Cxcr4, Fgf2 (bFGF), Fgf9, Grpr, Il10, Il1b, Myc, Stat4, Tgfa,
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Tgfb1, Tp53.
Cell Differentiation: Cntf, Fgf2 (bFGF), Fgf9, Nf1, Nrg1 (Hgl), Stat3, Tp53, Zfp91.
Cytokines and Receptors:
Cx3cr1, Cxcr4, Il10, Il10ra, Il1b, Il1r1, Il6, Il6r, Il6st (Gp130), Lif, Lifr,.
Apoptosis:
Bax, Bcl2, Cd40 (Tnfrsf5), Hspb1 (Hsp27), Il10, Il6, Myc, Ngfr, Ngfrap1, Fas (Tnfrsf6),
Tp53.
Inflammatory Response:
Il10, Il1b, Il6, Stat3, Tgfb1.
Immune Response:
Il10, Cd40 (Tnfrsf5), Lif, Fas (Tnfrsf6).
Transcription Factors and Regulators:
Fos, Fus, Maged1, Myc, Nr1i2, Ntf3, Stat1, Stat2, Stat3, Stat4, Tp53, Tgfb1i1, Zfp110.
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APPENDIX VI
Rat Synaptic Plasticity PCR Array: Functional Gene Grouping
Immediate-Early Response Genes (IEGs):
Arc, Bdnf, Cebpb, Cebpd, Creb1, Crem, Egr1, Egr2, Egr3, Egr4, Fos, Homer1, Jun,
Junb, Klf10, Mmp9 (Gelatinase B), Nfkb1, Nfkbib (Trip9), Ngf, Nptx2, Nr4a1, Ntf3,
Pcdh8, Pim1, Plat (tPA), Rela, Rgs2, Rheb, Srf, Tnf.
Late Response Genes: Inhba, Synpo.
Long Term Potentiation (LTP): Adcy1, Adcy8, Bdnf, Camk2a, Camk2g, Cdh2 (Ncadherin), Cnr1, Gabra5, Gnai1, Gria1, Gria2, Grin1, Grin2a, Grin2b, Grin2c, Grin2d,
Mapk1, Mmp9 (Gelatinase B), Ntf4, Ntrk2, Plcg1, Ppp1ca, Ppp1cc, Ppp3ca, Prkca,
Prkcg, Rab3a, Ywhaq (14-3-3).
Long Term Depression (LTD): Gnai1, Gria1, Gria2, Gria3, Gria4, Grip1, Grm1,
Grm2, Igf1, Mapk1, Nos1, Ngfr, Pick1, Plat (tPA), Ppp1ca, Ppp1cc, Ppp1r14a (Cpi-17),
Ppp2ca, Ppp3ca, Prkca, Prkg1.
Cell Adhesion: Adam10, Cdh2 (N-cadherin), Grin2a, Grin2b, Ncam1, Pcdh8, Ppp2ca,
Reln, Tnf.
Extracellular Matrix & Proteolytic Processing: Adam10, Mmp9 (Gelatinase B), Plat
(tPA), Reln, Timp1.
CREB Cofactors: Akt1, Camk2g, Grin1, Grin2a, Grin2b, Grin2c, Grin2d, Mapk1
(Erk2), Ppp1ca, Ppp1cc.
Neuronal Receptors: Ephb2, Gabra5, Gria1, Gria2, Gria3, Gria4, Grin1, Grin2a,
Grin2b, Grin2c, Grin2d, Grm1, Grm2, Grm3, Grm4, Grm5, Grm7, Grm8, Ntrk2.
Postsynaptic Density: Adam10, Arc, Dlg4 (Psd95), Gria1, Gria3, Gria4, Grin1, Grin2a,
Grin2b, Grin2c, Grm1, Grm3, Homer1, Pick1, Synpo.
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APPENDIX VII
Fold Chang and Fold Regulation Values
Tables below show data from RT2 PCR including gene symbol, p-value, fold
change and fold regulation. Data are sorted by p-value from lowest to highest. Fold-change
and fold-regulation values greater than 2 are indicated in red; fold-change values less than
0.5 and fold-regulation values less than -2 are indicated in blue.
A. FSA-treated Male Rats Comparing to Control Male Rats
Gene Symbol
Ccl11
Stat4
Bdnf
Nos2
Crhbp
Nell1
Cbln1
Arg1
Crh
Cntfr
Galr1
Sox2
Creb1
Il1b
Npy2r
Vegfa
Cd163
Camk2a
Fgf9
Crhr1
Grip1
Npy1r
Il6
Cd40
Gmfg
Camk2g
Tnf
Gfra3

p-value
0.03234
0.041333
0.089873
0.094423
0.158613
0.227599
0.280965
0.291588
0.35071
0.423522
0.436634
0.534786
0.550981
0.554228
0.566378
0.589248
0.633102
0.673144
0.719273
0.721574
0.754236
0.75501
0.760602
0.771506
0.771657
0.774906
0.785379
0.828051

fold change
3.7352
2.0813
3.851
0.50001
1.6378
1.2708
1.8809
0.7505
1.4626
0.874
1.1068
0.8478
0.719
0.5653
1.0393
0.9202
0.995
0.8677
1.019
0.956
0.9615
0.9634
0.6318
0.7912
0.7572
0.9605
0.617
0.4734
181

fold regulation
3.7352
2.0813
3.851
-2.0004
1.6378
1.2708
1.8809
-1.3325
1.4626
-1.1442
1.1068
-1.1795
-1.3908
-1.7691
1.0393
-1.0867
-1.0051
-1.1525
1.019
-1.046
-1.04
-1.038
-1.5827
-1.264
-1.3206
-1.0411
-1.6207
-2.1123

Cntf
Stat1
Stat3
il10ra
Crhr2
Fos
Plat
Tgfb1
Cxcr4
Stat6

0.850348
0.851229
0.895215
0.895902
0.953413
0.971686
0.972077
0.97797
0.991455
0.992385

0.8518
0.6064
1.0923
0.8025
0.897
1.0238
0.9203
0.6633
0.6021
0.8349

182

-1.1739
-1.649
1.0923
-1.246
-1.1148
1.0238
-1.0866
-1.5077
-1.6608
-1.1977

B. FSA-treated Female Rats Comparing to Control Female Rats
Gene Symbol
Sox2
Cntf
Creb1
Fos
Cntfr
Crhr2
Crhr1
Camk2g
Crh
Arg1
Galr1
Plat
il10ra
Crhbp
Fgf9
Gfra3
Bdnf
Cbln1
Vegfa
Camk2a
Stat4
Stat1
Npy2r
Il6
Tgfb1
Grip1
Ccl11
Nell1
Cd163
Nos2
Npy1r
Tnf
Cd40
Stat3
Gmfg
Stat6
Il1b
Cxcr4

p-value
0.047631
0.057901
0.059055
0.076262
0.099695
0.101033
0.10333
0.125511
0.147916
0.155278
0.155288
0.165041
0.202232
0.215802
0.225599
0.253349
0.272128
0.310568
0.337747
0.351778
0.356739
0.362456
0.367681
0.3708
0.378224
0.379007
0.395425
0.412523
0.4487
0.536738
0.57088
0.638525
0.63938
0.646504
0.715201
0.811588
0.824719
0.962157

fold change
2.5115
1.6898
1.4316
1.3918
1.7101
1.4342
2.4755
2.1039
2.3538
0.3795
1.7544
1.3647
1.4973
2.2195
1.8046
1.3295
1.9904
2.0208
1.2386
1.8665
1.3098
1.1966
1.4132
0.7732
1.487
1.3269
1.2771
2.1142
1.2084
0.8217
1.425
1.0934
1.1124
1.0171
0.7491
1.1616
0.974
1.0542

183

fold regulation
2.5115
1.6898
1.4316
1.3918
1.7101
1.4342
2.4755
2.1039
2.3538
-2.6353
1.7544
1.3647
1.4973
2.2195
1.8046
1.3295
1.9904
2.0208
1.2386
1.8665
1.3098
1.1966
1.4132
-1.2933
1.487
1.3269
1.2771
2.1142
1.2084
-1.217
1.425
1.0934
1.1124
1.0171
-1.335
1.1616
-1.0267
1.0542

C. Simvastatin-treated Male Rats Comparing to Control Male Rats
Gene Symbol
Ccl11
Crhr2
Cd163
Fos
Nos2
Cbln1
Galr1
Bdnf
Crhbp
Stat6
Plat
Cntf
Cntfr
Tgfb1
il10ra
Camk2a
Sox2
Camk2g
Grip1
Il6
Stat3
Npy2r
Cxcr4
Npy1r
Cd40
Creb1
Fgf9
Arg1
Nell1
Tnf
Gmfg
Crhr1
Il1b
Crh
Gfra3
Stat4
Vegfa
Stat1

p-value
0.022319
0.067797
0.073125
0.167572
0.181671
0.185183
0.19592
0.200537
0.222841
0.223868
0.256844
0.2591
0.264005
0.275765
0.292258
0.30005
0.316827
0.327571
0.346105
0.415327
0.425231
0.426295
0.429465
0.441851
0.489159
0.504883
0.521157
0.524046
0.550677
0.554736
0.574405
0.5775
0.723912
0.824846
0.880793
0.918165
0.947222
0.982461

fold change
2.3405
1.4184
1.7696
1.3642
0.7392
2.0057
1.4718
3.0055
1.4558
1.6405
1.1847
1.412
1.1983
1.4401
1.6629
1.2253
1.2873
1.1834
1.2544
0.865
1.4677
1.2733
1.4594
1.2411
1.485
1.1676
1.1251
1.1999
1.1268
1.1165
1.3142
1.0366
1.1045
0.8641
0.7031
1.0875
0.9915
0.9063

184

fold regulation
2.3405
1.4184
1.7696
1.3642
-1.3528
2.0057
1.4718
3.0055
1.4558
1.6405
1.1847
1.412
1.1983
1.4401
1.6629
1.2253
1.2873
1.1834
1.2544
-1.1561
1.4677
1.2733
1.4594
1.2411
1.485
1.1676
1.1251
1.1999
1.1268
1.1165
1.3142
1.0366
1.1045
-1.1573
-1.4223
1.0875
-1.0085
-1.1034

D. FSA-treated Female Rats Comparing to FSA-treated Male Rats
Gene Symbol
Fos
Gfra3
Cd163
Cntf
Il1b
Cntfr
Nos2
Crhr2
Sox2
Crhr1
Arg1
Creb1
Camk2g
Tnf
Tgfb1
Stat3
Plat
Cxcr4
Stat1
Ccl11
Grip1
il10ra
Cd40
Vegfa
Stat6
Crhbp
Gmfg
Il6
Camk2a
Npy2r
Nell1
Stat4
Fgf9
Galr1
Npy1r
Cbln1
Crh
Bdnf

p-value
0.051224
0.084574
0.089223
0.105728
0.150449
0.159912
0.174178
0.194493
0.199428
0.235838
0.243321
0.243441
0.265644
0.273191
0.295521
0.321568
0.327347
0.346437
0.352873
0.429505
0.440118
0.464164
0.487533
0.493297
0.496305
0.51346
0.582022
0.639032
0.656883
0.783806
0.844901
0.849211
0.873117
0.885226
0.887996
0.906738
0.910133
0.958841

fold change
1.47
5.8624
3.0674
2.2289
3.2735
1.4477
2.371
1.5751
1.7685
1.6742
1.9596
1.7837
1.5051
3.012
2.6995
1.6189
1.5035
3.4937
2.3304
0.6515
1.163
2.0297
2.4509
1.133
1.7039
1.4907
2.2929
2.3906
1.4105
1.0019
1.0061
1.0134
1.1626
1.3016
1.0873
0.6692
1.2329
1.2839

185

fold regulation
1.47
5.8624
3.0674
2.2289
3.2735
1.4477
2.371
1.5751
1.7685
1.6742
1.9596
1.7837
1.5051
3.012
2.6995
1.6189
1.5035
3.4937
2.3304
-1.5348
1.163
2.0297
2.4509
1.133
1.7039
1.4907
2.2929
2.3906
1.4105
1.0019
1.0061
1.0134
1.1626
1.3016
1.0873
-1.4944
1.2329
1.2839

E. Control Female Rats Comparing to Control Male Rats
Gene Symbol
Sox2
Cntfr
Creb1
Vegfa
Camk2g
Fgf9
Npy2r
Crh
Crhr1
Grip1
Cd163
Ccl11
Galr1
Npy1r
Cntf
Crhr2
Cbln1
Stat1
Plat
Arg1
Camk2a
Nell1
il10ra
Fos
Gfra3
Cxcr4
Gmfg
Il1b
Tgfb1
Stat4
Crhbp
Tnf
Stat6
Nos2
Bdnf
Il6
Stat3
Cd40

p-value
0.046977
0.074848
0.101809
0.129834
0.130036
0.1307
0.151455
0.162665
0.172162
0.213425
0.221681
0.242341
0.266493
0.268385
0.27722
0.27996
0.286772
0.306141
0.317554
0.343563
0.415672
0.443202
0.443591
0.464762
0.537377
0.711004
0.728997
0.737027
0.815698
0.817578
0.834578
0.845661
0.873237
0.877283
0.915087
0.969347
0.989123
0.992662

fold change
0.403
0.4995
0.6047
0.5682
0.4639
0.4431
0.4974
0.5171
0.4365
0.5689
1.7048
1.2864
0.5543
0.4962
0.7585
0.665
0.4205
0.7972
0.6844
2.6161
0.4426
0.4082
0.7343
0.7299
1.4092
1.347
1.5647
1.2825
0.8128
1.087
0.7425
1.1474
0.8267
0.9906
1.6769
1.3186
1.1736
1.1767

186

fold regulation
-2.4814
-2.0022
-1.6536
-1.76
-2.1558
-2.2566
-2.0105
-1.9337
-2.2911
-1.7579
1.7048
1.2864
-1.8041
-2.0152
-1.3185
-1.5038
-2.3784
-1.2544
-1.4611
2.6161
-2.2593
-2.4496
-1.3618
-1.3701
1.4092
1.347
1.5647
1.2825
-1.2303
1.087
-1.3468
1.1474
-1.2096
-1.0095
1.6769
1.3186
1.1736
1.1767

F. Neurotrophic Factors-regulated Gene Expressions in FSA treated Male Rats
Comparing to Control
Gene Symbol
Gdnf
Fas
Il1b
Nr1i2
Cntf
Il10
Pspn
Mt3
Zfp91
Galr2
HcRt
Npffr2
Grpr
Lif
Hspb1
Ucn
Stat3
Fus
Il6
Zfp110
Hcrtr2
Nell1
Cckar
Npy
Crhr2
Cxcr4
Bdnf
Ntrk1
Ntrk2
Nf1
Ptger2
Ngfrap1
Npy1r
Fgf2
Stat4
Ngf
Tgfb1i1
Lifr

p-value
0.027147
0.03166
0.032286
0.039786
0.051449
0.059186
0.11014
0.116473
0.119956
0.120142
0.128589
0.129714
0.132977
0.149851
0.160027
0.184827
0.196704
0.200037
0.210604
0.210782
0.212278
0.235502
0.237235
0.251874
0.255905
0.260175
0.275876
0.27955
0.291239
0.317303
0.326239
0.335346
0.336204
0.348263
0.357587
0.363967
0.369922
0.375133

fold change
0.5286
0.4035
0.3877
3.7774
0.6523
0.4512
1.6954
0.7846
1.4965
1.5424
9.9214
0.5853
2.2403
0.2841
0.3582
1.5905
0.6712
0.7883
0.3641
1.2478
1.4767
1.4848
0.6939
1.3044
1.4652
0.4393
3.9795
0.7334
1.3084
1.2141
0.554
1.2111
1.377
0.789
1.5701
1.2321
1.2762
1.2643
187

fold regulation
-1.8919
-2.4784
-2.5795
3.7774
-1.533
-2.2165
1.6954
-1.2746
1.4965
1.5424
9.9214
-1.7085
2.2403
-3.5205
-2.7916
1.5905
-1.49
-1.2686
-2.7461
1.2478
1.4767
1.4848
-1.4411
1.3044
1.4652
-2.2765
3.9795
-1.3636
1.3084
1.2141
-1.8049
1.2111
1.377
-1.2674
1.5701
1.2321
1.2762
1.2643

Tp53
Bax
Gfra2
Frs3
Cx3cr1
Cbln1
Hcrtr1
Npy4r
Fgf9
Myc
Ntf3
Vgf
Fgfr1
Frs2
Crh
Maged1
Ntf4
Il1r1
Il10ra
Stat1
Tgfb1
Cntfr
Il6r
Crhbp
Nrg2
Artn
Tacr1
Il6st
Npy2r
Fos
Nrg1
Adcyap1r1
Galr1
Cd40
Gfra1
Ngfr
Tfg
Gmfg
Mc2r
Gmfb
Tgfa

0.381005
0.407826
0.414646
0.439885
0.452364
0.454712
0.457167
0.45726
0.481014
0.490162
0.506506
0.523186
0.545401
0.566019
0.571825
0.58919
0.591481
0.643553
0.659463
0.663928
0.682868
0.690641
0.691259
0.696538
0.698461
0.72308
0.730063
0.736219
0.739882
0.741683
0.743462
0.764325
0.779722
0.785942
0.786957
0.817439
0.817747
0.828249
0.831922
0.883504
0.908245

1.1799
0.6913
1.2027
1.1153
0.562
1.6227
1.1227
1.3753
0.9783
0.4904
1.4581
0.9217
0.7876
1.1046
0.9597
1.0137
0.6727
0.6298
0.5726
0.754
0.7713
0.7825
0.6581
0.8017
1.0591
0.8388
1.0187
0.9564
1.4755
0.8284
0.9605
0.7279
0.619
0.5142
0.8671
0.7037
1.0206
0.5432
0.8033
0.9415
0.9966
188

1.1799
-1.4465
1.2027
1.1153
-1.7793
1.6227
1.1227
1.3753
-1.0222
-2.0393
1.4581
-1.0849
-1.2696
1.1046
-1.042
1.0137
-1.4865
-1.5877
-1.7464
-1.3263
-1.2965
-1.2779
-1.5195
-1.2473
1.0591
-1.1921
1.0187
-1.0456
1.4755
-1.2071
-1.0412
-1.3739
-1.6154
-1.9447
-1.1532
-1.4211
1.0206
-1.841
-1.2449
-1.0621
-1.0034

Crhr1
Stat2
Gfra3
Ntsr1
Bcl2

0.923336
0.932098
0.937607
0.985155
0.995706

0.7899
0.9141
0.5988
0.8096
0.9074

-1.266
-1.094
-1.6699
-1.2353
-1.102

F. Synaptic Plasticity-regulated Gene Expression in FSA treated Male Rats
Comparing to Control
gene
Pim1
Klf10
Nr4a1
Mmp9
Cebpd
Jun
Pcdh8
Timp1
Cdh2
Ntf3
Akt1
Sirt1
Tnf
Cebpb
Cnr1
Rab3a
Pick1
Nfkbib
Nos1
Rela
Gria1
Egr2
Grin2c
Igf1
Synpo
Ntf4
Prkcg
Gnai1
Egr1
Reln

p value
0.12664
0.151032
0.167991
0.177072
0.186163
0.192471
0.218854
0.219116
0.235217
0.25607
0.269585
0.291652
0.295738
0.308731
0.330611
0.342813
0.371536
0.374321
0.374801
0.380306
0.386969
0.394857
0.397816
0.401632
0.402157
0.439379
0.443998
0.446055
0.455676
0.468039

fod change
0.6422
0.5412
1.8715
0.4552
0.3841
0.6844
2.851
0.5087
0.6657
1.555
0.7898
1.1592
0.5748
0.5608
0.5847
1.0856
1.1874
0.7592
1.2927
0.8689
0.5336
1.1844
0.5966
0.4222
1.2184
0.811
1.0263
0.6494
1.0975
1.0898
189

fold regulation
-1.5572
-1.8478
1.8715
-2.1968
-2.6035
-1.461
2.851
-1.9657
-1.5023
1.555
-1.2661
1.1592
-1.7399
-1.7832
-1.7102
1.0856
1.1874
-1.3172
1.2927
-1.1509
-1.8742
1.1844
-1.6761
-2.3683
1.2184
-1.233
1.0263
-1.5398
1.0975
1.0898

Nfkb1
Egr4
Gabra5
Prkg1
Plat
Ngfr
Ncam1
Junb
Ppp2ca
Creb1
Ppp1cc
Bdnf
Ywhaq
Rheb
Grm3
Grin2d
Gria3
Gria2
Ppp3ca
Ngf
Grm7
Fos
Grin1
Ppp1ca
Homer1
Ephb2
Ppp1r14a
Camk2g
Srf
Gria4
Camk2a
Mapk1
Grip1
Grin2a
Prkca
Plcg1
Egr3
Dlg4
Grm8
Inhba
Adcy8

0.474956
0.491043
0.505539
0.506751
0.521329
0.521657
0.530234
0.540034
0.541094
0.546866
0.553437
0.56377
0.567824
0.590702
0.598756
0.610027
0.620373
0.629791
0.637036
0.640312
0.649373
0.657628
0.66239
0.677821
0.699038
0.715093
0.7184
0.731992
0.75282
0.759192
0.760477
0.768616
0.77556
0.777394
0.794296
0.799546
0.799952
0.806109
0.82198
0.834537
0.840848

1
1.0349
0.5208
1.1523
0.928
0.9013
1.1187
1.1783
1.2053
0.7586
0.9584
0.8524
1.0896
1.1023
0.7269
0.913
0.8035
0.775
1.0658
1.2567
0.9665
0.7617
0.6966
0.9423
1.0384
0.8469
1.0842
0.8209
1.0424
0.8568
0.7767
0.8512
0.8592
0.8951
0.8962
1.0633
0.934
0.6941
0.719
0.7964
0.9416
190

1
1.0349
-1.9201
1.1523
-1.0775
-1.1095
1.1187
1.1783
1.2053
-1.3183
-1.0434
-1.1731
1.0896
1.1023
-1.3756
-1.0953
-1.2446
-1.2904
1.0658
1.2567
-1.0347
-1.3129
-1.4355
-1.0612
1.0384
-1.1807
1.0842
-1.2182
1.0424
-1.1671
-1.2874
-1.1748
-1.1638
-1.1172
-1.1159
1.0633
-1.0706
-1.4407
-1.3907
-1.2557
-1.062

Crem
Nptx2
Grin2b
Ntrk2
Kif17
Grm5
Arc
Grm4
Grm2
Adam10
Rgs2
Grm1
Adcy1

0.847683
0.851677
0.856433
0.858551
0.920053
0.921761
0.93635
0.947561
0.968087
0.972659
0.97654
0.987763
0.995551

0.8908
1.0505
0.8759
1.1388
0.9983
0.7531
0.7814
0.7526
0.9456
0.9301
1.0286
0.7249
0.8225

191

-1.1226
1.0505
-1.1417
1.1388
-1.0017
-1.3279
-1.2798
-1.3287
-1.0576
-1.0751
1.0286
-1.3795
-1.2158

